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Abstract
The pituitary gonadotrophins luteinising hormone (LH) and follicle stimulating
hormone (FSH) are differentially secreted from the gonadotroph cells of the
anterior pituitary in response to gonadotrophin releasing hormone (GnRH).
Both LH and FSH are members of the glycoprotein hormone family and are
comprised of a common alpha glycoprotein subunit (aGSU) and a function
specific beta subunit (LHp or FSH(3). GnRH also differentially regulates all three
genes; however, the factors that mediate this have yet to be fully elucidated. The
LPT2 cell line recapitulates a differentiated gonadotroph cell and was used as a
model system for differential display RT-PCR analysis (DD-RT-PCR) of GnRH
regulated transcripts. These transcripts were characterised and are described in
this thesis.
DD-RT-PCR showed that different pulse regimes of GnRH differentially
regulated gene expression and identified rapid changes in mRNA transcript
levels in response to GnRH. Both myosin light chain and a putative tyrosine
phosphatase were upregulated by GnRH. Other transcripts included two
expressed sequence tags (ESTs), one expressed in the testes, the other in the
mammary glands of pregnant or lactating mice. In addition GnRH also down-
regulated Fanconi's anaemia complementation group A (FAA) mRNA
expression levels.
Fanconi's anaemia (FA) is an autosomal recessive human disease, characterised
by aplastic anaemia, short stature, developmental abnormalities, microcephaly,
and infertility. The majority of FA genetic abnormalities map to the FAA gene,
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which is thought to have a role in DNA repair, and cell cycle checkpoint control.
The role of FAA in controlling gonadotrophin gene expression was investigated
by transient transfection assay in L(3T2 and aT3-l gonadotroph cells. cxT3-l cells
represent gonadotrophs from an earlier developmental stage compared with
L|3T2 cells and only synthesise ocGSU. The results indicated that FAA
specifically repressed the GnRH response of the aGSU promoter in L(3T2 cells.
The regulatory region of the FAA mRNA was mapped to between lbp and
965bp, which encodes the region on the FAA protein between amino acid (aa)
residues laa and 322aa. The results also suggest that FAA may mediate its
effects through a paired homeodomain binding site on the aGSU promoter.
Therefore DD-RT-PCR has identified a number of mRNA transcripts that are
regulated by GnRH. These may have roles in secretion or second messenger
signalling pathways. Furthermore, the discovery that GnRH regulated FAA
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TSH thyroid stimulating hormone
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UV ultra-violet
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Chapter one: Literature Review
1.1 Introduction
The gonadotrophins, luteinising hormone (LH) and follicle stimulating
hormone (FSH), are essential for reproduction. Lack of LH and FSH leads to
subfertility in the male and sterility in the female. They are synthesised and
secreted from the gonadotroph cells of the anterior pituitary, in response to
gonadotrophin releasing hormone (GnRH) released from the hypothalamus.
LH and FSH are members of the glycoprotein hormone family. They consist
of a common alpha subunit, a glycoprotein subunit (aGSU) and a function
specific (3 subunit; LH(3 and FSH(3, which are differentially expressed in
response to GnRH. aGSU and LH(3 subunit are expressed at a basal level
within gonadotroph cells, and are up-regulated by GnRH. However the
frequency of GnRH administration is crucial, aGSU is up-regulated in
response to constant GnRH administration, but LH(3 transcription is only up-
regulated with a pulsatile administration of GnRH (Mercer and Chin 1995).
FSH(3 transcription is not as strongly affected by GnRH pulsatility, in fact a
significant up-regulation of FSH(3 subunit transcription only occurs in the
presence of activin (Turgeon, Kimura et al. 1996; Dalkin, Haisenleder et al.
1999; Graham, Nusser et al. 1999).
Until recently, the focus of study has been on the physiological role of LH
and FSH in regulating gonadal function. With the advent of molecular
biology and transgenic technology, the differential regulation of LH(3, FSH|3
and aGSU biosynthesis is being unraveled. This literature review aims to
describe the current understanding of both basal and GnRH regulated
transcription, and the factors which mediate this. An overview of the
1
physiological roles of LH and FSH and their importance in reproductive
function will be followed by a detailed discussion of the development of the
pituitary and the transcription factors that are responsible for programming
this development and controlling basal gonadotrophin gene expression. The
mechanisms that control the differential regulation of gonadotrophin gene
expression will be discussed, including the signalling pathways that may be
involved in this. The factors involved in up-regulating the gonadotrophin
subunits in response to GnRH and the effect of gonadal peptides and steroid
hormones will be described. Finally, the regulation and mechanism of
secretion of LH and FSH from the gonadotrophs will be discussed.
1.1.1 Hypothalamic pituitary gonadal axis (HPA)
The hypothalamic pituitary gonadal axis (HPA) describes the positive and
negative hormonal feedback mechanisms that exist between these three
glands. The ultimate driver of the HPA is the hypothalamus, which secretes
gonadotrophin releasing hormone (GnRH), a decapeptide of the following
amino acids; Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly. This acts on the
anterior pituitary, specifically the gonadotroph cells, via the GnRH receptor
(GnRH-R). GnRH is released from the hypothalamus in discrete pulses,
generally once every 1 or 2 hours, except at the LH surge, and its action
results in pulsatile secretion of LH and FSH from the gonadotrophs.
1.1.2a The Female Reproductive Cycle
GnRH, LH, and FSH control the reproductive cycle in non-reflex ovulatory
females. Reflex ovulators only ovulate after mating and are not discussed in
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this thesis. The reproductive cycle is known as the menstrual cycle in
primates, and the oestrus cycle in rodents. It can be divided into two phases,
follicular and luteal, which are separated by the LH surge (see Fig. 1.1.2a).
The follicular phase is characterised by a steady increase of oestrogen,
secreted from developing follicles, whose development is initially dependent
on FSH, and low levels of progesterone (see Fig. 1.1.2b). These small follicles
also secrete activin and inhibin, which are involved in selecting the dominant
follicle (Perheentupa, Critchley et al. 2000). Inhibin also inhibits secretion of
FSH, therefore maintaining a low serum level. During this phase, GnRH is
secreted approximately every fifteen minutes. As the LH surge approaches,
the pulses of GnRH increase in frequency, to the point where they are
indistinguishable as individual pulses, and instead are constantly elevated
(Clarke, Thomas et al. 1987). The transition to the luteal phase is signalled by
a sharp surge in LH secretion (see Fig. 1.1.2c), triggered as a consequence of
the increase in GnRH, and concomitant with an increase of oestradiol (Pant,
Hopkinson et al. 1977). This in turn inhibits the synthesis of inhibin and
activin, which results in an increase in FSH serum levels (McNeilly 1988;
Baird, Campbell et al. 1991). The LH surge, triggers release of the ovum
from the mature follicle (ovulation). The remaining cells, left behind after the
follicle has ruptured, develop into the corpus luteum, which in primates
secrete oestradiol and progesterone hence the luteal phase is characterised
by a high level of progesterone (Hauger, Karsch et al. 1977). The cells of the
corpus luteum also secrete large amounts of inhibin, which is involved
3
Follicular Luteal
Fig. 1.1.2a: A diagram of the reproductive cycle showing the plasma levels of the
gonadotrophins, gonadal hormones, and the follicular development of an ovum in
the ovary during the cycle.













Fig. 1.1.2b: Feedback control of FSH and LH secretion during the Follicular
Phase.













Fig. 1.1.2c: Control of the LH surge at ovulation.












Fig. 1.1.2d: Feedback control during the Luteal Phase.
Adapted from Human Physiology 2nd Ed. Lauralee Sherwood.
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in maintaining the low level of FSH during the luteal phase (see Fig. 1.1.2d).
If the ovum is not fertilised and implanted, then the corpus luteum is broken
down, the levels of progesterone decrease, and the cycle enters the follicular
phase once more.
1.1.2b The Rodent Oestrus Cycle
The rodent oestrus cycle is divided into 4 stages, oestrus, met-oestrus, di-
oestrus and pro-oestrus. The oestrus cycle of rodents is similar to the
menstrual cycle of primates, but there are some differences (Greenwald and
Roy 1994). In rodents, there is a high level of FSH due to reduced circulating
levels of inhibin, which produces relatively large follicles. Therefore the
follicles require a shorter period of growth and hence the follicular phase
(proestrus) is short, lasting for 1 to 2 days (Greenwald and Choudary 1969).
If the ovum remains unfertilised, the corpus luteum degenerates within 2 to
3 days (Marshall 1984). The rapid degeneration of the corpus luteum leads to
a shorter luteal phase and contributes to the decreased levels of circulating
inhibin (Marshall 1984).
1.1.3 The Male
FSH and LH control spermatogenesis and testosterone secretion
respectively. LH acts on the Leydig cells, stimulating production of
testosterone, which is involved in mitosis and meiosis of the germ cells, and
FSH acts on the seminiferous tubules, specifically the Sertoli cells, to enhance
spermatogenesis, and spermatid remodelling (Sherwood 1993). Again, as in
the female, there are negative feedback loops that act on both LH and
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FSH (see Fig. 1.1.3). Testosterone exerts most of its inhibitory effects on LH,
by inhibiting the pulse frequency of GnRH at the level of the hypothalamus
and decreasing the GnRFl receptor sensitivity to GnRH at the anterior
pituitary. Inhibin is also secreted from the Sertoli cells and negatively
regulates FSHp synthesis and secretion (Carroll, Corrigan et al. 1989).
1.1.4 Disruption of GnRH, LH or FSH causes gonadal
abnormalities and can lead to infertility.
The importance of regulating gonadotrophin synthesis and secretion has
been shown in a number of mouse models, and in humans with mutations in
gonadotrophin genes that result in subfertility, or infertility. Transgenic mice
models in particular, have helped to define the reproductive role of each
gonadotrophin subunit.
A transgenic mouse with a targeted disruption of aGSU was reported in
1995 (Kendall, Samuelson et al. 1995). Since aGSU dimerises with LH(3, FSHp
and thyroid stimulating hormone p (TSHp) to form functional hormones, the
mice lacked TSH, LH and FSH. These mice displayed hypogonadism and
also hypothyroidism, which resulted in dwarfism. Thyroid development was
arrested in late gestation suggesting that TSH was required for the
development of the thyroid. However foetal and neonatal gonadal
development were normal, so gonadotrophins are only required for gonadal
maturation and genital development after birth, and they are not required
for sexual differentiation, or genital development in the foetal rodent. So,
the reproductive role of the gonadotrophins has been defined in a number of


















Fig.1.1.3: Control of Testicular Function.
Adapted from Human Physiology 2nd Ed. Lauralee Sherwood.
and the LH and FSH receptors. Additionally, transgenic mice have also been
used to confirm the role of the individual gonadotrophin subunits, these
studies are described below.
A frameshift deletion in the FSHfi gene of a female patient resulted in FSH
deficiency, with amenorrhoea, infertility, and an elevated LH circulating
plasma level (Matthews, Borgato et al. 1993). An inactivating mutation in the
FSH receptor in men essentially leading to lack of FSH function, resulted in
subfertility and reduced spermatogenesis (Tapanainen, Aittomaki et al. 1997).
To study the role of FSH in fertility, a FSHft gene disrupted mouse was
generated (Kumar, Wang et al. 1997). The testes of these mice were smaller
than their wild type littermates, and histological analysis showed a decrease
in the number of Sertoli cells, however the stages of spermatogenesis
appeared normal and the seminiferous tubules contained mature
spermatozoa. This is in keeping with the reported role of FSH in Sertoli cell
multiplication during embryonic development (Kluin, Kramer et al. 1984;
Orth 1984; Orth 1986). The ovaries and uteri of the female mutants were also
examined, and were shown to be smaller and thinner than their wildtype
counterparts, moreover, folliculogenesis was abnormal. The ovaries of the
mutant mice lacked any corpora lutea or normal follicles beyond the
primary follicle stage, suggesting that these mice did not undergo normal
oestrus cycles and infertility of the female mice was due to a block in follicle
maturation. Examination of the serum LH levels of these mice revealed that
LH levels were only elevated in the female mice, therefore the mutant
female mice mimicked the female patient with primary amenorrhoea
described previously. Genetic rescue of these gene disrupted mice was
performed by targeting expression of a human FSH(3 transgene to the
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pituitary, this rescued the phenotype of the mutant mice and the females
showed normal fertility (Kumar, Low et al. 1998). FSH receptor gene
disrupted mice have a similar phenotype to FSH/3 gene disrupted mice.
However, the female transgenic mice had high serum levels of FSH and LH,
which may be due to a loss of oestradiol negative feedback from the ovaries.
The male mice were fertile, which further suggests that testosterone, not
FSH is required for spermatogenesis (Abel, Wootton et al. 2000). Recently, a
transgenic mouse model with intact FSH synthesis and secretion, but lacking
LH synthesis and secretion was described (Allan, Haywood et al. 2001). This
model was used to identify the in vivo effects of FSH alone. In the male
transgenic mouse, FSH appears to induce the completion of meiosis,
however further progress in spermatogenesis does not occur. FSH is not
involved in Leydig cell development or function, but does appear to affect
Sertoli cell function. The ovaries of the transgenic mice were larger than the
control mice, and showed increased follicle recruitment and development,
however there was no evidence of corpus luteum formation or oestradiol
response to FSH.
A LH/3 gene disrupted mouse has not yet been described, so the in vivo role
of LH has been elucidated mainly by over expression models, however a LH
receptor/choriogonadotrophin (CG) receptor knockout has recently been
reported (Lei, Mishra et al. 2001). These mice had under-developed gonads,
the null males displaying micropenes, Leydig cell disruption, seminiferous
tubule disarray, and arrested spermatogenesis. The female null mice
displayed under-developed uteri and ovaries with arrested follicular growth.
Both mice had elevated serum LH levels, but low testosterone, oestradiol
and progesterone levels, and both male and female mice were infertile.
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Patients with a deactivating mutation in the LH receptor have also been
reported and present with reproductive abnormalities. Males have been
reported with pseudohermaphroditism, displaying female genitalia, and
abdominal testes with fully differentiated Sertoli cells, but an absence of
Leydig cells (Berthezene, Forest et al. 1976). A female carrying this mutation
presented with a milder phenotype, displaying primary amenorrhoea, with
both primary and secondary sexual characteristics (Toledo, Brunner et al.
1996). The ovaries of this female displayed all stages of follicular
development, however there was an absence of preovulatory follicles and
corpora lutea. Both male and female patients show elevated serum LH
levels, and low levels of testosterone, oestradiol, and progesterone. The
male showed normal FSH levels, but the female showed elevated FSH levels
(Themmen and Huhtaniemi 2000).
Female patients that have elevated serum androgen levels present with
hirsutism, chronic anovulation, polycystic ovaries and infertility, otherwise
described as polycystic ovary syndrome (PCOS) (Franks 1989). These
patients also present with elevated levels of LH. A transgenic mouse that
over-expressed LH was developed in 1996, and appeared to share some of
the phenotypic symptoms of PCOS patients. The female mice exhibited
enlarged ovaries with multiple corpora lutea, ovarian cysts and tumours and
were anovulatory (Risma, Clay et al. 1995). Further analysis of these mice
revealed that elevated LH caused precocious puberty (Risma, Hirshfield et al.
1997), consistent with reports of a male patient with an activating LH
receptor mutation (Schedewie, Reiter et al. 1981; Rosenthal, Grumbach et al.
1983), and hyperandrogenemia consistent with PCOS (Risma, Hirshfield et al.
1997).
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The report of a mutant mouse with hypogonadism (Cattanach, Iddon et al.
1977) has allowed further studies of the control of synthesis and secretion of
the gonadotrophins. Hypogonadal mice (hpg) have immature gonads and
the males presented with small penes, an under-developed scrotum, and
small testes. Females present with failure of the vagina to open, an under¬
developed uterus and very small ovaries (Cattanach, Iddon et al. 1977).
Concentrations of LH and FSH levels in the pituitary were markedly reduced
compared with normal mice, and GnRH levels were undetectable
(Cattanach, Iddon et al. 1977). Thus the hypogonadism seen in these mice is
due to a loss of GnRH stimulation on the gonadotrophs. Plasma LH could be
restored with administration of GnRH, but not with stimulation of the
hypothalamus, implying that the loss of GnRH is due to a loss of synthesis at
the hypothalamic level, rather than a loss of sensitivity to GnRH at the
pituitary level (Charlton, Halpin et al. 1983; Lewis, Morris et al. 1986). The
mutation in these mice has been localised to a partial deletion in the GnRH
gene (Seeburg, Mason et al. 1989). This deletion removes two exons that
encode the GnRH associated peptide (GAP) moiety of the GnRH mRNA
precursor, resulting in a nonfunctional mRNA GnRH precursor, and hence
no GnRH peptide. In the males, some testosterone synthesis occurred
indicating that the gonadotrophs were intact and capable of synthesising
some LH (Fink, Sheward et al. 1984).
Therefore, GnRH is required to up-regulate gonadotrophin levels. FSH is
required for follicle recruitment in females and Sertoli cell function and
possibly development in males. LH appears to be directly involved in
ovulation, and indirectly involved in spermatogenesis. Loss of both
hormones results in hypogonadism.
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1.2 Development of the Anterior Pituitary
1.2.1 The initial patterning of the anterior pituitary.
The anterior pituitary consists of 5 different cell lineages, characterized by the
hormones they produce. These are; the adrenocorticotropin (ACTH)
secreting corticotropins, thyrotropes, which secrete thyroid stimulating
hormone (TSH), somatotrophs that secrete growth hormone (GH),
lactotrophs which secrete prolactin, and the gonadotrophs, which secrete LH
and FSH (Japon, Rubinstein et al. 1994; Dasen and Rosenfeld 2001).
Differentiation of the pituitary cell types depends on a signalling gradient
similar to initial patterning in drosophila (Treier and Rosenfeld 1996).
Pituitary factor 1 (Pitl) and a zinc finger transcription factor (GATA2), that
binds the DNA sequence (A/T)GATA(A/G), are required and sufficient to
determine the terminal differentiation of all the anterior pituitary cell types
except the corticotrophs (Simmons, Voss et al. 1990). Initially, the ventral
dorsal bone morphogenic protein 2 (BMP2) gradient induces GATA2 in a
corresponding gradient in the developing thyrotrophs and gonadotrophs
(Couly and Le Douarin 1988; Ericson, Norlin et al. 1998). The high levels of
GATA2 restrict the expression of Pitl in the forming gonadotrophs. At a
more dorsal region, the level of GATA2 decreases, and the inhibition of Pitl
expression is removed. Cells in this region will express both GATA2 and
Pitl, and will develop into thyrotrophs. The most dorsal cells express high
levels of Pitl, which inhibit the effects of GATA2. The cells in this region will
go on to develop into somatotrophs and lactotrophs. Mutating the
homeodomain of either transcription factor disrupts this gradient and leads
to a loss of one or more cell types (Dasen, O'Connell et al. 1999). This
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BMP-2
Fig. 1.2.1: A diagram showing the cells of the pituitary and the signalling
gradient of transcription factors required to organise the spatial
arrangement of the pituitary.
BMP-2 is initially expressed at the border between Rathke's pouch and the
oral ectoderm at embryonic day 10.5 (e10.5) and establishes a
ventraldorsal signalling gradient and initiates GATA2 expression in a
corresponding gradient (red arrow). Pit1 expression is detected at e13.5,
however its expression is restricted by high levels of GATA2 (expression
level is indicated by the blue arrow) therefore, cells that express Pit1 alone
form the somatotrophs, lactotrophs (S/L) and melanotrophs (MSH) and
cells that express Pit1 and GATA2 form the thyrotrophs (T). Cells that
express GATA2 alone form the gonadotrophs (G). The rostral tip
thyrotrophs are also indicated (Tr).
(Adapted from Dasen, J. and Rosenfeld, M.J. 1999).
overlapping gradient is required for the correct temporal transcriptional
activation of factors that positionally determine the different cell-types (see
Fig. 1.2.1). The gradient also delineates the mature differentiated cell, by
activating expression of transcription factors that specifically regulate
expression of the hormonal markers that identify the cell-type.
1.2.2 Specification of basal transcription factor gene expression
and how these regulate expression of gonadotrophin subunit
genes
Transcription of the gonadotrophin subunits is highly regulated, and can be
divided into basal regulated transcription (non-GnRH), and GnRH stimulated
transcription. In this section I will discuss the known transcription factors,
which are involved in specifying the pituitary and transcribing the
gonadotrophin subunits, and I will discuss the factors, which control GnRH
regulated gonadotrophin subunit transcription, in a later section.
1.2.2a Rpx/Hesxl
One of the first transcription factors activated in the pituitary primordium is
Rathke's pouch homeobox (Rpx), which can be detected as early as
embryonic day 6.5-7 (e6.5-7) in the anterior neural plate of the embryo
(Thomas, Johnson et al. 1995). Its expression however is quickly restricted to
Rathke's pouch and is extinguished by el3.5 with the activation of the
pituitary specific POU domain transcription factor Pit-1 (Hermesz, Mackem
et al. 1996). The role of Rpx appears to be in the initial determination of the
anterior (prechordal) region of the embryo, and in restricting the further
differentiation of the anterior pituitary. Analysis of targeted Rpx gene
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disrupted mice show that Rpx is essential for the development of the
forebrain, eyes, and other anterior structures, including development of the
anterior pituitary. Furthermore, the associated mutation in man causes
combined pituitary hormone deficiency (CPHD) (Dattani, Martinez-
Barbera et al. 1998).
1.2.2b LIM proteins
The next step in the development of the anterior pituitary is the
differentiation of the different cell types. The LIM homeobox gene P-Lim or
Lhx-3 (Bach, Rhodes et al. 1995), is expressed throughout development in the
pituitary and is also expressed in the adult. Histological analysis of Lhx-3
gene disrupted mice showed that these mice lacked the anterior and
intermediate lobes of the pituitary (Sheng, Zhadanov et al. 1996). Growth
arrest was also accompanied by changes in the expression of the pituitary
specific marker genes. In the wild type mouse, Rpx expression is still
detected at el2.5, along with Lhx-3 expression, indicating that initial
expression of Rpx is independent of Lhx-3 protein. However, in the null
mutant Rpx expression had ceased by el2.5. aGSU, which is expressed in
thyrotropes and gonadotrophs, is the earliest pituitary specific marker and is
missing in Lhx-3 mutants (Simmons, Voss et al. 1990). Thus Lhx-3 is essential
for the differentiation and proliferation of the gonadotroph, thyrotroph,
somatotroph and lactotroph cell lineages, and is also required for the
continued expression of Rpx and transactivation of aGSU (Bach, Rhodes et al.
1995). A further LIM protein, Lhx-2 can also bind and stimulate the aGSU
promoter (Roberson, Schoderbek et al. 1994) and is required for basal
expression of aGSU in vitro. Recently a melanocyte specific gene-regulated
gene 1 (MRG1) has been identified by yeast two hybrid analysis, to interact
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with Lhx-2. MRG1 can trans-activate aGSU gene expression, and mutation
of the Lhx-2 DNA binding site disrupted this activation (Glenn and Maurer
1999).
1.2.2c Pitxl
In the Lhx-3 mutant, all but the corticotrophs fail to form in the anterior
pituitary. Therefore, another factor induces corticotroph development. The
homeobox transcription factor, pituitary homeobox factor-1 (Pitxl), was
isolated as a transcription factor involved in control of proopiomelanocortin
(POMC) gene expression (Lamonerie, Tremblay et al. 1996). It is expressed
throughout development of the pituitary, and is the earliest known marker
for all stomodeal derivatives including Rathke's pouch (Lanctot, Lamolet et
al. 1997; Lanctot, Moreau et al. 1999). However it is also a potent activator of
several pituitary specific promoters and interacts with lineage restricted
transcription factors to achieve cell and promoter specific transcriptional
activation (Tremblay, Goodyer et al. 2000). On prolactin and growth
hormone promoters it interacts with Pitl (Tremblay, Lanctot et al. 1998;
Szeto, Rodriguez-Esteban et al. 1999), with NeuroDl/Panl on the POMC
promoter (Poulin, Turgeon et al. 1997), and with steroidogenic factor-1 (SF-1)
and early growth factor protein-1 (Egr-1) on the LH(3 promoter (Tremblay,
Marcil et al. 1999). Pitxl gene deleted mice however, still have an intact
pituitary, indicating that it does not have a role in pituitary development
(Szeto, Rodriguez-Esteban et al. 1999) and suggests that there may be
functional redundancy between this factor and another paired-like
homeobox transcription factor Pitx2. Disruption of Pitx2 causes Reiger
syndrome (Lu, Pressman et al. 1999), but the function of this factor in
regulating pituitary gene expression has not been investigated.
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Pitxl activates the LHfh FSH(3 and aGSU promoters, and deletion of the
Pitxl binding site, disrupts this activation. In addition, Pitxl also acts in
synergy with SF-1 to up-regulate LH(3 promoter activity (Tremblay, Lanctot
et al. 1998) by a protein-protein interaction between the C-terminus of Pitxl
and the N-terminal half of SF-1 (Tremblay, Marcil et al. 1999). It is also
essential for aGSU and Lhx3 gene expression, the mRNA levels of both are
virtually undetectable in aT3-l cells that have been transfected with an anti-
sense Pitxl clone (Tremblay, Lanctot et al. 1998). The Pitxl and SF-1 binding
sites are 20bp apart on the LHp promoter, and are conserved in many
species, both can independently activate transcription of the LH|3 promoter
but they can also act in synergy, to specifically up-regulate LH(3 transcription
(Halvorson, Kaiser et al. 1996; Tremblay, Marcil et al. 1999).
1.2.2d Pitl
As development progresses two other transcription factors appear, the POU
domain transcription factor, Pitl and the orphan nuclear receptor, SF-1. Both
are first detectable at el3.5 in the anterior pituitary (Treier and Rosenfeld
1996).
Pitl is a member of the POU family of transcription factors and regulates the
genes encoding growth hormone (GH), prolactin and TSHp subunit. During
the development of the anterior pituitary Pitl expression is switched on as
Rpx expression is switched off. Mutations in either Pitl (Snell dwarf mutants)
or prophet of Pitl (Propl)/ Ames dwarf gene (df) (Sornson, Wu et al. 1996)
lead to severe proportional dwarfism, hypothyroidism, and infertility
(Radovick, Nations et al. 1992). Propl null mice have anterior pituitary
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hypocellularity, due to a reduction in thyrotropes, somatotropes and
lactotropes (Gage, Brinkmeier et al. 1996). Two complete loss of function
alleles of Pitl leads to the failure to activate TSHp, GH and prolactin, and loss
of cell proliferation after el4.5 (Li, Crenshaw et al. 1990). This evidence
suggests that Pitl and Propl lie on a common development pathway, which
involve the formation of the thyrotropes, somatotropes and lactotropes. In
situ hybridisation has shown that Propl is required for the repression of Rpx,
long before initial activation of Pitl and indeed may be responsible for the
activation of Pitl by day el5.5 (Gage, Brinkmeier et al. 1996).
It has also been shown that Pitl synergises with P-LIM and may be involved
in the activation of TSH/3 and prolactin genes, though P-LIM is not required
for Pit 1 activation (Bach, Carriere et al. 1997).
1.2.2e Steroidogenic factor 1 (SF-1)
SF-1 is classified as an orphan nuclear receptor, since an activating ligand has
not yet been identified (Duval, Ellsworth et al. 1999). Its importance in
endocrine function was first illustrated in SF-1 gene deleted mice, equivalent
to Ftz-Fl gene deletions in Drosophila (Luo, Ikeda et al. 1994). The null mice,
all died within eight days, and when analyzed for corticosterone levels, were
found to have lower levels than normal. This indicates that death was due to
adrenocortical insufficiency. These mice were also devoid of adrenal glands
and gonads, unsurprising since the gonads are the second major site of SF-1
expression in embryogenesis (Ikeda 1996). Therefore, SF-1 is essential for
gonadal development. SF-1 also acts at the pituitary, immunohistochemical
analysis revealed that these SF-1 gene disrupted mice were also lacking the
gonadotrope specific markers, LHp and FSH(3, and pituitary expression of
2 1
GnRH-R transcripts was also undetectable. However TSH, GH, ACTH were
present (Ingraham, Lala et al. 1994).
Further studies showed that SF-1 was also expressed in the ventral
diencephalon, which gives rise to the endocrine hypothalamus, suggesting
that it may act at other levels of the reproductive axis. Immunohistochemical
analysis in the adult mouse brain revealed that expression of SF-1 was
restricted to the ventral medial hypothalamic nucleus (VMH). In SF-1 gene
disrupted mice the VMH is structurally abnormal, with decreased cellularity
and organisation of the nucleus. In developing embryos, the gene-disrupted
mice had early stages of VMH development, which later regressed.
The SF-1 gene disrupted mice were treated with GnRH, and the
gonadotrophin expression profile was restored. This indicated that the
gonadotrope lineage was not ablated, in fact the mice were able to synthesise
GnRH however they were unable to secrete it (Ikeda, Luo et al. 1995).
Recently, a pituitary specific SF-1 gene disrupted mouse has been described
(Zhao, Bakke et al. 2001). This transgenic mouse was viable but infertile, and
the gonads were hypoplastic. The LH and FSH expression levels in these
mice were also decreased, suggesting a pivotal role for SF-1 in
gonadotrophin expression (Bakke, Zhao et al. 2001; Zhao, Bakke et al. 2001).
SF-1 DNA binding sites are known as gonadotrope specific elements (GSE)
and are found in the promoter regions of both LH(3 subunit (Brown,
McNeilly et al. 1993; Keri and Nilson 1996) and aGSU (Horn, Windle et al.
1992; Barnhart and Mellon 1994). Gel electrophoretic mobility shift assays
(EMSA) determined that SF-1 bound to the GSE, and that mutagenesis of the
DNA sequence, identified a consensus SF-1 DNA binding site TGACCTTGT
(Halvorson, Kaiser et al. 1996). Transfection studies showed that SF-1
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transactivates both aGSU (Barnhart and Mellon 1994), and rat LHp
promoters (Halvorson, Kaiser et al. 1996) in vitro and the cow LHp promoter
in transgenic mice (Keri and Nilson 1996). SF-1 transcription has been
reported to be up-regulated by GnRH administration (Haisenleder, Yasin et
al. 1996) however, other reports have shown that SF-1 transcription is not
affected by GnRH in vivo (Brown and McNeilly 1997). SF-1 therefore poses a
conundrum, it is clearly an essential co-factor in up-regulating transcription,
but numerous studies have shown that its mRNA levels are unvarying
(Parker and Schimmer 1997), although transcriptional up-regulation of the
target gene is seen in response to peptide hormone action. This would
suggest that SF-1 activation is brought about by post-translational
modifications, i.e. phosphorylation (Zhang and Mellon 1996). This has been
located to a single serine residue (Ser-203) within the activation domain of
SF-1 (Hammer and Ingraham 1999).
Drean (Le Drean, Liu et al. 1997) was able to show that SF-1 could recruit
different transcription factors, depending on distinct cis acting elements on
gonadotropin gene promoters. Therefore, SF-l's role in regulating
transcription may be to recruit specific transcription factors to specific
promoters. It also regulates gonadotrope gene transcription by synergising
with other factors.
1.3 GnRH Regulation of Gonadotrophin Subunit
Expression
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The gonadotrophs are unique in the anterior pituitary in that they transcribe,
translate, and secrete LH and FSH differentially in response to GnRH. This
means that GnRH can act at different sites after receptor activation. The
signalling pathways from the receptor to either the nucleus, or the secretory
mechanisms are not characterised. However, a number of different
mechanisms have been postulated for controlling this, which include; pulse
frequency, pulse amplitude, second messenger pathways, and/or GnRH-R
number and turnover. Therefore the available scientific information that
starts to unravel how the GnRH signal may be differentially transduced is
described below.
1.3.1 In vivo studies of GnRH regulation of gonadotrophin
synthesis and secretion
Initial studies were carried out in ovariectomised (OVX), and castrated sheep
and rats, to remove steroidal and peptide feedback from the gonads. The
serum LH and FSH levels in these animals increased, however
administration of oestrodiol reduced them to pre-gonadectomy levels
(Gharib, Wierman et al. 1990), highlighting the significant effect of steroid
hormones on synthesis and secretion. However, disrupting the GnRH
stimulus to the gonadotrophs by surgically isolating the pituitary from the
hypothalamus in OVX ewes, reduced LH and FSH levels, which
demonstrated the importance of pulsatile administration of GnRH.
Interestingly, manipulation of GnRH pulse frequency in the hypogonadal
mouse, substantiated that synthesis and secretion of LH and FSH was
sensitive to the pattern of GnRH administration. Administration of a single
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daily injection of GnRH resulted in an increase of serum FSH, and only a
slight increase in serum LH levels. However, 12 injections a day increased
serum LH and FSH levels to almost normal. The development of the gonads
of both male and female mice was increased (the testes and uterine weight
increased) suggesting that a more frequent GnRH injection regime, would
mimic the condition found in normal mice (Charlton, Halpin et al. 1983).
1.3.2 GnRH pulse Frequency/Amplitude
Before puberty, GnRH is released sporadically from the hypothalamus, and
LH and FSH are at basal plasma levels. At puberty, in males, GnRH pulse
frequency increases to approximately one an hour and remains at this
frequency throughout adult life (Lincoln, Fraser et al. 1985). In contrast, in
the adult female, GnRH pulse frequency varies depending on the stage of the
reproductive cycle (Knobil 1980). The period that leads up to the LH surge,
and triggers ovulation is characterised by an increase in GnRH pulse
frequency, initially one every 45-60 minutes, increasing until the GnRH
pulses appear continuous, returning to one pulse every hour, after ovulation
(Clarke, Thomas et al. 1987; Moenter, Caraty et al. 1991). The pulsatile
nature of the GnRH delivery is crucial since a constant infusion of GnRH to
either ovariectomised or hypogonadal sheep leads to cessation of LH
secretion, with LH(3 and FSH(3 mRNA levels dropping to 50% of the levels
found in sheep treated with pulses (Mercer, Clements et al. 1989).
The importance of GnRH pulse frequency and amplitude was recapitulated
in mice and rats. Experiments carried out in rat models showed that
administration of pulsatile GnRH increased mRNA levels of aGSU and LH|f
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(Haisenleder, Khoury et al. 1987; Haisenleder, Dalkin et al. 1991; Jakubowiak,
Janecki et al. 1991). However, the pattern of increase was different, an
increase in mRNA levels of LH|3 occurs with 30 min pulse frequencies
(Kaiser, Conn et al. 1997), and LH|f mRNA up-regulation is only seen with a
specific pulse frequency (Papavasiliou, Zmeili et al. 1986; Shupnik 1990;
Weiss, Duca et al. 1990; Haisenleder, Dalkin et al. 1991), whereas cxGSU
mRNA up-regulation is seen with either continuous or pulsatile GnRH
administration.
A more recent study investigated the effect of pulse amplitude on all three
subunits. LH(1 subunit expression was increased in response to low levels of
GnRH (35pg/ml) and FSHp and aGSU responses were maximal at 70pg/ml.
Interestingly LH release was maintained over a 10 fold range of GnRH pulse
dose, suggesting that LH secretion was not coupled to synthesis (Salton,
Blum et al. 1988; Weiss, Jameson et al. 1990; Weiss, Crowley et al. 1992;
Haisenleder, Ortolano et al. 1993). Therefore GnRH amplitude controls
gonadotrophin secretion rather than synthesis, since LH secretion is
increased over a broad range of GnRH amplitude administration.
In contrast to aGSU and LHfl, FSH(3 was not significantly up-regulated by
either continuous or pulsatile administration of GnRH, in fact only slow
GnRH pulse frequencies (one every 120 minutes) increased FSH mRNA
levels (Dalkin, Haisenleder et al. 1989). FSHJ3 up-regulation also requires a
further signal, which has been identified as activin (Weiss, Crowley et al.
1993; Dalkin, Haisenleder et al. 1996; Graham, Nusser et al. 1999).
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1.7.1 GnRH and The GnRH-R
The GnRH signal activates the GnRH-R, which transduces the signal to the
nucleus and the secretory machinery through second messenger signalling
pathways. There have been reports of a number of structural variants of
GnRH (King and Millar 1979) and so far, 14 novel peptides have been
identified (Sherwood, Lovejoy et al. 1993; Sealfon, Weinstein et al. 1997). In
addition to the classical GnRH peptide another, designated as GnRH II, is
present in individual species of most vertebrates studied (Sherwood, Lovejoy
et al. 1993; Sealfon, Weinstein et al. 1997; White, Eisen et al. 1998). Recently a
GnRH-R that specifically binds this GnRH II has been cloned and
characterised (Millar, Lowe et al. 2001), therefore this section will discuss both
the GnRH type I receptor, and the GnRH type II receptor.
1.3.3a The GnRH Type I receptor
Type I GnRH (GnRH) binds the GnRH type I receptor (GnRH-R). The gene
for the pituitary GnRH-R was originally cloned from aT3-l cells and encodes
a protein of 327 residues (Tsutsumi, Zhou et al. 1992). In addition, the
human, rat and sheep genes have also been cloned (Kaiser, Zhao et al. 1992;
Chi, Zhou et al. 1993; Illing, Jacobs et al. 1993). Like other G-protein coupled
receptors, the GnRH-R has seven transmembrane domains however, the
mammalian GnRH-R lacks an intracellular carboxyl terminal tail (see Fig.
1.3.3) (Kakar, Musgrove et al. 1992; Chi, Zhou et al. 1993). Functional and
regulatory studies have shown that, unlike other G-protein coupled
receptors, the mammalian GnRH-R does not undergo rapid desensitisation
(Davidson, Wakefield et al. 1994; Anderson, McGregor et al. 1995; McArdle,






(Willars, Heding et al. 1999; Heding, Vrecl et al. 2000). This means that the
GnRH-R is maintained in an agonist sensitive state, which may have
implications for the differential regulation of the gonadotrophin subunits.
1.3.3b GnRH II and the GnRH type II receptor
GnRH II is widely distributed in tissues, and has been shown to regulate
potassium channels in sympathetic ganglia and stimulate reproductive
behaviour (King and Millar 1979; Sherwood, Lovejoy et al. 1993; Maney,
Richardson et al. 1997). Other studies have shown that GnRH II can also
preferentially stimulate FSH release (Yu, Karanth et al. 1997; Yu, Karanth et
al. 2000). Recently the GnRH type II receptor (GnRH-R II) has been cloned
from marmoset (Millar, Lowe et al. 2001). It is also a seven transmembrane
receptor, however it contains a carboxyl terminal tail. Like the GnRH-R type
I, it activates G /n, and extracellular regulated kinase 1/2 (ERK1 /2), however
it differs in its activation of p38 mitogen activated kinase. It is distributed
throughout the brain, especially in areas that are involved in sexual arousal,
and in gonadotrophs. Its function in the gonadotrophs has not been fully
elucidated, therefore, in this thesis, only type I GnRH and type I GnRH-R are
discussed.
1.3.4 GnRH receptor number.
The ability of the gonadotroph cells to respond to GnRH depends on
receptor number and turnover. It has been established that GnRH-R
numbers vary during the oestrus cycle (Savoy-Moore, Schwartz et al. 1980;
Barkan, Regiani et al. 1983) increasing during the period leading to the LH
surge (Brooks, Taylor et al. 1993). Furthermore, GnRH-R numbers are
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increased by pulsatile administration of GnRH (Katt, Duncan et al. 1985), and
GnRH-R gene expression levels are augmented by oestradiol (Yasin, Dalkin
et al. 1995). Interestingly, the GnRH-R mRNA levels in female rats appear to
be more dependent on GnRH pulse frequency, than in male rats (Yasin,
Dalkin et al. 1995), which suggests that GnRH-R number may be involved in
controlling the events, such as the LH surge, during the oestrus cycle.
GnRH-R mRNA levels also increase in ovariectomised and castrated rats,
suggesting that gene expression is regulated by factors that are involved in
regulating gonadotrophin synthesis and secretion (Rosen, Dalkin et al. 1991;
Yasin, Dalkin et al. 1995). DNA sequence analysis of the GnRH-R promoter
has identified 2 GSEs within 600bp of the start site, and the GSE identified
between -250bp and -232bp was part of a tripartite, tissue specific enhancer
conferring gonadotroph specific expression to the mouse GnRH-R (Clay,
Nelson et al. 1995). This enhancer region includes an AP-1 site (White, Duval
et al. 1999) and a GnRH-R activating sequence (GRAS) (Duval, Nelson et al.
1997). SF-1 has also been shown to interact with the GSE region to up-
regulate GnRH-R mRNA expression levels (Ngan, Cheng et al. 1999). Activin
and inhibin can also regulate the receptor number both at the transcriptional
level through the GRAS region of the promoter (Fernandez-Vazquez, Kaiser
et al. 1996; Duval, Ellsworth et al. 1999) and at the translational level (Braden
and Conn 1992).
1.3.5 GnRH receptor uncoupling
The third mechanism that may be involved in differential regulation of the
gonadotroph subunits is GnRH-R uncoupling, and activation of different
second messenger pathways. The GnRH-R is a seven transmembrane
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receptor coupled to the G proteins, Gq and Gn (Hsieh and Martin 1992).
There are a number of different signalling pathways that can be used by G
protein coupled receptors. These include protein kinase C, mitogen activated
protein kinase (MAPK), protein kinase A, and calcium influx. Many studies
have been carried out to identify which pathways are involved in signalling
differential transcription of the gonadotrophin subunits, either by different
signalling pathways, (G protein uncoupling) or by unique pathways, which
activate gonadotrophin subunit transcription individually. These are
discussed in the following section and are summarised in Fig. 1.3.4.
1.3.5a Activation of Protein Kinase C and Protein Kinase A
Coupling of the GnRH-R to the Gq/n protein initiates the phospholipase C
(PLC) cascade. Hydrolysis of phosphatidylinositol 4,5-bisphosphate, forms
inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), which induces a
rise in intracellular Ca^+, mobilizing both cellular and extracellular calcium
pools (Naor, Leifer et al. 1980). This activates protein kinase C (PKC),
causing a rapid secretion of LH. However inhibition of IP3 does not inhibit
secretion, suggesting that this pathway is not essential for secretion (Hawes,
Marzen et al. 1992). PKC can also be uncoupled from GnRH stimulated LH
secretion and has been suggested to have a role in modulating gonadotrope
responsiveness to GnRH (Johnson, Mitchell et al. 1988). PKC has also been
implicated in LH biosynthesis (Papavasiliou, Zmeili et al. 1986), and depletion
of PKC in rat pituitary cell cultures inhibits the GnRH stimulated increase in
LH(3 mRNA (Andrews, Maurer et al. 1988). GnRH-R can also couple to Gs,
and Gi, activating protein kinase A (PKA) and cyclic adenosine
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Fig.1.3.4: Schematic representation of the signalling pathways that may be
involved in up-regulating transcription of the gonadotrophin subunits.
GnRH binds to and activates the GnRH receptor (GnRH-R) and releases
the a subunit of the G protein. This binds and activates phospholipase C
(PLC) which activates protein kinase C(PKC) via the diacylglycerol (DAG),
inositol phosphate pathway (IP3). PKC can then activate a number of other
pathways including the mitogen activated protein kinase (MAPK) cascade,
voltage gated Ca2+ ion channels and the jun N-Terminal kinase (JNK)
cascade via jun/fos. The activin signalling mechanism through the SMAD
proteins is also shown.
mono-phosphate (cAMP), although cAMP release has not been observed
(Stanislaus, Pinter et al. 1998). The PKA pathway is possibly involved with
increasing LH biosynthesis (Starzec, Moumni et al. 1989), regulating
gonadotropin subunit mRNA (Ishizaka, Tsujii et al. 1993), or GnRH-R mRNA
(Alarid and Mellon 1995).
The activation of PKC results in a number of different effects, one of which is
to activate transcription. PKC itself is activated by DAG phosphorylation
(Borner, Eppenberger et al. 1988; Pears and Parker 1991), and a recent review
details a number of pathways that regulate PKC phosphorylation beyond
that of DAG and calcium activation. This review suggests that a number of
priming phosphorylations are required before activation takes place. These
include phosphorylation of the activation loop site (Cazaubon, Bornancin et
al. 1994; Hansra, Garcia-Paramio et al. 1999), the autophosphorylation site
(Flint, Paladini et al. 1990), and the hydrophobic C-terminal site (Bornancin
and Parker 1996; Bornancin and Parker 1997). At this point, ligand
dissociation can occur, so that the kinase is held in a latent state, which can be
recruited back to the membrane and reactivated by DAG (Parekh, Ziegler et
al. 2000).
The existence of a primed PKC has implications for how a pulsatile GnRH
signal is interpreted by the second messenger signal transduction systems.
GnRH could differentially regulate a number of different pathways,
including transcription and secretion, in particular transcription of aGSU and
LH(3 subunit, and secretion of LH. As already described, aGSU transcription
and LH secretion only require the presence of GnRH. At the LH surge, the
pulse frequency of GnRH increases, mimicking a state of constant GnRH
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administration, which has already been shown to favour transcription of
aGSU. A change in GnRH-R coupling/signalling, possibly due to primed
PKC, could possibly direct increased transcription of aGSU, but certainly
stimulate secretion of LH.
The downstream targets of PKC are varied, and many are yet to be
identified. Transcription of the gonadotrophin subunits, has been shown to
be controlled by a PKC activated pathway (Cesnjaj, Catt et al. 1994). In this
paper the early response gene expression profiles, in particular c-fos, c-jun
and junB, were stimulated in response to GnRH. This response was rapid,
the maximal effect occurring 30min after GnRH treatment, and was linked to
the activation of the PKC pathway. Interestingly, sequence analysis of the
ovine FSHp subunit has identified a number of potential activating protein-1
sites (AP-1). These AP-1 sites bind the jun/fos complex, up-regulating the
transcription of FSH(3 (Strahl, Huang et al. 1997). By using a series of
deletion constructs the authors were able to show that expression of the
ovine FSH(3 gene was enhanced by c-jun, and c-fos proteins in transiently
transfected mammalian cells. This was localised to 2 functionally linked
elements which bound AP-1 proteins, and were also activated by 12-0-
tetradecanoyl phorbol-13-acetate (TPA), a known activator of PKC.
Induction of aGSU gene expression is mediated through the PKC/mitogen
activated kinase kinase (MEK) pathway (Week, Fallest et al. 1998) and it has
been suggested that LH(3 transcription is mediated through the PKC/MEK
pathway (Saunders, Sabbagh et al. 1998). LHp mRNA expression is also
increased with the addition of phorbol esters to a perifused rat pituitary
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system (Ben-Menahem and Naor 1994), which lends credence to the
argument that it is the PKC pathway rather that the calcium pathway that
up-regulates LH(f transcription. However the regulation of transcription
may not be limited exclusively to one pathway or the other, especially when
considering the transcriptional regulation of the gonadotrophin subunits.
1.3.5b Calcium Signalling Pathways
Although calcium-signalling pathways may have a possible role in the
gonadotroph to signal transcription and secretion, the evidence is
contradictory. It has been shown that calcium induces both transcription and
secretion of cxGSU (Holdstock, Aylwin et al. 1996), as well as inducing
transcription of LH(3 (Ben-Menahem and Naor 1994; Week, Fallest et al.
1998). A role for calcium in transcriptional regulation of c-fos has recently
been shown (Hardingham, Chawla et al. 1997), but it is not clear if this could
operate in gonadotrophs. Two separate signalling pathways could activate c-
fos mediated transcription; one through the cAMP response element (CRE)
by increasing the nuclear calcium levels and the other through the serum
response element (SRE) by increasing levels of calcium in the cytoplasm and
both signalling pathways can act independently. This has interesting
possibilities for the control of FSH(> mRNA transcription, which can be up-
regulated by c-jun and c-fos.
1.3.5c Mitogen Activated Protein Kinase (MAPK) Activation
MAPK is the major downstream effector of GnRH. GnRH-R couples to
either G; or Gq, activating PKA and PKC (Hawes, van Biesen et al. 1995),
which activates MAPK in castrated testosterone replaced adult male rats
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(Haisenleder, Cox et al. 1998), and in GH3 cells stably transfected with
GnRH-R (Han and Conn 1999).
Both aGSU and LHp gene expression levels are regulated by MAPK
(Saunders, Sabbagh et al. 1998; Week, Fallest et al. 1998). On the aGSU
promoter, this regulation is likely to be mediated through an Ets binding site,
since the Ets family of transcription factors are known to mediate
transcriptional responses to the MAPK pathway (Maurer, Kim et al. 1999).
There is also evidence for combinatorial cross-talk between PKC and Ca2+,
which may be involved in fine-tuning the regulation of transcription by these
pathways (Shacham, Harris et al. 2001).
1.3.5d Jun N-Terminal Kinase Pathway Activation
The Jun N-terminal kinase (JNK) pathway, has also been shown to be
activated by GnRH through a PKC and tyrosine kinase dependent manner
(Levi, Hanoch et al. 1998). The stimulation of the JNK cascade was shown to
be greater, although slower than and independent of, the MAPK pathway
and seemed to involve PKC, cSrc, CDC42/Racl. LPT2 cells were identified as
having a c-jun dependent JNK kinase (Yokoi, Ohmichi et al. 2000), but it is
not known if the activation of the JNK cascade is sufficient to activate the
LHp promoter.
1.3.6 Regulation of FSH|3 by gonadal peptide activation of
TGF(3 signalling
The primary factors that regulate FSH synthesis and secretion, are the
gonadal peptides activin, follistatin, and inhibin (Carroll, Corrigan et al.
1989). These were originally purified from porcine and bovine follicular fluids
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(Ying 1988), and activin and inhibin are members of the transforming
growth factor (3 (TGF(3) family (Vale, Rivier et al. 1988). They bind and signal
through serine/threonine kinase receptors (Mathews and Vale 1991;
Massague 1998). Specifically, activin binds to the activin type II receptor,
which recruits the type I receptor (Attisano, Wrana et al. 1996), and signals
through the SMAD (SMADs are downstream components of
serine/threonine kinase receptors) second messenger pathway to up-
regulate transcription (Lebrun, Takabe et al. 1999). Follistatin binds to
activin, preventing activin from interacting with the activin type II receptor,
thus regulating its activity (Shimonaka, Inouye et al. 1991). Inhibin also binds
the type II receptor, but cannot recruit the type I receptor, thus blocking
activation of the second messenger system however, this does not
completely inhibit activin activation (Martens, de Winter et al. 1997).
Recently, evidence for an inhibin specific receptor has been reported. The
betaglycan type III IGF (3 receptor can bind inhibin and act as an inhibin
specific co-receptor with the activin type II receptor (Lewis, Gray et al. 2000).
A membrane bound inhibin specific binding protein has also been isolated
(pl20), which may also interact with the activin type II receptor (Chong,
Pangas et al. 2000), though its function is still unclear. However, mutations in
the human pl20 protein cause Pettigrew Syndrome, and human ovarian
carcinomas (Choi, Cho et al. 1997; Lagerstrom-Fermer, Sundvall et al. 1997),
the phenotype of which was recapitulated in a loss-of-inhibin transgenic
mouse model (Matzuk, Finegold et al. 1992; Matzuk, Kumar et al. 1996).
1.4 GnRH regulated transcription of gonadotrophins.
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GnRH activation of second messenger signalling is eventually transduced
into transcriptional regulation of the gonadotrophin subunits. Progress in
this field has been hampered due to the inaccessibility of gonadotroph cells in
the anterior pituitary and due to the distribution of gonadotrophs in the
pituitary. Gonadotrophs are evenly spread throughout the pituitary, so are
difficult to isolate and dissection has not yielded primary gonadotroph cells
or cell-lines, and human pituitary tumours yield a heterogeneous mix of
pituitary cell-types. Therefore, GnRH regulated transcription has only
recently been studied using in vitro transformed cell lines of the anterior
pituitary and it was only with the advent of these cell-lines that the GnRH-R
was cloned (Tsutsumi, Zhou et al. 1992). These cell lines were developed by
the targeting of SV40 T antigen oncogene to gonadotrophs by the 5' flanking
sequences of either the mouse aGSU or rat LHp gene promoter and injected
into eggs. The resultant transgenic mice developed tumours of the anterior
pituitary, from which transformed gonadotroph cells were derived. aT3-l
cells are able to synthesise and secrete aGSU, and express GnRH receptor,
but do not synthesise either LH(3 or FSH(3 subunit (Windle, Weiner et al.
1990). L(1T2 cells synthesise and secrete LH in response to GnRH (Turgeon,
Kimura et al. 1996), and secrete FSH in response to activin A, thus proving
that L|3T2 cells are gonadotrophs (Graham, Nusser et al. 1999).
1.4.1 LH|3 transcription
A gonadotroph-specific transcription factor, which uniquely up-regulates
LH(! transcription has not been identified. Instead, the current hypothesis is
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Fig. 1,4A: A schematic representation (not to scale) of the
transcription factors that regulate basal transcription of the
gonadotrophin subunit genes (adapted from Brown et al 1999).
The PGBE region of the aGSU gene promoter and the proximal
region (P.R.) of the LH(3 gene promoter are also shown.
39
Fig. 1.4B: A schematic representation (not to scale) of the transcription
factors involved in up-regulating transcription of the gonadotrophin
subunits in response to GnRH (adapted from Brown et al 1999).
The GnRH-RE and the PGBE regions of the aGSU promoter, and the
distal and proximal regions (D.R. and P R.) of the LH(i promoter are
also included.
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that transcription is up-regulated by a number of transcription factors, that
are also expressed in other cell-types, these interact with each other and in
this way provide combinatorial specificity (Brown and McNeilly 1999).
Characterisation of the LH(3 promoter is most advanced in the rat. There are
2 regions involved in GnRH stimulated transcription, one at -490bp to
-352bp (distal region), and the other maps between -207bp and -82 bp
(proximal region). The distal region contains a GSE and a GnRH specific
regulatory region (Kaiser 1998), which binds Spl. In the proximal region, a
number of other transcription factor binding sites have been identified, these
are summarised in Fig 1.4 A and B. In addition a binding site for nuclear
factor-Y (NF-Y) has been identified in the bovine FH(3 promoter (Keri,
Bachmann et al. 2000) but the importance of this factor in regulation of
transcription in other species is not known. The transcription factors
regulated by GnRH, and shown to modulate LH/3 gene expression are now
discussed in more detail below.
1.4.1a Spl
Spl is a transcription factor that is ubiquitously expressed, and binds to a
consensus DNA sequence of (G/T)GGGCGG(G/A) (G/A). Two Spl binding
sites were identified, which acted synergistically (Kaiser, Sabbagh et al. 1998)
in response to GnRH stimulation. However there was no change in the
expression pattern or EMSA pattern of Spl either in the presence, or absence
of GnRH. This implies that Spl is not regulated by GnRH and is
constitutively active, in a similar fashion to SF-1. More recently, Spl has been
identified as part of a tripartite GnRH response element (GnRH-RE), which
also binds SF-1 and Egr-1 (see Fig. 1.4B). Interestingly, mutations in the Spl
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binding site do not affect basal or GnRH regulated LH(> transcription,
however mutating the Spl, and Egr-1 binding sites does repress the GnRH
regulated LHf> promoter activity, and both are required to mediate the full
GnRH response (Kaiser, Halvorson et al. 2000).
1.4.1b Egr-1 and synergistic factors
Egr-1 (NGFI-A, Krox-24) is a zinc finger transcription factor, initially
identified as an immediate early serum response or nerve growth factor
response gene product. Targeted disruption of the Egr-1 gene in mice
rendered females infertile due to lack of LH/3 gene expression (Lee, Sadovsky
et al. 1996). The LHf> promoter has potential binding sites for Egr-1 (DNA
consensus sequence GCGTGGGCG), and is marginally up-regulated by Egr-1 in
in vitro transfection assays, but co-transfection of SF-1 in this assay markedly
increased this response (Lee, Sadovsky et al. 1996), indicating synergism
between the factors. The synergism between Egr-1 and SF-1 is a major
regulatory mechanism in the LH[3 promoter in a number of species (Lee,
Sadovsky et al. 1996; Ito, Yu et al. 1997; Dorn, Ou et al. 1999; Wolfe and Call
1999). The original study by Lee et al has been expanded by a report of
another Egr-1 disrupted mouse with a wide-ranging phenotype (Topilko,
Schneider-Maunoury et al. 1998). These transgenic animals have fewer
somatotroph cells, but similar numbers of gonadotroph cells when
compared to their wildtype littermates. So, Egr-1 regulates LHp
transcription in gonadotrophs, and possibly cell survival in somatotrophs.
There may also be redundancy between Egr-1 and another family member
Egr-4, which can partially activate LH synthesis and explain how the males
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were fertile in the earlier study, since Leydig cell steroidogenesis was
maintained (Tourtellotte, Nagarajan et al. 2000).
Additionally, Egr-1 synergises with Pitxl as well as SF-1. Unlike Pitxl and SF-
1, Egr-1 seems a likely mediator of GnRH induced signals for activation of
the LH/3 gene, (Tremblay and Drouin 1999), and although transfection data in
LflT2 cells suggests that mutating the Pitxl site has no effect on the GnRH
regulated activity of the LHp promoter (Quirk, Lozada et al. 2001), in vivo
studies contradict this (Quirk, Lozada et al. 2001).
Egr-1 is responsive to GnRH. Addition of GnRH to cells leads to an increase
in the mRNA levels of Egr-1 through activation of the PKC and MAPK
pathways, therefore Egr-1 modulates LH() subunit gene transcription in a
GnRH dependent manner (Dorn, Ou et al. 1999; Halvorson, Kaiser et al.
1999; Wolfe and Call 1999). It is likely that the action of Egr-1 is also
modulated by GnRH, since it is known that Egr-1 protein has an internal
inhibitory domain comprising a region of 34 amino acids that can bind a
group of proteins known as Egr-1/NGF1-A binding proteins Nab 1 and Nab
2 (Russo, Sevetson et al. 1995; Svaren, Sevetson et al. 1996; Swirnoff, Apel et
al. 1998). Nabl mRNA was shown by Northern blot analysis, to be
regulated by GnRH, and may therefore be a factor involved in regulating
Egr-1 action (Wolfe and Call 1999).
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1.7.1 FSH|3 transcription
1.4.2a Regulation of FSHp by gonadal peptides
The gonadal peptides activin and inhibin are also locally synthesised in the
anterior pituitary in response to GnRH (Kirk, Dalkin et al. 1994; Dalkin,
Haisenleder et al. 1998) and are involved in regulating expression of the
FSH/3 gene via the SMAD proteins (Dalkin, Haisenleder et al. 1999). Activin
up-regulates FSHp by stabilising the mRNA (Carroll, Corrigan et al. 1991)
and by increasing transcription (Weiss, Guendner et al. 1995). Inhibin and
follistatin both down-regulate FSHp and aGSU mRNA levels (Attardi and
Winters 1993; Pernasetti, Vasilyev et al. 2001), and can inhibit FSH secretion
(McNeilly 1988). Inhibin, in particular, can decrease the transcription rate of
the FSH/3 subunit gene (Clarke, Rao et al. 1993). Activin and inhibin are
known to regulate FSH/3 transcription in vivo (Carroll, Corrigan et al. 1989),
and it has recently been shown that addition of activin to LPT2 cells, will
activate transcription of FSHf3 in vitro (Graham, Nusser et al. 1999). Activin
binds to, and activates the type II activin receptor, which recruits the type I
receptor (Mathews and Vale 1991). This phosphorylates and activates SMAD
2/3, which interacts with SMAD4 and translocates to the nucleus. The SMAD
complex can then bind DNA and up-regulate transcription (Lebrun, Takabe
et al. 1999).
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1.4.2b Regulation of FSHp through Activating Protein-1 sites
Sequence analysis of the ovine FSHp promoter has identified a number of
putative activating protein-1 (AP-1) sites with near or identical homology to
the consensus AP-1 site (TGAg/cTCA). As described in section 1.3.4a, these
AP-1 sites are functionally linked to up-regulate the FSH(3 gene promoter,
mediated by c-jun and c-fos (Strahl, Huang et al. 1998). There is additional
evidence to suggest that Jun and Fos proteins may be involved in FSH/3
transcription since activin was able to up-regulate Jun and Fos mRNA levels
in vitro (Hashimoto, Gaddy-Kurten et al. 1993). The importance of these AP-
1 sites in up-regulating FSHjl promoter was investigated in transgenic mice
carrying either the wild type ovine FSHfl promoter, or an ovine FSH(3
promoter with mutated AP-1 sites (Huang, Sebastian et al. 2001). The results
showed that the GnRH response of the FSH(3 promoter acted through the
AP-1 sites, however, activin was the major regulator of FSHp promoter
activity, and it did not act through the AP-1 sites (Huang, Sebastian et al.
2001). A DNA binding site for the activin activated SMAD2/3/4 complex has
yet to be identified, however a recent paper has identified that several
anterior nuclear proteins can bind to an -800bp upstream region of the
TATA box, it is perhaps in this region that an activin effector site will be
identified (Kato, Tomizawa et al. 1999).
1.4.2c Regulation of FSH(3 synthesis by Bone Morphogenic Proteins
There may also be a role for bone morphogenic proteins (BMP) in the
synthesis of FSH. BMP-6 and BMP-7 mRNAs have been detected in mouse
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pituitaries and L(3T2 cells (Huang, Wu et al. 2001). BMPs belong to the same
superfamily of transforming growth factor-(1 (TGF-(3) proteins as activin, and
were originally identified by their ability to induce bone and cartilage
formation (Wozney 1989). When transfected with the ovine FSHp promoter,
BMP-6 and BMP-7 both up-regulate FSH(3 transcription (Huang, Wu et al.
2001) but their site of action has yet to be identified. The known
transcription factor binding sites have been summarised in Fig 1.4 A and B.
1.4.4 aGSU transcription
1.4.4a Pituitary Glycoprotein Hormone Basal Element
aGSU mRNA up-regulation by GnRH is mediated by the MAPK pathway
(Roberson 1995) and mobilisation of extracellular Ca2+ (Holdstock, Aylwin et
al. 1996). Sequence analysis of the aGSU promoter identified two regions
that are involved in GnRH regulated aGSU expression (Schoderbek,
Roberson et al. 1993), these have been designated as the pituitary
glycoprotein hormone basal element (PGBE) and the GnRH responsive
element (GnRH-RE). In addition to a SF-1 and Pitxl binding site, the PGBE
region contains two E-boxes aEBl and aEB2, at -51bp to -45bp and -21bp to
-16bp respectively, which can bind helix-loop-helix proteins. aEB2 can bind
upstream stimulatory factor (USF), which has been previously shown to up-
regulate SF-1 transcription (Harris and Mellon 1998) and is required for
maximal up-regulation of the aGSU promoter (Jackson, Gutierrez-Hartmann
et al. 1995). The transcription factors that bind to the PGBE are summarised
in Fig. 1.4A.
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1.4.4b GnRH Responsive Element
Further analysis of the GnRH-RE identified a core Ets binding site (GGAA),
which, when mutated, inhibits GnRH responsiveness of the aGSU promoter.
Experiments identified that Ets-2 could bind to this region and initiate a
GnRH response (Roberson 1995). Lhx2 has also been implicated in mediating
GnRH regulated transcription since it interacts with the Ets transcription
factor, and synergises up-regulation of aGSU expression (Glenn and Maurer
1999). Ca2+ mobilisation also induces an as yet unidentified protein, which
binds to a -420bp and -224bp region of the aGSU promoter and also up-
regulates the GnRH response (Holdstock, Aylwin et al. 1996). The up-
regulation of aGSU expression by different signalling mechanisms, therefore
ensures adequate amounts of aGSU over LH or FSH (l-subunits. The
transcription factors that bind to both the PGBE and the GnRH-RE are
summarised in Fig. 1.4B.
1.4.5 Steroid hormone regulation of transcription
In females, LH and FSH levels are also regulated by oestradiol. Animals that
were gonadectomised to remove the negative feedback effects of steroid
hormones, showed increased mRNA levels of LH(3, FSH(3, and aGSU
(Gharib, Bowers et al. 1986). Oestradiol was shown to inhibit transcription
of all three gonadotrophin subunits, specifically LH(3 (Shupnik, Gharib et al.
1988). Further experiments on normal, OVX and ovariectomised-oestradiol
replaced rats produced conflicting results. In the pituitaries of OVX rats
either left untreated or treated with oestradiol, LH|3 mRNA levels were
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increased in response to oestradiol. In the pituitaries of normal rats,
oestradiol treatment down-regulated LHp mRNA expression levels
(Shupnik, Gharib et al. 1989). However, a positive steroid response was
mediated by a region on the LH(I promoter which was able to bind the
oestrogen receptor (Shupnik, Weinmann et al. 1989). This region may be
responsible for the positive feedback of oestradiol on LH synthesis and
secretion during the preovulatory LH surge and may explain the divergent
effects seen in the pituitaries seen in the OVX, and non-OVX rats. Oestradiol
treatment of GnRH treated L(3T2 cells enhanced the mRNA levels of LH(3
and this was attributed to an increase in GnRH-R number (Turgeon, Kimura
et al. 1996). Oestradiol treatment of the hypogonadal mouse did not show
any significant increase in LH(3 or FSH(3 mRNA levels but did increase aGSU
mRNA levels, however the authors suggest that the increase in mRNA level
was not due to an increase in transcription rate (Stanley, Lyons et al. 1988).
In vivo studies in OVX mice suggested that the increase in FSH(3 mRNA and
FSH serum levels was not due to an increase in FSH(! transcription rate and
that inhibin may have a non-transcriptional role in regulating FSH|3 mRNA
levels (Dalkin, Knight et al. 1993). FSH(3 mRNA levels are also decreased in
response to oestradiol treatment, and a study has shown that oestradiol and
progesterone decrease steady state mRNA levels in ovine pituitary cultures
(Phillips, Lin et al. 1988). In vitro studies, using primary cultures of sheep
pituitaries has identified a region of the ovine FSH(1 promoter between
-105bp and -72bp, which can repress transcription when stimulated with
oestradiol. This repression is mediated by oestrogen receptor/protein
interactions with basal transcription factors (Miller and Miller 1996).
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1.5 LH and FSH secretion
1.5.1 Regulation of secretion
The gonadotrophs differentially secrete LH and FSH, in response to GnRH
through constitutive and regulated secretory pathways (Muyan,
Ryzmkiewicz et al. 1994). LH and FSH are normally packaged into separate
secretory granules and the LH containing granules are secreted mainly
through the regulated pathway, while the FSH containing granules are
secreted through the constitutive pathway (Farnworth 1995), however some
granules contain both LH and FSH. The granins are acidic proteins that are
found in endocrine secretory granules (Winkler and Fischer-Colbrie 1992)
and have been implicated as sorting proteins since they are present in the
secretory granules of gonadotrophs (Deftos 1991; Watanabe, Uchiyama et al.
1991). These granins are known as chromogranin A (CgA), chromogranin B
(CgB) and secretogranin II (Sgll), and may have a role in the regulated
secretion of gonadotrophins.
GnRH, after primary application, can alter the responsiveness of
gonadotrophs so that further treatment with GnRH induces greater LH
secretion. This is known as the priming effect (Aiyer, Chiappa et al. 1974;
Fink, Chiappa et al. 1976; Pickering and Fink 1979) and acts through the PKC
pathway that initiates the release of arachadonic acid via the up-regulation of
phospholipase A2 (Thomson, Johnson et al. 1994). In vitro treatment of
mouse pituitaries with GnRH induced this priming effect, secretory granules
were translocated to subplasmalemmal regions around the cell
circumference, which would allow greater LH release when the cells were
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further exposed to GnRH, (Lewis, Morris et al. 1986). This is thought to be
mediated by changes of the microfilaments of the cytoskeleton (Lewis,
Morris et al. 1985). Transmission electron microscopy (EM) of sheep
pituitaries throughout the oestrus cycle revealed that only granules between
130nm and 150nm in diameter migrated through the cytoplasm to the
plasma membrane close to blood vessels (these cells are described as being
polarised). The number of polarised cells increased throughout the follicular
phase so that during the LH surge, 90% of gonadotrophs were polarised.
After the LH surge, the gonadotrophs were almost devoid of LH granules,
those that remained were 300nm in diameter, demonstrating the preferential
exocytosis of the smaller granules (Currie and McNeilly 1995). This suggests
that the preovulatory LH surge is due to increased numbers of polarised
gonadotroph cells, rather than an increase in LH synthesis. This priming
effect is concomitant with an increase in GnRH-R numbers and mRNA levels
(Brooks, Crow et al. 1992), and is enhanced by oestradiol (Thomas and
Clarke 1997). The larger granules show immunoreactivity for LH, FSH and
CgA, however the smaller granules only contain LH and Sgll (Watanabe,
Uchiyama et al. 1991). Immunocytochemistry of gonadotrophs after
oestradiol treatment also identified that the polarised LH granules only
contained LH and Sgll (Thomas, Takahashi et al. 1998). This is evidence of a
role for Sgll in exocytosis of small LH granules at the LH surge.
Studies of granules within chromaffin cells has identified that out of 20000
granules, only 1000 are within lOnm of the plasma membrane (Steyer,
Horstmann et al. 1997). Actin may act as a barrier between the granules and
the plasma membrane. Investigation in cultured lactotrophs of female rats
identified that the F-actin network dissociated with the addition of
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secretagogues such as forskolin and the secretory granules moved to the
plasma membrane (Carbajal and Vitale 1997) possibly via myosin motor
activation (Mooseker and Cheney 1995). Inhibition of this dissociation
inhibited secretion of prolactin (Carbajal and Vitale 1997). Recently Ca2+ has
been shown to disassemble the F-actin network in GH3 cells, and
substantiates the hypothesis that F-actin acts as a barrier to exocytosis, and
postulates that Ca2+ directly controls cytoskeletal changes (Yoneda, Nishizaki
et al. 2000). Thus the actin barrier may have a role in the storage and
regulated secretion of LH granules by preventing premature secretion of LH
(Fig. 1.5.1).
FSH secretion is independent of GnRH (Farnworth 1995), but is regulated by
activin, which increases FSH secretion. Inhibin and follistatin, which also
inhibit FSHji transcription, regulate activin activity and hence secretion
(Schwall, Nikolics et al. 1988; Carroll, Corrigan et al. 1989). Additionally, FSH
synthesis appears to be closely linked to secretion after GnRH treatment
(Brooks, Crow et al. 1992). Polarisation of FSH granules to the plasma
membrane has not been shown, instead, the granules remain dispersed
throughout the cytosol (Thomas and Clarke 1997).
1.5.2 Exocytosis
Much of what is currently known about neuroendocrine exocytosis has been
shown in chromaffin cells. A number of key proteins, which have a role in
exocytosis have been identified. Rab3 is a member of a family of membrane
associated guanine nucleotide binding proteins with GTPase activity, that are























Fig. 1.5.1: Schematic representation of GnRH induced secretion including the signalling
pathways involved.
GnRH activates the GnRH receptor (GnRH-R), which activates the a subunit of the G
protein. This activates phospholipase C (PLC), which cleaves phosphoinositide 4,5
bisphosphate (PIP2), creating DAG and IP3. Both DAG and IP3 increase intracellular Ca2+
levels. This activates the Ca2+ dependent actin severing protein, which enables the granule
to migrate to the plasma membrane. The secretory granule then fuses with the membrane
and releases LH.
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(Novick and Brennwald 1993). GnRH stimulated exocytosis is dependent on
a Rab3 isoform, Rab3b (Tasaka, Masumoto et al. 1998), possibly by
interacting with membrane associated proteins (Lledo, Johannes et al. 1993;
Lledo, Johannes et al. 1994). These proteins include soluble n-ethylamide-
sensitive factor attachment protein receptors (SNARE), which are found on
vesicle membranes (vSNARE) and on target membranes (tSNARE). The two
SNAREs interact, establishing contact between the vesicle membrane and the
target membrane. These fuse and the contents of the vesicle are released,
after the binding of the fusion molecules n-ethylamide-sensitive factor (NSF)
and soluble n-ethylamide sensitive factor attachment proteins (SNAPs) to the
SNARE complex (Burgoyne and Morgan 1993). This is summarised in Fig.
1.5.2. Exocytosis is a calcium dependent response, which in gonadotrophs, is
released from intracellular Ca2+ stores, not from voltage activated
extracellular Ca2+influx (Tse, Tse et al. 1993; Tse and Tse 1999).
Currently, there has only been one report about exocytosis in the
gonadotroph cell-line L(3T2, which suggested that oestradiol increased the
exocytotic response by sensitising the fusion machinery (Thomas, Mellon et
al. 1996).
1.6 Summary
This chapter has described the physiological role of the gonadotrophins and
has highlighted the importance of regulated LH and FSH synthesis and
secretion. GnRH, a decapeptide released in pulses from the hypothalamus,
controls this regulation and has a number of targets within the gonadotroph.









Docking Assembly of Membrane fusion andFusion machinary Exocytosis
Fig. 1.5.2: A diagram showing the predicted mechanism of exocytosis in
neuroendocrine cells.
The vesicle SNARE (v-SNARE) docks with the target SNARE (t-SNARE),
which allows n-ethylamide sensitive factor (NSF) and soluble n-ethylamide
sensitive factor attachment proteins (SNAPs) to bind. These catalyse the
fusion of the vesicle membrane and the plasma membrane, converting
Rab-GTP to Rab-GDP.
This diagram is adapted from Molecular Biology of the Cell, 3rd edition,
Bruce Alberts.
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activates PKC, this then activates a number of other second messenger
pathways, some of which have been elucidated. They include the MAPK
cascade, JNK kinase cascade, and Ca2+ signalling. The LH(3, FSH(3 and aGSU
subunits are differentially regulated by different pulse frequencies and this
may be mediated by one of the pathways mentioned. The exact pathways
that regulate transcription of each of the gonadotrophin subunits are yet to
be defined. aGSU mRNA levels are increased by all frequencies of GnRH
pulses, this ensures that aGSU protein is synthesised in excess of both FSHp
and LFF(3 proteins. LHp mRNA is more tightly regulated, since up-regulation
only occurs with fast pulses of GnRH and FSHp mRNA is up-regulated by
slow pulses of GnRH. In fact, regulation of FSHp mRNA levels appears to be
mediated by the gonadal peptides activin, inhibin and follistatin. Inhibin and
follistatin, down-regulate FSHp mRNA levels and activin up-regulates
mRNA levels. These act through type I and type II activin receptors via
SMAD proteins, although there is evidence to suggest that inhibin can also
act through a betaglycan receptor. Differential regulation of transcription
occurs by binding of different transcription factors. Although a gonadotroph
specific transcription factor has yet to be identified, current evidence suggests
that a number of common transcription factors bind to the promoters of the
gonadotroph subunits in different combinations. GnRH regulated
transcription appears to be up-regulated by a different sub-set of
transcription factors, which again are not specific to gonadotrophs. GnRH
also controls secretion of FSH and LH. FSH is secreted through the
constitutive secretory pathway, and secretion is closely linked to
transcription. LH secretion however, seems to be dissociated from LHp
transcription and follows a Ca2+ dependent regulated secretory pathway.
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A large number of studies have contributed in understanding the
physiological roles of LH and FSH and how they are differentially regulated.
The evidence points to a complex mechanism of intracellular signalling
pathways and proteins that facilitate regulation of the gonadotrophins.
1.7 Aims of this Thesis
The main aim of these studies is to identify factors that are GnRH regulated,
with particular focus on factors that may be involved in regulating LH and
FSH synthesis and secretion. L|3T2 cells are a fully differentiated
gonadotroph cell-line that can synthesise and secrete LH and FSH. Therefore
L(TT2 cells have all the mechanisms required for regulating gonadotrophin
hormone biosynthesis and secretion. Since neither these mechanisms nor
the factors that are GnRH regulated are fully elucidated, differential display
RT-PCR (Liang and Pardee 1992) will be used to identify and isolate
differentially expressed mRNA transcripts from L(3T2 cells (Turgeon, Kimura
et al. 1996) that have been left untreated, or have been treated with GnRH.
The differentially regulated transcripts will then be cloned, sequenced,
identified and characterised. Using DD-RT-PCR, it is hoped that a profile of
GnRH regulated factors can be produced, that will add to the current
information available about the downstream effects of GnRH-R activation.
Full length clones of potential regulatory factors will then be used in
transfection assays to identify if they are involved in regulating
gonadotrophin subunit gene expression.
1.8 Layout of this Thesis
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Chapter 2 has two parts, chapter 2a will detail the general materials and
methodologies that were used throughout this project. Chapter 2b describes
the materials and methodologies employed in the differential display RT-
PCR technique, and the modifications made to this technique during the
project. It will be presented as a mini-results chapter. Chapter 3 and 4 are
the main results chapters. Chapter 3 describes the factors that were isolated
by DD-RT-PCR, and their initial characterisation. Chapter 4 describes the
results of further analysis of one of these factors, and its role in regulating
gonadotrophin gene expression. Chapter 5 is a general discussion of the
factors that have been identified, their possible roles in the gonadotroph, and
how these roles can be further elucidated in future studies.
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Chapter 2a:
General Materials and Methods
2.1 Introduction
This chapter describes the general molecular biology methods used, with a
separate section for Differential Display RT-PCR (Chapter 2b), and the
modifications made to this procedure. A complete list of suppliers can be
found in Appendix I. Control of Substances Hazardous to Health (COSHH)
safety guidelines for the handling of hazardous chemicals and bio-hazardous
materials were followed.
2.2 General Materials
General Chemicals were purchased from Merck-BDH (UK), Roche (UK) or
Sigma-Aldrich (UK), and were Analar grade. All water was double distilled
and deionised before autoclaving.
The tables below contain details of specialised materials, grouped into
general areas of methodology.
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NovaBlue Singles™ endAl hsdR17 (rK12" mK12+)
supE44 thi-1 recAl gyrA96
relAl lac [F' proA+B+
lacFZAM15::TnlO (TcR)]
Novagen (UK)
Luria Bertani (LB) Broth and Agar Anachem (UK)
Kanamycin Sigma-Aldrich (UK)
Ampicillin Sigma Aldrich (UK)




Isopropyl p-D-thiogalactopyranoside (IPTG) Roche (UK)
Miracloth Calbiochem (UK)
Ultracentrifuge tubes Kendro (UK)
Table 2.2b: Sources of clones and Vectors
Genetic Material Size of Plasmid Source
pcDNA 3 5.4kb Invitrogen (UK)
pA3LUC 6.36kb W.M. Wood (Denver,
USA)
pBluescript (SK+/-) 2.96kb Stratagene (UK)
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pGEM®-4 2.87kb Promega (FJK)
pTAL-Luc 5kb Clontech (UK)
pnlacF 6.3kb Jacques Peschon
(Seattle/US)
ppl786/pnlacF 8kb P. Brown (MRC)
dLH2/pnlacF 7kb P. Brown
dFFI5/pnlacF 6.9kb P. Brown
«480/pA3FUC 6.84kb P. Brown
al20/pA3FUC 6.48kb P. Brown
al09/pA3FUC 6.47kb P. Brown
FAA/pCEP 4 14.9kb H. van de Vrught
(Amersterdam)
pT7-Blue 2.89kb Novagen (UK)
pst-Blue-1 3.85kb Novagen (UK)
Table 2.2c: Molecular Biology
Kit /Reagent /Enzyme Supplier
Ready to Go ™ T4 DNA Eigase Amersham
Mobio Mini prep Cambio (UK)
Jet Star 5 mini prep AMS Biotechnology (UK)
Qiagen Maxiprep Qiagen (UK)
Miniprep Sigma (UK)
Big Dye Terminator II Applied Biosystems (UK)
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Direct Protect Lysate Ribonuclease
Protection Assay Kit
Ambion (UK)
T7 Sequencing Kit Amersham-Pharmacia (UK)
AGS Gold Taq Polymerase Hybaid (UK)
Extensor Hi-Fidelity PCR Master Mix ABGene (UK)
Perfectly Blunt Cloning Kit Novagen (UK)
First Strand cDNA Synthesis Kit Amersham Pharmacia (UK)
Hybond-N Amersham Pharmacia (UK)
Restriction Enzymes Roche (UK)
Shrimp Alkaline Phosphatase Roche (UK)
GTG Agarose FMC (UK)
Bio-Rad Protein Assay Bio-Rad (UK)
RNAzol ™ B AMS Biotechnology (UK)
HYBAID RECOVERY™ DNA
Purification Kit II protocol
Hybaid (UK)
T4 Polynucleotide Kinase Roche (UK)
Oligonucleotides Sigma-Genosys (UK)
Rediprime™ II random prime
labelling kit
Amersham-Pharmacia (UK)
abS a dATP lOOOCi/mmol Amersham-Pharmacia (UK)
32P a dCTP 3000Ci/mmol Amersham-Pharmacia (UK)





Table 2.2d: Mammalian Cell lines and materials
L(3T2 mouse gonadotroph cells P. Mellon (San Diego, USA)
aT3-l cells P. Mellon (San Diego, USA)
Fugene™ Roche (UK)
GenePorter™ Gene Therapy Systems (UK)
Dulbecco's Modified Eagle's Media
(DMEM)
Sigma (UK)
Phosphate Buffered Saline (PBS) Sigma (UK)
Dimethyl sulfoxide (DMSO) Sigma (UK)
Trypsin Sigma (UK)
Penicillin/Streptomycin Sigma (UK)
Fetal Calf Serum (FCS) Sigma (UK)
Matrigel™ Becton Dickinson Labware (UK)
Culture flasks 25cm2 and 75cm2 Costar (UK)




Cell scrapers (rubber policeman) Nalge Nunc (UK)
2.3 General Molecular Biology Methods
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2.3.1 Restriction Endonuclease Digestion
Restriction endonuclease digests were set up according to manufacturer's
instructions, using supplied buffers, ensuring that the volume of enzyme did
not exceed 10% (v/v) of the total reaction volume to minimise star activity,
particularly when multiple digests were performed. In general, the digests
were performed with 2-3 units of restriction enzyme per pg of DNA, and
were digested for at least 2 hours.
2.3.2 Agarose Gel Electrophoresis
Agarose gel electrophoresis was used to resolve and analyse different sizes
of DNA fragments after restriction endonuclease digestion or polymerase
chain reaction (PCR). Tris-borate electrophoresis buffer (lxTBE pH 8.3;
90mM Tris, 90mM boric acid, 20mM EDTA pH8) was used for separation of
small DNA fragments (typically <1000bp), and Tris-acetate electrophoresis
buffer (lxTAE pH 7.7: 40mM Tris.Acetate, 2mM EDTA) was used for
separation of large DNA fragments (>1000bp). The percentage agarose
varied from 0.8% to 2% (w/v) and the gels were electrophoresed at 8-
lOV/cm. Ethidium bromide was added at a final concentration of 0.5pg/pl.
The agarose gel was trans-illuminated with low wavelength (302nm) UV
light (UV transilluminator 2000, BioRad), to visualise the DNA.
2.3.3 Native Polyacrylamide gel electrophoresis (PAGE)
This technique was used to distinguish the cloning of a 45bp oligonucleotide
into a plasmid. Colonies were picked and mini preps grown from agar
plates. The DNA was extracted, and 20pl was digested with Banl (Roche). A
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12% acrylamide (19:1 acrylamide:bis-acrylamide) gel was prepared
(Sambrook et al 1989) and the complete digest was loaded and
electrophoresed at 12V/ cm for 2 hours. The gel was stained with ethidium
bromide (10pg/ml) in lxTBE buffer, for 10 minutes, and destained in water
for 5 minutes. The bands were visualised under UV light, and the positive
clones identified.
2.3.4 Purification of restriction digested DNA
Agarose gels were used to fractionate DNA prior to purification. At least
30pg of plasmid DNA was digested overnight in a lOOpl reaction volume
with the specific enzymes to generate the required fragment. A small
fraction of the reaction was electrophoresed on an 8cm agarose gel to check
if the plasmid had cut to completion. The reaction was frozen to inactivate
the enzyme, and loaded onto a 20cm gel with either 6x Orange G dye (15%
Ficoll, 0.05% SDS, 20mM EDTA ph8, 0.15% Orange G), or lOx DNA loading
dye (50% glycerol, 0.42% bromophenol blue, 0.4% xylene cyanol FF). The gel
was electrophoresed overnight at 1.5V/cm. The fragment was visualised by
ethidium bromide staining as described earlier, and the band of interest was
cut from the gel with a sterile scalpel blade, and purified from the agarose
following the Hybaid recovery DNA purification kit II protocol (Hybaid).
2.3.5 Purification of annealed oligonucleotides on a native
PAGE gel
The reaction was set up so that the final annealed oligonucleotide
concentration was lpg/pi (5pl of each oligonucleotide (4pg/pi), 2pl annealing
buffer (140mM Tris pH 7.6, 14mM MgCl^ lOmM DTT), 8pl water to give a
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final reaction volume of 20pl). The oligonucleotides were heated at 100°C for
10 minutes and allowed to cool slowly back to room temperature. The
annealed oligonucleotide was loaded onto a 12% acrylamide (19:1
acrylamide:bisacrylamide) gel, run at 160V for 2 hours and stained with
10pg/ pi ethidium bromide. The oligonucleotide was excised from the gel and
placed into 300pl of DNA elution buffer (20mM Tris.HCl pH 8, 400mM NaCl,
2mM EDTA pH8, 0.5% SDS) and incubated overnight at 37°C. After adding
700pl of 100% ethanol and lpl of 10mg/ml dextran sulphate, the eluted DNA
was precipitated at -70°C for 30 minutes. The DNA was pelleted by
centrifugation at 13000 rpm for 20 minutes, and reconstituted in lOOpl STE
(0.3mM NaCl, lOmM Tris pH7.4, ImM EDTA pH 8). The DNA was
quantified spectrophotometrically (see section 2.3.8).
2.3.6 Deproteination of DNA by Phenol Chloroform Extraction
Proteins were removed from DNA by phenol chloroform extraction. A half
volume of Tris-HCl (pH7.4) saturated phenol was added to the DNA sample,
and mixed vigorously. Then a half volume of chloroform was added, and
mixed. The tube was centrifuged at 13000rpm in a bench top centrifuge for
10 minutes to separate the layers, and the top layer was transferred to a
fresh tube. One volume of chloroform was added, to remove the last traces
of phenol, and the tube was vortexed and centrifuged again. The top layer
was transferred to another fresh tube ready for ethanol precipitation.
2.3.7 Ethanol Precipitation of Nucleic Acids
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Ethanol precipitation was used to purify and concentrate the DNA or RNA.
Typically, 1/10 of the sample volume of 3M sodium acetate pH 5, and 2.5 to 3
times the sample volume of 100% ethanol was added to the DNA. This was
mixed and stored at either -20°C for >1 hour or -70°C for >20 minutes. If
the DNA sample was dilute, a co-precipitant of lpl of lOmg/ml dextran
sulphate, or See-DNA (Amersham) was added. Yeast tRNA (5mg/ml,
Ambion) was used to co-precipitate RNA. The sample was then centrifuged
at 13000rpm for 10-15 minutes to pellet the nucleic acid, then washed with
70% ethanol (optional), re-spun, and allowed to air dry. DNA was re-
suspended in an appropriate volume of TE (lOmM Tris pH7.4, ImM EDTA
pH 8), and RNA was re-suspended in DEPC treated water.
1.8.1 Spectrophotometrical Analysis of Nucleic Acids
Spectrophotometric analysis was performed using GeneQuant™
(Amersham-Pharmacia). At 260nm, an OD reading of 1 is equivalent to
50pg/ml of double-stranded DNA or 40|ig/ml of RNA or single-stranded
DNA. An OD reading at 280nm indicates the presence of other high
molecular weight molecules such as proteins. A high quality DNA or RNA
preparation should possess a 260nm:280nm ratio of 1.8 or 2 respectively.
2.3.9 Cloning
2.3.9a Dephosphorylation of linearised plasmid DNA
To prevent self-ligation of linearised plasmid, and hence a high background
of vector compared to clones of interest, shrimp alkaline phosphatase
(Roche) was used, as per manufacturer's instructions.
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2.3.9b Ligation of DNA fragments into plasmid DNA vectors
Ligation of DNA and vector with compatible overhanging DNA ends was
performed using the Ready-to-go™ ligation tubes (Amersham-Pharmacia).
Briefly, the insert and plasmid DNA were added to the ligation tubes at a
ratio of 3:1 ends. The amount of insert required depended on its size, and
the following formula was used to work out how much insert was required
for ligation to lOOng of plasmid:
[(lOOng of vector x kb size of insert)/kb size of vector] x 3
= ng of insert
Blunt ended inserts were either generated by restricting the DNA with
enzymes that produce blunt ends, or by Klenow (DNA polymerase I large
fragment) treatment (Roche), or T4 DNA polymerase treatment (Roche).
Klenow treatment (Anderson, S 1980) and T4 DNA polymerase treatment
(Challberg, M.D. and Englund, P.T. 1980) were carried out as per
manufacturer's instruction. PCR fragments were cloned using the perfectly
blunt cloning kit, (Novagen). Briefly, 0.05pmol of insert was added to 5pl of
end conversion mix and made up to lOpl with double distilled water. The
reaction was incubated at 22°C for 15 minutes, then lpl of blunt vector
(pstBLUE-1) and lpl of T4 DNA ligase was added to the end conversion
reaction and incubated at 22°C for 15 minutes.
2.3.9c Transformation of Competent Cells
Chemically competent cells were thawed on ice and gently re-suspended,
before adding 2pl of ligation reaction. The cells were incubated on ice for 15
minutes and heat shock treated at 42°C for 30 seconds before being returned
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to ice for two minutes. A 250pl volume of SOC medium (GibcoBRL) was
added, and the cells were incubated at 37°C with shaking for 30 minutes.
Between 50pl and 250pi were plated onto Luria-Bertani-agar (LB-agar) plates,
and incubated overnight at 37°C.
Transformation efficiency was calculated by transforming a known quantity
of a purified supercoiled plasmid DNA. The number of colonies formed
(CFU) were counted and the transformation efficiency was calculated using
the following formula:
Number of colony forming units(CFU) x 103ng x final dilution plated
ng of supercoiled vector plated lpg
= transformation efficiency (cfu/ ug)
2.3.9d Preparation of LB-Agar Plates
LB-Agar (Anachem) was prepared as per manufacturer's instructions, and
autoclaved. The LB-Agar was melted in a microwave, and allowed to cool to
60°C before addition of ampicillin (lOOpg/ml) or kanamycin (30pg/ml)
depending on the plasmid selection marker. The plates were prepared by
pouring 30ml of the LB-Agar into 7.5cm petri dishes and were left to set. For
blue/white colour selection lOOpl of 20mg/ml X-Gal, (Roche) and lOOpl 0.1M
IPTG (Roche) were spread over the plates and allowed to soak into the agar,
before transformations were plated out.
2.3.10 Propagation of DNA Clones and Their Purification
2.3.10a Small Scale Purification of Plasmid DNA
Colonies were picked from LB-agar plates and transferred to 5ml of LB-
broth containing ampicillin or kanamycin. These were grown overnight at
37°C with vigorous shaking. The DNA was extracted using either the Mobio
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mini-prep kit (Cambio), Mini-prep kit (Sigma), or jetSTAR™ mini-prep kit
(AMS Biotechnology) according to manufacturers' protocol. Typically, a
yield of 0.5pg to 20pg was obtained depending on the mini-preparation kit
used. Positive plasmid clones were identified by restriction digest, and by
automatic DNA sequencing (refer to section 2.3.11c). These positives were
stored as glycerol stocks of bacterial cultures.
2.3.10b Glycerol stocks of bacterial cultures
Glycerol stocks were made by adding 500pl of bacterial culture, grown to
stationary phase, to 500pl of freezing mix (40% glycerol, lOmM MgS04 0.5%
NaCl). These were inverted to mix, and stored in the -70°C freezer.
2.3.10c Large scale purification of plasmid DNA
2.3.10ci Qiagen column method
This method was used to isolate >lmg of plasmid DNA rapidly. 100ml of LB-
broth with either ampicillin or kanamycin, was seeded from the mini-
preparation and allowed to grow overnight at 37°C with shaking. The
Qiagen protocol was followed, with a final phenol chloroform step added
after propan-2-ol precipitation of the DNA.
2.3.10cii Equilibrium Centrifugation of Plasmid DNA in CsCl ethidium
bromide gradients
This method was used to generate about 3mg of high quality, supercoiled
DNA to be used in applications such as transfections. It involves DNA
extraction by the alkaline lysis method (Birnboim, H.C., Doly, J. 1979) and
subsequent plasmid purification by centrifugation.
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A small-scale bacterial culture, was seeded into 500ml of LB-broth (Anachem,
prepared as per manufacturer's instructions), with suitable antibiotic added,
and grown overnight at 37°C with shaking. The bacterial culture was
harvested into two 250ml centrifuge bottles, and centrifuged at 6000rpm in
the J2-21 Beckman centrifuge, with the JA-14 rotor at 4°C for 10 minutes.
The broth was decanted into 5-10% Presept (Johnson & Johnson) and the
bacterial pellets re-suspended in 36ml of solution PI (50mM Glucose, 25mM
Tris-HCl pH 8, lOmM EDTA). Addition of 36ml of solution P2 (0.2M NaOH,
1% w/v SDS), and incubation at room temperature for 5 minutes, was
followed by addition of 36ml of chilled solution P3 (3M KAc pH 4.8). This
was incubated on ice for 15 minutes, then centrifuged at 7000rpm, at 4°C for
15 minutes. The supernatant was filtered through Miracloth (Camlab) into
clean centrifuge bottles and 67ml of propan-2-ol (0.7 volumes) was added.
The DNA was pelleted by centrifugation at 7000rpm at 4°C for 15 minutes,
the pellet re-suspended in 4ml TE, and transferred to 15ml culture tubes
(Elkay).
The plasmid DNA was phenol chloroform extracted, and ethanol
precipitated. The DNA was centrifuged using a JA-20.1 rotor at 8000rpm at
4°C for 5 minutes and washed with 70% ethanol. The centrifugation step
was repeated and the ethanol removed. The DNA pellet was air-dried, and
re-suspended in 2ml of TE.
To prepare the CsCl gradient, 11.2ml distilled water was pipetted into a 15ml
orange screw cap (Costar) tube, and the meniscus was marked on the tube.
The water was discarded, and 9.46g of CsCl (Roche) was added with all the
plasmid DNA and 500pl of 10mg/ml ethidium bromide was added. The
volume was made up to the meniscus mark with TE and pipetted into two
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Sorvall ultracentrifugation tubes. The tubes were balanced, and
centrifugation was carried out at 50000rpm in the Sorvall UltraPro 80 in a TV
1665 upright rotor (Sorvall) at 20°C for 16 hours.
The bands ofDNA were visualised using long wavelength (302nm) UV light.
An 18 gauge needle attached to a 2ml syringe, was used to draw out the
plasmid band which was transferred to a 15ml screw cap tube (Costar).
Ethidium bromide was removed by adding one volume of CsCl saturated
propan-2-ol, the tube was shaken and the upper phase was removed and
discarded. This was repeated until both phases were clear and colourless.
The DNA was ethanol precipitated at -20°C for 1 hour.
The tubes were centrifuged at 8000rpm for 10 minutes, and the supernatant
removed. The pellet was washed with 500pl 70% ethanol and re-centrifuged.
The ethanol was removed, and the pellet allowed to air-dry before re-
suspending in 500pl TE and transferred to a 1.5ml eppendorf tube. The DNA
was phenol chloroform extracted, and transferred to a fresh eppendorf tube.
The DNA was ethanol precipitated centrifuged at 13000rpm, the supernatant
was discarded, and the pellet allowed to air-dry. The final pellet was re-
suspended in 1ml of low TE (lOmM Tris-HCl pH 8, O.OlmM EDTA) and
quantified.
2.3.11 DNA sequencing
2.3.11a Manual DNA sequencing
Manual sequencing was performed using the Pharmacia T7 sequencing kit,
and 35S a dATP (lOOOCi/mmol) (Amersham-Pharmacia). Briefly 2pg of CsCl
purified DNA, or 8pl of mini-prep DNA was used. 2pl 2M NaOH (freshly
made up) was added, and the volume increased to lOpl with water. The
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sample was ethanol precipitated with 6pl 3M sodium acetate pH 5.4, 60pl
ethanol, arid 7pl of water and reconstituted in lOpl of water before annealing
with lpl of 40pg/pi of primer, 2pl of annealing buffer, and lpl water at 37°C
for 20 minutes, and allowed to cool back to room temperature. Tubes were
labelled A, C, G, T, and 2.5pl of the relevant dideoxy terminator was added
to the relevant tube. The enzyme premix was prepared (for each tube, 2pl
enzyme dilution buffer, 0.35ul T7 DNA polymerase, lpl water, 3pi labelling
mix A, and lpl 35S a dATP was required), and kept on ice. A 6pl aliquot of
the premix was added to the annealed template and primer and incubated at
room temperature for 5 minutes. The dideoxy sequencing terminators were
warmed to 37°C, before 4.5pl of the labelling reaction was added to each of
the sequence terminators, and incubated for 5 minutes at 37°C. Stop
solution, (5pl) was added and the sample stored on ice until required. Just
before loading, the samples were heated to 100°C, and 2pl were loaded onto
a 6% /7M urea denaturing acrylamide (19:1 acrylamide:bis-acrylamide) gel.
2.3.11b Denaturing Acrylamide gel electrophoresis
The sequencing plates (Bio-Rad) were cleaned thoroughly with Decon 90,
distilled water, and polished with ethanol. The back plate was siliconised
with Glass Shield (Genomyx). A 6%/7M urea denaturing (19:1
acrylamide:bis-acrylamide) acrylamide gel was prepared, polymerised with
300pl 10% ammonium persulphate (APS) and 30pl TEMED, and poured. The
samples were heated to 80°C before 2pl was loaded and electrophoresed for
2 hours at 60W. The acrylamide gel was fixed in 10% acetic acid and dried on
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a gel drier, at 80°C for 1 hour. The gel was exposed to Kodak AR
autoradiographic film overnight.
2.3.11c Automatic DNA sequencing
This method was performed using the ABI BigDye™ terminator kit. The
PCR reaction was set up according to the user protocol, and was carried out
using 25 cycles of denaturation at 96°C for 30 seconds, followed by annealing
at 50°C for 15 seconds, and extension at 60°C for 4 minutes, finishing with
indefinite cooling at 4°C. To precipitate the DNA, 16pl of water and 64pl of
95% ethanol were added. After 15 minutes at room temperature, the
samples were centrifuged at 13000 rpm for 20 minutes, the supernatant
removed and the DNA pellet air dried, then reconstituted in 4gl loading
buffer (5:1 deionised formamide, 25mM EDTA pH8). A 12%/8M urea
denaturing (19:1 acrylamide:bis-scrylamide) acrylamide gel was prepared
and poured. The sample was heated to 100°C before loading onto the gel in
alternate lanes and electrophoresed on an ABI 373A sequencer.
2.3.12 Southern blotting of genomic DNA
2.3.12a Restriction digest of genomic DNA and agarose gel
electrophoresis
Hindlll and BamHl (Roche) was used to digest 20pl of mouse genomic DNA
overnight at 37°C in a total digest volume of 200pl. Approximately lOgg of
this restricted DNA was loaded onto a 14cm 0.8% lxTAE agarose gel, with
lOpl of lpg/pl of bacteriophage lambda DNA restricted with Hindlll as a size
marker. The gel was electrophoresed at 2V/ cm overnight.
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2.3.12b Depurination, and denaturing of DNA in an agarose gel
The gel was stained with lx TAE running buffer containing 0.5pg/pi
ethidium bromide for 10 minutes, and destained for 20 minutes in fresh Ix
TAE running buffer. To aid transfer of DNA onto the Hybond-N nylon
membrane (Amersham-Pharmacia), the DNA was treated with 0.2N
hydrochloric acid for 10 minutes, then immersed in denaturing solution
(1.5M NaCl, 0.5N NaOH) for 45 minutes, rinsed with distilled water and
neutralised with neutralisation solution (1.5M NaCl, 1M Tris pH 7.4) for 30
minutes, this was discarded and fresh solution added for a further 15
minutes.
2.3.12c Transfer of nucleic acid to a nylon membrane
A sheet of Hybond-N (Amersham-Pharmacia) and 3 pieces of 3MM
(Shleicher and Schuel) were cut to the size of the gel. A further two pieces of
3MM were cut length-ways to act as a wick. A glass dish was filled to half
way with 20x SSC (0.3M sodium citrate, 3M NaCl) and a platform was made
over this reservoir. The long pieces of 3MM were soaked in 20xSSC and
placed on the platform, with their ends in the reservoir. The gel was placed
on the wick and the gel edges were surrounded with Saran wrap. The
Hybond-N was pre-soaked in 20x SSC and was placed on top of the gel,
followed by the pre-soaked pieces of 3MM. A 5cm stack of absorbent towels
were placed on top of the 3MM, with a glass plate and a weight balanced on
the stack. During the first hour of transfer, the paper towels were changed
every 15 minutes, then the transfer was left to proceed overnight.
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2.3.12d Cross-linking the DNA to the membrane and storage
A piece of 3MM was cut slightly larger than the gel and soaked in 20x SSC
and placed on a bed of clingfilm. The transfer apparatus was dismantled.
Before removing the membrane from the gel, a small cut was taken from the
right hand corner and the wells marked with a pencil. The membrane was
removed from the gel, inverted 180° and placed on the wet 3MM, so that the
DNA side faced upwards. The membrane was cross-linked using an UV
cross-linker (Spectrolinker™ XL-1000, Spectronic corporation), washed
gently in 20x SSC, and the excess liquid removed. The membrane was
wrapped in Saran wrap, and stored at 4°C until required.
2.3.13 Guidelines for working with RNA
All non-disposable glass was baked at 200°C and where possible, unopened
disposable plastic-ware was used. Water was treated with 1/100 volume
diethyl pyrocarbonate (DEPC, Sigma), left overnight, and autoclaved 3 times
to remove all traces of DEPC. All solutions for RNA use were prepared
using DEPC treated water.
2.3.14 RNA extraction
RNA from LPT2 cells was extracted using the protocol supplied with RNAzol
B (AMS Biotechnology) based on the method published by Chomczynski
and Sacchi (1987). Briefly, the cells were washed twice with cold PBS and an
appropriate volume of RNAzol B was added. The mix was scraped using a
rubber-policeman (Nalge Nunc) into either 1.5ml eppendorf tubes or 15ml
blue cap culture tubes (Elkay), 0.2 volumes of chloroform was added, the
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tubes were mixed vigorously and incubated on ice for 5 minutes. The
samples were centrifuged at 13000 rpm for 15 minutes/ the top phase was
removed to a fresh tube, and an equal volume of propan-2-ol was added.
The tubes were capped, inverted to mix, then incubated on ice for 15 minutes
before being centrifuged at 13000 rpm at 4°C for 15 minutes. The pellet was
washed in 75% ethanol, centrifuged at 8000 rpm, and reconstituted in an
appropriate volume of DEPC water and spectrophotometrically quantified
(refer to section 2.3.8). The sample was then either stored under ethanol or
frozen, at -70°C.
2.3.15 Preparation of cultured cell lysate for ribonuclease
protection assays
Cells were washed twice in cold PBS before 1ml per 1 xlO7 cells of Direct
Protect™ Lysis buffer (Ambion, AMS) was added to the cells, and scraped
with a rubber policeman into appropriate sized tubes. The lysate was then
drawn up and down a thin gauge needle to shear the DNA and stored at -
70°C until required.
2.3.16 Reverse Transcriptase Polymerase Chain Reaction
First strand cDNAs were generated using the first strand cDNA synthesis kit
(Amersham-Pharmacia) for subsequent differential display and PCR analysis.
A 5pg aliquot of total RNA was pipetted into an eppendorf tube and brought
up to a total volume of 8pl with DEPC treated water. The RNA was
denatured at 65°C for 10 minutes, and chilled on ice. Into a fresh 1.5ml
eppendorf tube, 5pl of bulk first strand mix was added with the heat-
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denatured RNA, and lpl of dithiothreitol (DTT), and dT12VN primer (where
V = A, G, C, T and N = A, G, C, 24pM, 8pM each of N). The sample was
pipetted to mix, and incubated at 37°C for 1 hour. The subsequent cDNA was
aliquoted as 2pl aliquots into labelled 0.5pl eppendorf tubes.
2.3.17 Northern blotting of total RNA
2.3.17a Agarose gel electrophoresis under denaturing conditions
Agarose, (1.5% w/v) was melted in lxMOPS [20mM MOPS (3N-Morpholino
propanesulfonic acid), ImM EDTA pH8, 5mM sodium acetate pH 7] buffer.
The gel was allowed to cool to 60°C, before 17ml of formaldehyde was
added, per 100ml of gel.
The RNA was denatured at 65°C for 5 minutes in 38pl of denaturing buffer
(25pl formamide, 5pi lOxMOPS buffer, 8pl formaldehyde) per 12pi RNA.
This was snap cooled on ice, and lOx RNA loading dye solution added (50%
(v/v) glycerol, O.lmg/ml bromophenol blue). This was loaded onto the gel
including a control lane of 5pg total RNA, and electrophoresed in lxMOPS
buffer at 1.5V/cm overnight.
2.3.17b Transfer of RNA to nylon membranes
The transfer apparatus was exactly the same as the one used for DNA
transfer described in section 2.3.12c except, the nylon membrane and the 3
pieces of 3MM were soaked in 3x SSC. Before the nylon membrane was
placed on the gel, the control lane was cut off, using a sterile scalpel. This
was stained with lxMOPS running buffer containing 0.5pg/pi ethidium
bromide to visualise the ribosomal RNA bands of 18S and 28S rRNA. After
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overnight transfer, the RNA was cross-linked to the membrane as before
(section 2.3.12d), gently washed in 3x SSC, and stored in Saran wrap at 4°C.
2.3.17c Preparation of DNA probes
The DNA probes were digested from plasmid DNA, and separated by gel
electrophoresis on a 2-4% low melting agarose gel. This was melted at 37°C,
and a small aliquot was run on a standard agarose gel for quantification. The
DNA was not extracted from the gel.
2.3.17d Radioactive labelling of DNA probes
DNA probes were radiolabelled using the Rediprime™ II random labelling
kit (Amersham-Pharmacia), and these were hybridised to both Southern and
Northern blots. Approximately 25-30ng of the DNA probe was made up to
45pl with TE, heated to 100°C for 5 minutes, cooled to 37°C and added to the
Rediprime™ tube. Then 5pl of 32P adCTP (3000ci/mmol, Amersham-
Pharmacia) was added, and incubated at 37°C for 30 minutes. A 2pl aliquot
of the reaction was pipetted onto glass filter paper (GFP), washed three times
in 5% TCA (tri-chloroacetic acid)/2mM PPi (pyrophosphate), and once in
100% ethanol. The GFP was placed in a scintillation vial and counted in a
beta-counter (1450 Microbeta Trilux (Wallac)), using the Cherenkov counting
protocol. The resultant figure was halved and the specific activity calculated;
Cpm (value given by the counter/2) x mass of DNA used x 3 = specific
activity/ pgDNA
After pre-hybridising the membrane (see below), the radiolabelled DNA
probe was denatured with 250pl 2M NaOH at 37°C for 5 minutes, then 700pl
of water and 50pl of 0.05M EDTA were added.
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2.3.17e Hybridisation of radiolabeled probe to membrane
The membrane was pre-hybridised for 10 minutes in hybridisation tubes
(HB-OV-BM, Hybaid) with hybridisation buffer (0.5M NaP04 pH 7.2, ImM
EDTA pH 8, 7% SDS, 15% (v/v) formamide, 1% (w/v) BSA) that was pre¬
heated to 65°C. This buffer was decanted, and fresh buffer added with the
radiolabeled probe. The hybridisation was rotated overnight at 65°C. After
hybridisation, the membrane was washed in pre-heated wash solution
(2xSSC/0.1%SDS) 3x for 20 minutes. The membrane was then removed and
wrapped in Saran wrap.
2.3.17f Detection of the hybridised probe
The membrane was fixed in a Phosphoimage cassette and exposed for 2 to 7
days. The image was then scanned using a Phosphoimager (Storm 860,
Molecular Dynamics).
2.3.17g Stripping Northern blots
To enable the nylon membrane to be re-probed (e.g. 18S, for quantification),
it was bathed in boiling 0.1% SDS solution. This was allowed to cool, with
gentle agitation, back to room temperature. The membrane was re-exposed
in a phosphoimage cassette, to ensure that all the hybridising probe had
been removed.
2.3.18 Ribonuclease Protection Assays
2.3.18a Radiolabelling in vitro transcribed RNA
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The template DNA was transcribed in the anti-sense orientation, usually with
T7 RNA polymerase, and in general, did not exceeded 350bp in length.
MAXIscript™ Invitro transcription kit (AMS, Ambion) was used to make the
RNA probes. Template was linearised, phenol chloroform extracted, ethanol
precipitated and re-constituted in DEPC treated water at a concentration of
lpg/pi. The reaction was set up at room temperature, with enough DEPC
treated water to make a final volume of 20pl. Then, 2pl lOx transcription
buffer, lpl lOmM NTPs (excluding UTP), lpg linearised DNA, 2.5pl 32P y UTP
(NEN, 800Ci/mmol), and 2pl T7 or SP6 polymerase was added. The control
DNA template was supplied with the kit, and was either glyceraldehyde-6-
phosphate dehydrogenase (GAPDH), or 18s ribosomal RNA (18s). The
reaction was modified to include, lpl of cold ImM, or lOmM UTP for the
GAPDH, and 18s reactions respectively and 1.25pl of the radionucleotide was
added to the GAPDH reaction, and lpl of a 1:40 dilution of the
radionucleotide was added to the 18S reaction. All reactions were incubated
at 37°C for 1 hour, before addition of lpl of RNase free DNasel, and the
incubation continued at 37°C for 15 minutes. The reaction was stopped by
the addition of 20pl of RNase free formamide dye. This was heated to 90°C
for 2 minutes, and loaded onto a 5% acrylamide (19:1 acrylamide:bis-
acrylamide), 8M urea gel. The gel was electrophoresed at 12.5V/cm for 1.5
hours using a Protean II xi cell electrophoresis tank (BioRad). The radio-
labelled bands were cut out of the gel, and the gel fragment was transferred
to 300pi of RNA elution buffer (0.5M NH4OAC, ImM EDTA pH 8, 0.1% SDS)
and incubated overnight at 37°C. The lOObp ladder (supplied in the kit) was
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transcribed and radio-labelled using the same reaction conditions as the
GAPDH probe, however it was purified using a Chromaspin 10 column
(Clontech) as per manufacturers instructions.
After incubation overnight, an equal volume of Tris-HCl pH 8 saturated
phenol was added, the tubes were vortexed and centrifuged at 13000 rpm for
3 minutes. The top phase was removed to a fresh tube, and RNase free 100%
ethanol, with lpl of yeast tRNA ( 5pg/pl AMS, Ambion) was added. The
RNA probes were precipitated at -20°C for 30 minutes, centrifuged at 13000
rpm for 5 minutes, the ethanol decanted, and the pellet washed with 80%
ethanol. The pellet was re-suspended in 50-100pl Direct Protect™ lysis
buffer, then 2pl was pipetted onto GFP, and Cherenkov counted on a
betacounter (Wallac) as already described (section 2.3.17d). The cpm values
were used to calculate the amount of probe required for the hybridisation.
2.3.18b RNase Protection Assay
The final reaction volume was 50pl and the hybridisations were set up as
follows: test probes were added at 1x10s cpm/tube; and the control probes
GAPDH and 18s were added at 6xl04 cpm/tube and lxlO4 cpm respectively.
L(3T2 cell lysate was added and the volume made up to 50pl with Direct
Protect ™ lysis buffer. The hybridisations were incubated overnight at 37°C.
The next day, a RNase master mix was prepared (lOpl RNase cocktail, 50pl
lOx RNase digestion buffer, and 440pl water) and added to each
hybridisation. This was inverted and incubated at 37°C for 30 minutes, then
20pl of 10% (w/v) sarcosine and lOpl of 20mg/ml proteinase K were added.
The tubes were vortexed, and incubated at 37°C for 30 minutes. The RNA
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was precipitated by adding 500pl of propan-2-ol and incubated at -20°C for
30 minutes. The samples were centrifuged at 13000rpm for 15 minutes, the
supernatant decanted, and the tubes re-spun for a further 4 minutes. The
excess supernatant was pipetted off, and lOpl of formamide dye was added.
The pellets were re-suspended by vortexing, heated to 100°C for 2 minutes,
and loaded onto a 5% acrylamide (19:1 acrylamide : bis-acrylamide) /8M urea
gel. In addition, lOOOcpm each of the unhybridised RNA probes, and
lOOOcpm of marker in lOpl of dye were also loaded onto the gel. The gel was
electrophoresed at 12.5V/cm for 3 hours, fixed in 10% (v/v) acetic acid,
transferred onto 3MM paper and dried at 80°C on a gel drier. The gel was
exposed to a Phosphor screen for over 48 hours, and scanned into a
Phosphoimager (Molecular Dynamics). The bands were quantified using the
ImageQuant (Molecular Dynamics) and Excel (Microsoft) packages.
2.4 Mammalian Cell Culture
2.4.1 General notes
Dulbecco's Modified Eagle's Medium (DMEM, Sigma) which contained 10%
(v/v) Fetal Calf Serum (FCS, Sigma) and 1% (v/v) Penicillin/Streptomycin
(Pen/Strep, Sigma) was used, and will hereafter be described as DMEM. All
solutions used were pre-heated to 37°C.
2.4.2 Cell lines used
The cell lines used, were HeLa cells (ECACC), L(3T2 cells and aT3-l cells. The
LpT2 (Turgeon et al 1996) and aT3-l (Wendle et al 1990) transformed cell
lines were both derived by in vivo transformation and are of gonadotroph
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lineage. The aT3-l cells correspond to an earlier developmental age mouse
pituitary embryonic age (el2-13.5) than L(TT2 cells (el6.5). Therefore, cxT3-l
cells only synthesise and secrete aGSU, whereas L(3T2 cells can synthesise
and secrete aGSU and both LH and FSH (3-subunits (Turgeon et al 1996, Low
et al 2000) and both cell-lines are responsive to GnRH.
2.4.3 Coating of culture flasks with Matrigel
All cell culture flasks (Costar), and 12 well plates (Costar/Nalgene) were
coated with a 1/30 dilution of a basement membrane matrix (Matrigel™
Becton Dickinson Labware). The Matrigel™ was thawed overnight on ice, as
the matrigel solidifies above 4°C, and 200pl were aliquoted into pre-chilled
cryotubes (Nalge Nunc) and stored at -20°C. The Matrigel™ was used at a
1/30 dilution, so an aliquot was thawed on ice for 2 hours, and added to
5.8ml of cold phosphate buffered saline (PBS, Sigma) in a 15ml blue capped
culture tube (Elkay), then aliquoted into 2.5ml aliquots, and stored in 5ml
culture tubes at -20°C. To coat flasks, Matrigel™ was pipetted onto the base
of the flasks or plates to be used, ensuring the whole area was covered,
excess Matrigel™ was removed, and the flasks and/or plates were allowed
to air-dry.
2.4.4 Resuscitation of Cell lines
Cells were removed from liquid nitrogen, and placed on ice. They were
thawed by adding 500gl of pre-warmed DMEM (Sigma), then transferred
into a pre-coated 25cm2 culture flask (Costar) containing 4mls of DMEM.
Resuscitated EleLa cells were transferred into flasks that had not been coated
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with Matrigel™. The cells were incubated at 37°C in a humidified, 5% C02
atmosphere and the media was changed every 3-4 days.
2.4.5 Passaging of Cell lines
L(3T2 and «T3-1 cells were passaged once weekly. The DMEM was removed,
then the cells were washed with 2 changes of 2.5ml of PBS. Trypsin (Sigma)
was diluted 1/10 with PBS and 500pl (for a 25cm2 flask) or 1.5ml (for a 75cm2
flask) was added before the flasks were returned to the incubator and left for
1-2 minutes. After the cells detached from the flask, the trypsin was inhibited
by the addition of 4.5ml (25cm2 flask) or 14.5ml (75cm2) of DMEM. The cells
were dispersed, and LPT2 cells were then split 1:4 into 25cm2 flasks, and
lOOOOOcells/ml into 12 well plates. aT3-l cells were split 150000cells/ml into
25cm2 flasks, and lOOOOOcells/ml into 12 well plates. HeLa cells were split
lOOOOOcells/ml using lx trypsin into non-Matrigel™ coated wells and flasks.
2.4.6 Estimation of Cell number
Cell number was estimated using a hemacytometer (Weber Scientific
International Ltd). After the trypsin was inactivated, 10pl of cells was
removed into lOOjil of DMEM, and transferred to the hemacytometer. The
cells were counted, and an average taken, this was the cell number x 105 per
ml. The cells were then diluted accordingly.
2.4.7 Long Term Storage of Cell lines
Cells were stored under liquid nitrogen and were prepared as follows. The
LpT2 cells and aT3-l cells were grown to 80% confluency before they were
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trypsinised as previously described (section 2.4.5) and the volume made up
to 5ml (for 25cm2 flasks) or 10ml (for 75cm2 flasks) with DMEM before
spinning at lOOOrpm (Econospin, Sorvall) for 5 minutes. The media was
decanted, and the cells gently re-suspended in either 0.5ml or 1.25ml of FCS
per 25cm2 or 75cm2 flask respectively. The cells were then combined before
500|a,l was aliquoted into pre-chilled, labelled cryotubes, and 500pi of 20%
(v/v) of dimethyl sulfoxide (DMSO, Sigma) diluted in FCS was added. The
vials were mixed, and transferred into a cryo 1°C freezing container
(Nalgene) and stored at -70°C overnight, before they were transferred to
liquid nitrogen.
2.4.8 GnRH treatment of cells
GnRH (Peninsula) was dissolved in PBS at a concentration of lOOpM, 500pl
aliquots were made, and stored at -20°C. The stock was diluted by addition
of 1/100 volume of GnRH to DMEM, and mixed thoroughly. To pulse cells
with GnRH, the media was removed from the cells and the DMEM+GnRH
was added. The cells were incubated at 37°C for 15 minutes, before the
DMEM+GnRH was removed, and replaced with normal DMEM. The cells
were harvested for RNA as previously described (see section 2.3.14). For
transiently transfected cells, 1ml of GnRH+DMEM was added to each of the
wells, but not removed. The cells were harvested 6 hours post GnRH
treatment, as described below.
2.4.9 Transient transfection of DNA into in vitro cultured cells
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The cells were plated into 12 well plates (Costar/Nunc) 24 hours prior to use.
Fugene™ (Roche) and GenePorter™ (GTS), which are cationic liposome-
mediated techniques (Feigner, P.L. 1987), were used to transfect plasmid
DNA into the cells, and the total plasmid DNA transfected into each well was
2pg. The plasmid carrying the gene promoter/reporter construct to
plasmid DNA ratio was always 6:1, so pBluescript (Stratagene) was added
when necessary to make up the final mass of transfected DNA to 2pg per
well. A (3-galactosidase reporter construct, or a chloramphenicol acetyl
transferase (CAT) reporter construct was co-transfected at lOOng per well as
a control for transfection efficiency. Each transfection condition was carried
out in triplicate and each experiment was repeated three times.
2.4.9a Transient transfection of aT3-l cells and HeLa cells using
GenePorter™
aT3-l cells were transfected using GenePorter™ (GTS) following the
manufacturer's protocol. Cells were plated in 12 well plates 24 hours prior to
use, the media was removed, and the cells were incubated with 500pl of
Optimem (GibcoBRL) for 2 hours. The GenePorter™ was prepared by
adding 5pl per lpg plasmid DNA. This mix (2pg DNA/well) was transfected
and incubated for 4 hours in the C02 incubator, then the Optimem was
removed, and DMEM added. The cells were returned to the incubator for 48
hours.
2.4.9b Transient transfection of LJ3T2 cells using Fugene™
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Fugene™ (Roche) was used to transfect plasmid DNA into L(3T2 cells. DNA
(2gg), was added to the bottom of a 5ml culture tube (Elkay). Optimem was
pipetted, to give a final transfection volume of lOOjil per well, into a separate
5ml culture tube, Fugene™ (3[il/ljig DNA) was then added to the Optimem
and this mix was transferred onto the DNA drop-wise. This was mixed and
incubated at room temperature for at least 15 minutes. Then lOOpl of
transfection mix, was added drop-wise to each well, the plate was swirled
gently to mix, and the cells were returned to the incubator for 48 hours.
Cells were harvested, as described below, 6 hours post GnRTI treatment.
2.4.10 Luciferase/|3-galactosidase chemiluminescent reporter
gene assay
These assays were carried out using the Dual Light™ kit (Tropix). The
DMEM was removed from the wells, and the cells washed 3 times with cold
PBS before adding 250jil of lysis buffer with protease inhibitors (Roche). The
cells were shaken on a plate shaker for 20 minutes before being transferred
to 1.5ml eppendorf tubes. The tubes were centrifuged at 13000rpm for 2
minutes to pellet the cellular debris. Duplicate 10pl aliquots of each sample
were pipetted into two wells of a white 96 well plate (Nunc) and the
luciferase gene activity was determined by the amount of light produced, in
an automatic injection microplate luminometer (LB 96V, Microlumat Plus,
EG+G Berthold). The plates were incubated for another 30 - 60 minutes and
measured for the (3-galactosidase activity. Luciferase light units were
corrected by the relative amount of (3-galactosidase activity in each sample.
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2.4.11 (3-galactosidase chemiluminescent reporter gene assay
Gene activity was assayed using the p-galactosidase reporter gene assay kit
(Roche). The cells were washed in PBS and lysed using the buffer supplied.
Duplicate 50pl aliquots were pipetted into 2 wells of a 96 well plate, and lOOpl
of substrate reagent was added manually. This was incubated at room
temperature for 1 hour, before (3-galactosidase activity was measured by the
injection of 50pl of initiation reagent on the LB 96V luminometer.
2.4.12 Chloramphenicol acetyltransferase (CAT) assay
Transfection efficiency was measured by pipetting 30pl of cell extract into
1.5ml eppendorf tubes, and adding 164pl of 0.25M Tris-HCl pH 7.8. Heating
to 65°C for 10 minutes inactivated endogenous acetyltransferases, before lpl
of 14C-Chloramphenicol (50 -62mCi/mmol), 5pl of 50mM Acetyl Coenzyme
A and enough 250mM Tris.HCl pH 7.8 to increase the volume to 200pl was
added and incubated at 37°C overnight. Next day, 600pl of ethyl acetate
was added to each reaction, which was vortexed 3 times for ten seconds each
before centrifuging for 2 minutes at 13000rpm and removing the top organic
phase to a fresh tube. The tubes were dried at 45°C under a stream of
nitrogen gas. Thin layer chromatography (TLC) plates (Camlab) were cut to
make 2 plates of 20cm x 10cm and marked 1cm from the bottom edge and
along this line, spot positions were marked 1.3cm apart. The
chromatography solvent (chloroform:methanol at a ratio of 95:5) was freshly
prepared, and allowed to equilibrate for 10 minutes in the chromatography
tank.
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The dried reactions were reconstituted in 20pl of ethyl acetate and spotted
onto the marked TLC plates, 2pl at a time. The TLC plates were placed in the
tank until the solvent front reached the top of the plate, then removed from
the tank and allowed to air-dry before being wrapped in Saran wrap and
exposed to a Phosphoimage screen for 1 week. The activity of CAT was
measured by quantifying the two faster migrating bands (the modified
mono- and di-acetylated forms of 14C-chloramphenicol) and dividing this by
the quantified, lower unmodified band of 14C-chloramphenicol. The result
was multiplied by 100, which gave the percentage conversion rate.
2.4.13 Protein Quantification
Protein concentration was determined using the Bradford protein assay
(Bradford, M. 1976) reagent (BioRad). A standard curve using different
concentrations (0pg/10|il, 0.5pg/10|il, l|ig/10(xl, 5pg/10pl, and lOpg/lOpl) of
BSA was prepared for each assay and made up to 800pl with deionised water
in 1.5ml eppendorf tubes. The protein concentration of each cell lysate was
measured by pipetting lOpl of the sample into 790pl of deionised water,
before 200pl of protein assay dye reagent (BioRad) was added to the water,
the standard curve samples, and the samples to be measured. The reaction
was mixed, and incubated at room temperature for 5 minutes, before
measuring absorbance on a calibrated spectrophotometer (6150 UV/Vis
Spectrophotometer, Jenway) at 595nm. The standard curve was plotted as a
graph and the linear equation of the line determined. This equation was
used to calculate the concentration of the protein from the absorbances.
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Chapter 2b: Differential Display Materials and
Methods
2.5.1 Introduction
Differential Display RT-PCR (DD-RT-PCR), developed by Liang and Pardee
(Liang and Pardee 1992), is a method used to identify differentially expressed
mRNAs, and a schematic of the major steps in the technique are shown in
Fig. 2.5.1. DD-RT-PCR has a number of advantages over other methods of
isolating differentially expressed transcripts (e.g. subtractive hybridisation),
which include: (i) low quantities of starting material, as little as 200ng of total
RNA, (ii) allows a direct visual comparison of different samples or treatments
on the same gel, and (iii) high sensitivity. In addition, due to the variation in
the downstream anchored primers (see Fig. 2.5.1, Step 4) the technique
ensures amplification of all polyadenylated RNA, and since the technique is
PCR based, low copy number transcripts are also amplified, so are included
in the analysis. However, the major drawback to utilisation of this technique
is false positives. False positives are transcripts that appear to be
differentially expressed, but when double-checked are not. These can be
artefactual bands on the gel (Fig. 2.5.1, Step 6) and are produced by non¬
standard RNA extraction and cDNA synthesis, or can be due to identically
sized DNA fragments co-migrating with the band of interest. To minimise
this, samples were handled in an identical manner, so RNA was isolated and
cDNA was synthesised simultaneously. To minimise false positives due to
identical sized DNA fragments, single stranded conformation polymorphism
(SSCP) can be used (Miele, MacRae et al. 1998), which separates transcripts
based on conformation, rather than size.
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Fig. 2.5.1: Schematic representation of the DD-RT-PCR method
Step 1 GnRH treat cells
one 15 minute pulse
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Step 2 Harvest cells 1, 2, & 4
hours post treatment
harvest into RNAzol B and
store in the -70 freezer
1 1
Step 3 Extract RNA
following the RNAzol B
protocol
Step 4 first strand cDNA
synthesis
using the first strand cDNA
synthesis kit from Amersham-
Pharmacia, and adding 5pg
of RNA, and one of either
T12VA, T12VC, T12VG
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Gel Electrophoresis and exposure to
autoradiographic film
Samples were resolved on a 6%
0 0 A high resolution acrylamide gel using
the GenomxyLR, prog 10. The
gel was transferred to 3MM and
dried using prog 60. It was then
exposed to BiomaxMR film
■ Changing band pattern
Autoradiographic image of the
gel
the crosses were used to align
the film with the gel, and were
'produced with fluorescent tape
marked with crosses, and stuck
to the gel
I 92
Step 7 Isolating the changing
band from the gel
lane 12 3 4 lane 12 3 4
X X X X
—— MM —^
X X X X









The gel with the band
containing the DNA of
interest removed
The film is aligned with the
gel using the crosses and
the band excised from
the gel, using the window
cut out of the film as a
template
I
Step 8 Eluting the DNA from the gel
1 '-§^ " ^
The band was cut into smaller fragments and placed into a 0.5ml
eppendorf with 0.15ml TE, the gel was rehydrated at room
temperature for 20 min then heated to 100 degrees to elute the
DNA
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Step 9 Ethanol precipitation of
eluted DNA
The solution containing the DNA wastransferred to a fresh
eppendorf tube and the DNA precipitated with 3V 100%
ethanol, 1/10V sodium acetate, 1 pil of See-DNA and
precipitated in the -70 freezer
I
Step 10 PCR re-amplification of
DNA isolated from the gel
The DNA was pelleted by centrifugation, and re-constituted in
10pil low TE. This was amplified using AGS Gold Taq, the
5' random primers, the anchored 3' primers, in the DNA Engine
\
Step 11 Cloning of PCR product
The PCR product was cloned using the Perfectly Blunt cloning kit
Step 12 Automatic DNA sequencing and
identification
The cloned DNA fragment was sequenced on an ABI 373A DNA
sequencer, and the results were used in a BLAST search of the
EMBL, and mouse EST databases
4
Step 13 Confirmation of mRNA expression
patterns
The cloned PCR product was used as a radioactively labelled
probe in Southern andNorthern analyses, and as a template to
in vitro transcribe a radioactively labelled probe for ribonuclease
protection assays
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DD-RT-PCR was used to analyse changes in gene expression in the L(3T2
gonadotroph cell-line, that had been treated with GnRH. The differentially
expressed transcripts, that were analysed, are presented in chapter three of
this thesis. The next section briefly describes the DD-RT-PCR technique with
the modifications that had to be included and is presented as a mini-results
chapter.
2.5.2 Materials
Table 2.5: Components required for DD-RT-PCR
Reagents, kits and equipment Supplier
40% Genomyx acrylamide gel Beckman Coulter (UK)
a^S dATP lOOOCi/mmol Amersham-Pharmacia (UK)
RNazol B AMS Biotechnology (UK)
First Strand cDNA synthesis kit Amersham-Pharmacia (UK)
AmpliTaq™ Taq Polymerase Promega (UK)
AGS gold™ Hybaid (UK)
Pfu polymerase Stratagene (UK)
Ffigh Fidelity Extensor Mix AB Gene (UK)
KODAK BiomaxMR film 60cm x 33cm Amersham-Pharmacia(UK)
See DNA Amersham-Pharmacia (UK)
Oligonucleotides Sigma-Genosys (UK)
Ready-to-go Ligation tubes Amersham-Pharmacia (UK)
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Perfectly blunt cloning kit Novagen (UK)
Chromaspin columns Clontech (UK)
UNOII PCR machine Biometra
DNA Engine Gradient cycler PTC-200 GRI (UK)
GenomyxFR DNA analyser Beckman Coulter (UK)
32P a dCTP (3000Ci/mmol) Amersham-Pharmacia (UK)
2xMDE™ Flowgen (UK)
2.5.3 Method
2.5.3a Modified Differential Display RT-PCR (DD-RT-PCR)
A DNA marker was initially prepared by digesting pBluescript with Sau3Al
(New England Biolabs) in a final concentration of lpg/ pi. The DNA was end
labelled using Klenow (DNA Polymerase I large fragment, Roche) in the
following reaction and incubated at room temperature for 30 minutes:
lpg of Sau3Al digested DNA
2pl lOx Klenow buffer
5pl 32P a dCTP (3000Ci/mmol)(Amersham-Pharmacia)
lpl 2mM dNTP (without dCTP)(Amersham-Pharmacia)
2 units of Klenow
A Chromaspin 10 column (Clontech) was used to purify the marker
following the manufacturer's instructions and a Cherenkov count was
performed. An aliquot of the marker was diluted to 1000cpm/pl and
2000cpm, with 2pl 6x type 3 loading dye (30% glycerol, 0.25% bromophenol
blue, 0.25% xylene cyanol FF) was loaded onto each gel.
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2.5.3b Extraction of RNA
Briefly, L(3T2 RNA was extracted from cells (Fig. 2.5.1, Steps 1-3) that had
either been left untreated or treated with GnRH (refer to section 2.4.8), using
the RNazol B protocol (see section 2.3.14).
2.5.3c Reverse transcription PCR
Total RNA was reverse transcribed into specific populations of cDNA using
degenerate 3' oligo(dT) primers (Sigma-Genosys, Fig. 2.5.1, Step 4). The
oligo(dT) primers were designed with 12 Thymidine bases and a
combination of two random bases (AA, AG, AC, CA, CG, CC, GA, GG, GC;
see appendix II) which would anchor the 3' primer to the poly A tail junction.
In this way, all mRNAs within a sample of total RNA would be primed, and
reverse transcribed.
The reverse transcription PCR (RT-PCR) was carried out as described in the
previous section (see section 2.3.16). The oligo(dT) primers were pooled into
three 24pM mixes; T12VA, T12VC, and T12VG (see Appendix II), and used as
the anchored 3' primers to fractionate the RNA into cDNA sub-populations.
2.5.3d Differential Display PCR
The cDNA was representative of the mRNA population of each treatment,
and was used as a template in PCR reactions with the original 3' primers and
an additional 5' random, lOmer primer (see appendix II for a full list of all
primers used and Fig. 2.5.1, Step 5). Each cDNA sub-population was
amplified using random lOmer 5' primers (see Appendix II), and the relevant
anchored 3' primer mixes. Originally AmpliTaq™ (Perkin-Elmer) was the
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preferred Taq polymerase used, however a direct comparison with AGS
Gold™ (Hybaid) Taq polymerase, identified the latter as a more efficient
enzyme for DD-RT-PCR (Fig. 2.5.2) and the protocol described below has
been optimised for the AGS Gold™ Taq polymerase.
An aliquot of cDNA corresponding to each treatment, was diluted with 131pl
of water. A 5pl aliquot of this was pipetted into labelled 0.5ml eppendorf
tubes and 2pl of random primer (5pM) was added to each cDNA. A lx
master mix (see below) of the other PCR components was prepared on ice
and 15pl was added to the DNA and random primer mix:
2pl lOx reaction buffer
2pl Enhancer
2.5pl 25mM MgCR
2pi 24pM T12VN (N is A, G, or C)
2pi 20pM dNTP
lpl 35S a dATP (lOOOCi/mmol)
0.3pl AGS Gold Taq
1.2pl water
The PCR was carried out under the following conditions: heating at 94°C for
2 minutes, followed by 40 cycles of denaturation at 94°C for 30 seconds,
annealing at 40°C for 2 minutes, and extension at 72°C for 30 seconds. A
final extension of 72°C for 5 minutes was performed, before the reactions
were cooled indefinitely at 4°C, and 4pl of 6x type III loading dye was added.
2.5.3e Native Gel Electrophoresis
Changes in mRNA expression levels were visualised on autoradiographic
film after electrophoresis on a native 6% polyacrylamide gel (Fig. 2.5.1, Step
6). A 4pl aliquot was loaded onto a 6% high resolution acrylamide gel (40%
HR-1000 acrylamide, Genomyx, Beckman), and electrophoresed on a
GenomyxLR DNA analyser (Beckman) at 2700V for 2 hours 15 minutes at
9 8
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*
Fig. 2.5.2: DD-RT-PCR gel comparing the efficiency of AmpliTaq and AGS gold Taq
polymerases.
An autoradiographic image of a DD-RT-PCR gel that has been exposed to
a DD-RT-PCR dried gel for 6 hours. L|3T2 cells were either untreated (lane 1), or
treated with one 15 minute pulse of GnRH(lane 2), or treated with two 15 minute
pulses 30 minutes apart (lane 3). or treated with two 15 minute pulses 90 minutes
apart (lane 4). The DD-RT-PCR reactions with AGS Gold were carried out with
and without Enhancer (+/-E), to identify if the Enhancer improved enzyme efficiency
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50°C. The gel was transferred to 3MM paper, and dried in the Genomyx
machine. Fluorescent marker tape (Tracker tape™, Amersham-Pharmacia)
was used to align the film with the gel. The gel was exposed twice to
BiomaxMR film, for 6 hours, and overnight.
2.5.3f Isolation of bands of interest from the gel
Changing band patterns were indicative of changes in mRNA expression and
bands of interest were excised from the gel, using the film as a template and
guide (Fig. 2.5.1, Step 7). The gel was then cut into smaller fragments,
transferred into 0.5ml eppendorf tubes and re-hydrated in 150pl low TE at
room temperature, for 20 minutes. The DNA was eluted at 100°C for 20
minutes, with occasional flicking, transferred to a fresh tube, and ethanol
precipitated with lpl See-DNA at -20 °C for 1 hour. The sample was
centrifuged at 13000rpm for 20 minutes to pellet the DNA and was re-
suspended in lOpl of low TE (Fig. 2.5.1, Step 8 - 10).
2.5.3g SSCP analysis of differentially expressed transcripts
Originally, SSCP was performed on all transcripts isolated from differential
display gels to ensure that the band of interest only contained one species of
DNA, and to recapitulate the expression pattern seen on the differential
display gel.
The band of interest was cut out of the differential display gel as individual
lanes, and the DNA isolated as described above. The DNA from each lane
was re-amplified using the high fidelity extensor Taq polymerase (AB Gene)
as per manufacturer's guidelines, and one round of either 10 or 15 cycles of
PCR, using the PCR conditions described below (section 2.5.3h). A 15pl
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aliquot of the PCR reaction was taken, and 5pl of lOx denaturing dye (20mM
EDTA pH8, 0.05% (w/v) bromophenol blue, made up in deionised
formamide) was added. The sample was denatured at 95°C for 5 minutes
and stored on an ice/water mix before being loaded onto a 0.5x MDE™
(12.5ml 2x MDE™ [Flowgen], 37.5ml lxTBE ) minigel (Mini Protean 3,
BioRad). The samples were electrophoresed at 0.8mA/cm for 1.5 hours and
the bands were visualised by silver staining. The gel was fixed (50% (v/v)
methanol, 10% (v/v) acetic acid) for 30 minutes, and washed (10% (v/v)
ethanol, 0.005% (v/v) acetic acid) with 2x 3 minute washes. A 0.1% (w/v)
AgN03 solution was prepared, and added to the gel for 20 minutes. The gel
was developed by decanting the AgN03 solution and adding developer (3g
NaOH, 0.8ml formaldehyde, 200ml ddH20) until the bands were at the
desired intensity. The reaction was stopped with 0.75% (w/v) sodium
carbonate, the gel was wrapped in Saran wrap, and a photographic image
was taken (Fig. 2.5.3g).
In general only two bands were visible, which corresponded to the two
strands of a single transcript, and recapitulated the pattern seen on the
differential display gel. However, it was concluded that SSCP did not
confirm the pattern of expression directly, because the bands on the SSCP gel
were a direct comparison to the bands on the differential display gel, not a
confirmation of mRNA transcript levels. It was also difficult to interpret
SSCP gels that showed more than two bands, since it was impossible to
distinguish between multiple bands as a result of different species of DNA, or
as a result of a single species of DNA with more than one conformation.
Since SSCP did not confirm mRNA expression directly, nor did it definitely











Fig. 2.5.3g: Recapitulating the differential display profile
using SSCR
Individual lanes were cut from the differential display gel
and re-amplified using the high fidelity extensor PCR mix
R1 and T12VC primers, and 12 cycles of PCR. The DNA
was denatured and electrophoresed on this 1xMDE gel
and the bands visualised by silver staining. The pattern of
the lower band (b) followed that of the R13c pattern (Fig 3.2.5a)
and the upper bands (a) are probably un-denatured DNA. Size
markers are included to provide an approximate estimation.
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decided that SSCP would not be used, and the amplified DNA products
would be cloned directly. It was also concluded that, since I used a
transformed cell line, other contaminating mRNAs derived from other cell
populations found in tissue samples would not be present, therefore the
bands seen on a differential display gel were less likely to contain multiple
transcripts, probably due to lower molecular complexity.
2.5.3h Re-amplification ofDNA contained in the bands of interest
Once a transcript had been amplified it was cloned, sequenced, and identified
(Fig. 2.5.1, Step 11 - 12). To produce PCR products with restriction sites on
the end, EcoRI tagged 3' anchored primers and Xbal tagged 5' random
primers were designed and used with AmpliTaq™ to amplify the isolated
DNA fragments from DD-RT-PCR gels. Attempts to clone these products
into EcoRI and Xbal restricted pBluescript were unsuccessful, possibly
because the PCR reaction failed. To identify why these PCR fragments failed
to clone, a control PCR experiment was carried out using 1 and 2 units of the
AmpliTaq™ Taq polymerase, with aGSU specific primers, on sheep pituitary
DNA (Fig. 2.5.3h[i]). The results showed that the Taq polymerase was not
working efficiently. The next step was to test other Taq and Pfu
polymerases, to identify the most efficacious for amplifying DD-RT-PCR
isolated DNA fragments. PCR reactions were carried out using the
unmodified primers at 20pM concentration, and either Pfu polymerase
(Stratagene) or AmpliTaq™. Product could only be visualised with the Pfu
polymerase after two rounds of 40 cycles of PCR (Fig. 2.5.3h[ii]) therefore
AmpliTaq™ did not amplify the DNA eluted from the DD-RT-PCR gels as
efficiently as Pfu polymerase. To test if the modified primers (restriction site
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Fig. 2.5.3h[i]: PCR reamplification of aGSU with one or
two units of AmpliTaq.
PCR was performed using sheep pituitary DNA, aGSU
specific primers, and one (b) or two (a) units of AmpliTaq
DNA Taq polymerase to amplify a 416bp fragment. Since two
units of AmpliTaq increased the yield by two-fold, this enzyme
was not working efficiently.
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Fig. 2.5.3h[ii]: PCR reamplification of DD-RT-PCR isolated
DNA fragments using AmpliTaq (A) or Pfu polymerase (B)
and two rounds of 40 cycles of PCR.
DNA fragments were reamplified using unmodified differential
display primers, and either AmpliTaq or Pfu polymerase. A
control of one round of PCR was included (c). The volumes
correspond to the volume of first round PCR product
transferred to the second round of PCR.
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tagged) were actually priming the DNA fragments, PCR experiments were
set up with; the unmodified or the modified primers for both rounds of PCR,
and the unmodified and modified primers for the first and second rounds of
PCR respectively (Fig. 2.5.3h[iii]). In this experiment the modified primers
did not appear to be annealing to the DNA fragments. Changing the PCR
conditions (annealing temperatures, and MgCl2 concentrations) failed to
generate any product when the modified primers were used, therefore it
was decided that the unmodified primers would be used for re-amplification,
and the products would then be cloned. Initially AGS Gold ™ was used to re-
amplify the DNA isolated from DD-RT-PCR gels (Fig. 2.5.3h[iv]), and the
protocol described below was optimised for PCR with this Taq polymerase.








and 27.5pl of the master mix was added with 2.5pl of the relevant 5' primer
to the DNA. The PCR was performed in a DNA Engine PTC-200 (GRI) under
the following conditions; 94°C for 2 minutes, then 40 cycles of 94°C for 30
seconds, annealing at 40°C for 2 minutes, extension at 72°C for 30 seconds,
with a final extension at 72°C for 5 minutes, and cooled at 4°C indefinitely.
The PCR reaction was spun briefly and split into four lOpl aliquots, which
were re-amplified using the same reaction conditions as described above, this
ensured that the PCR volume was kept to a minimum, and increased the
likelihood of the PCR working during the second round of
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Fig. 2.5.3[iii]; Re-amplification of DD-RT-PCR isolated
fragments using Pfu polymerase.
DD-RT-PCR products were re-amplified using; unmodified
primers for both rounds of PCR (lanes 1 and 2), unmodified
primers for the first round of PCR and restriction site tagged
(modified) primers for the second round of PCR (lanes 3
and 4), and modified primers for both rounds of PCR (lanes




Fig. 2.5.3h[iv]: Reamplification of DD-RT-PCR fragments
using AGS Gold Taq polymerase.
DD-RT-PCR products were amplified using AGS Gold Taq
polymerase, R5 and T12VC primers, and two rounds of
40 cycles of PCR. A 5pl aliquot was electrophoresed on this
2% agarose gel to visualise the PCR products. Lane 3
contains two bands, and was gel purified.
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PCR. The reactions were pooled, and a small aliquot was run on an agarose
gel (Fig. 2.5.3h[iv]). If multiple bands were present, the sample was gel
purified using the Flybaid gel purification kit (Hybaid), and the PCR product
of the expected size was eluted and cloned, otherwise the sample was cloned
directly, using the Perfectly Blunt cloning kit (Novagen). The production of
smaller PCR products, than would be predicted from the DD-RT-PCR gel,
was a consistent feature of AGS Gold™ (Fig 2.5.3h[va]) and was considered a
problem. So, the protocol was further modified to use a Taq DNA
polymerase mix that included a combination of Taq DNA polymerase, Pfu
DNA polymerase and dNTPs. The High fidelity extensor mix (AB Gene)
improved both yield of PCR product and generated longer DNA fragments
in comparison to AGS Gold™ (Fig. 2.5.3h[va]). The re-amplification was
carried out using:
20gl 2x PCR mix
lOplDNA
2.5|il 20gM random primer
2.5(0.1 20pM T12VN
5pl water
initially for 40 cycles (Fig. 2.5.3h[va]), and although the PCR conditions
remained the same, the number of amplification cycles had to be reduced to
12 due to the high processivity and efficiency (Fig. 2.5.3h[vb]). As before,
this initial reaction was split into 4 and the PCR repeated.
2.5.3i Cloning and Identification of the PCR product
The products were cloned (Fig 2.5.1, Step 11-12) using the Perfectly Blunt
Cloning kit, as described in the previous section (2.3.9b) and sequenced.





Fig. 2.5.3h[va]: A comparison of the processivity and
efficiency of AGS Gold Taq polymerase and high fidelity
extensor PCR mix.
A DD-RT-PCR gel was electrophoresed with identical
differential display reactions in duplicate. The same
band from each duplicate was chosen, the DNA isolated,
and reamplified with two rounds of 40 cycles of PCR and
either AGS Gold Taq polymerase (lane 1), or high fidelity
extensor PCR mix (lane 2).
HO
1OObp 1 2
Fig. 2.5.3h[vb]: Reamplification of DD-RT-PCR fragments
using the high fidelity extensor PCR mix.
DD-RT-PCR fragments were amplified with R1 and T12VC
and 2 rounds of 12 cycles of PCR. A 5ul aliquot was
electrophoresed on this 2% agarose gel. The smaller number
of rounds has removed the smear seen in the previous gel,
and produced larger fragments.
in
a BLAST search (Wisconsin package version 10.0, Genetics Computer Group
(GCG), Madison, Wise).
2.5.3j Analysis and confirmation of differential mRNA expression
patterns of clones
Transcripts were initially analysed by hybridisation of a radiolabeled probe,
generated from the clones, to a Southern blot (see section 2.3.12 for
protocol), to determine the suitability of the clone to be used as a probe for
Northern analysis (for protocol see section 2.3.17), or RPA analysis (see
section 2.3.18 for protocol, Fig. 2.5.1, Step 13).
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Chapter 3:




The oestrus cycle is the recurring period of sexual receptivity and fertility in
female mammals, and is characterised by cyclical changes in luteinising
hormone (LH), follicle stimulating hormone (FSH), oestradiol and
progesterone levels (see Fig. 1.1.2a). During each cycle, the female
reproductive tract is prepared for the fertilisation and implantation of an
ovum released from the ovary at ovulation and is divided into two phases,
the follicular and luteal phase.
FSH and LH therefore, are differentially regulated during the oestrus cycle
by the steroid hormones, but more importantly, by GnRH (Marshall, Dalkin
et al. 1991). During the follicular phase, GnRH is secreted from the
hypothalamus at a rate of one pulse every 15 minutes, and this rate
dramatically increases towards the LH surge. In the luteal phase, the rate of
GnRH secretion falls to about one pulse every hour (Knobil 1980; Lincoln,
Fraser et al. 1985; Clarke, Thomas et al. 1987). Numerous studies have
identified the importance of GnRH pulse frequency in differentially
controlling the transcription and mRNA expression of the gonadotrophin
subunits. Initial experiments were carried out in vivo, in ovariectomised and
hypothalamic-pituitary disconnected sheep. These experiments identified
that in order to maintain LH(1 and FSHfl mRNA levels, the sheep had to
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receive pulses of GnRH, since a constant administration of GnRH resulted in
a 50% drop in mRNA levels (Mercer, Clements et al. 1988). These
experiments were recapitulated in rats and mice, which identified that LI 1(3
mRNA expression levels were actually dependent on a specific pulse
frequency, deviation from this frequency led to a decrease in LH(3 mRNA
levels (Papavasiliou, Zmeili et al. 1986). Varying pulse frequencies of GnRH
administered to the anterior pituitaries of ovariectomised or intact rats
identified that LH(3 and aGSU mRNA levels were increased with rapid pulses
of GnRH, while slow pulses up-regulated FSH(3 mRNA levels (Dalkin,
Haisenleder et al. 1989; Shupnik 1990; Weiss, Duca et al. 1990; Haisenleder,
Dalkin et al. 1991). Furthermore, there is a dissociation between LH(3
transcription and LH secretion indicating that GnRH pulse frequency
differentially controls these events (Salton, Blum et al. 1988; Weiss, Duca et al.
1990; Weiss, Crowley et al. 1992).
Since GnRH pulse frequency is responsible for differential expression of the
gonadotrophin subunits (Kaiser, Jakubowiak et al. 1997), then logically, the
factors involved in controlling synthesis of LH(3, FSH(3 and aGSU would also
be regulated differently with different GnRH pulse frequencies. In fact,
GnRH receptor numbers also increase with pulsatile administration of GnRH
(Katt, Duncan et al. 1985). Additionally, GnRH-R numbers are affected by
pulse frequency; there are fewer receptors expressed in response to a fast
GnRH pulse frequency than a slow GnRH pulse frequency (Kaiser,
Jakubowiak et al. 1997). However, receptor numbers have been observed to
increase during the period leading up to the LH surge (Savoy-Moore,
Schwartz et al. 1980; Barkan, Regiani et al. 1983; Brooks, Crow et al. 1992).
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GnRH regulated transcription has also been studied in vitro using in vivo
transformed cell-lines. Until recently, most experiments have been carried
out using «T3-1 cells, which are an early gonadotroph cell-line that
synthesise and secrete aGSU and express GnRH-R, but do not express the |3-
subunits (Windle, Weiner et al. 1990). L|3T2 cells were developed in 1996, and
are also of a gonadotroph lineage. These cells recapitulate differentiated
gonadotrophs and can synthesise and secrete LH and FSH in response to
GnRH (Turgeon, Kimura et al. 1996; Graham, Nusser et al. 1999). Pulsatile
treatment of LpT2 cells with GnRH has been shown to induce expression of
LHp mRNA and to promote secretion of LH storage granules (Turgeon,
Kimura et al. 1996). Interestingly, neither aGSU nor GnRH receptor mRNA
levels were altered in response to 15 minute pulses of GnRH in these cells.
However FSH(3 gene expression is only activated by treatment with activin
and GnRH, suggesting involvement of the SMAD signalling pathway in
these cells (Graham, Nusser et al. 1999; Lebrun, Takabe et al. 1999; Pernasetti,
Vasilyev et al. 2001). Therefore these cells mimicked in vivo expression of
gonadotrophins in an in vitro model system. Although it is known that the
GnRH receptor number is differentially regulated, the differences
downstream of this are not known. There is a significant gap in the literature
regarding the regulation of GnRH action. Although some second messenger
signalling pathways have been implicated, there is a deficit of information on
how this could differentially control and express two different hormones
from the same cell and how all of this is controlled by pulsatile input of
GnRH.
11 5
3.1.2 The Aims of this Chapter
Thus, the in vivo transformed gonadotroph cell line LPT2 was chosen to
investigate changes in gene expression induced by GnRH, with the specific
aim of discovering new and novel factors regulated by GnRH, that would
also explain how GnRH can differentially modulate biosynthesis and
secretion. LPT2 cells are GnRH responsive, express LHp, FSHp and aGSU
(Turgeon, Kimura et al. 1996; Graham, Nusser et al. 1999) and are naive to
GnRH, therefore de novo synthesis in response to GnRH could also be
studied. Using a cell-line ensured that GnRH administration was controlled
and consequently allowed the effect of different pulse regimes to be studied.
To try and identify transcripts that are regulated by GnRH, LPT2 cells were
either left untreated or treated with GnRH. RNA was isolated from these
cells and reverse transcribed before being used for DD-RT-PCR analysis
(Liang and Pardee 1992).
3.2 Results
3.2.1 GnRH but not Matrigel™ has an effect on transcription
LPT2 gonadotroph cells are grown in vitro on a Matrigel™ basement
membrane mix. Matrigel™, as well as containing collagen and other proteins
found in extracellular basement membranes, contains a number of growth
factors, metalloproteinases and other factors that promote cell adherence.
These factors may up-regulate gene expression. Therefore differential
display was performed to identify if gene expression was affected by
Matrigel™ in LPT2 cells. The cells were also treated with GnRH to confirm
that mRNA expression altered in response to GnRH (Fig. 3.2.1).
1 16
TK A1 A2 MAX1 MAX2 MAX3 R21
Fig. 3.2.1: Differential display showing that GnRH, not matrigel, has an effect on gene expression.
LfST2 cells were treated as follows: no GnRH or matrigel (lane 1); no GnRH, with matrigel (lane 2);
with 3 pulses of GnRH and with matrigel (lane 3); with 6 pulses of GnRH and with matrigel
(lane 4). The differential display RT-PCR was performed using the specified primers and
T12VA anchored primers. Arrows show transcripts that are not affected by matrigel (a and b),
and others that are up-regulated by GnRH (* and d).
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Cells were left untreated, and left without Matrigel™, (Lanes 2 and 1
respectively), or seeded on Matrigel™ (section 2.4.3) with three 15 minute
pulses of GnRH over one day (section 2.4.8), or six 15 minute pulses of GnRH
over two days (Lane 3 and 4 respectively). The differential display gel
showed that the Matrigel™ had no effect on gene expression, whereas GnRH
up-regulated gene expression.
3.2.2 Myosin Light Chain mRNA is regulated by GnRH
Having established that GnRH up-regulated mRNA expression levels,
further experiments were carried out to investigate this. Cells were either
left untreated (lane 1) or treated with GnRH for either one 15 minute pulse
(lane 2), or two 15 minute pulses of GnRH with an inter-pulse interval of
either 30 minutes (lane 3, follicular phase) or 90 minutes (lane 4, luteal phase).
Cells were harvested 4 hours later, the RNA extracted (section 2.3.14) and
DD-RT-PCR (section 2.5.3a) performed (Fig 3.2.2a). The band illustrated
appeared to be up-regulated after one pulse of GnRH, down-regulated after
two pulses of GnRH 30 minutes apart, and again up-regulated after 2 pulses
of GnRH 90 minutes apart. This band was isolated (section 2.5.3f), reamplifed
using AGS Gold™ Taq polymerase (section 2.5.3h), cloned into psTBlue-1
(section 2.3.9b) and sequenced (section 2.3.11c). The 212bp sequence was
compared to the EMBL database using BLAST (section 2.5.3i) and a match
was found with myosin light chain (Fig. 3.2.2b). A probe was generated
from the clone and Northern analysis on lOpg total RNA (section 2.3.17),
from the same RNA samples used to generate the cDNAs used in DD-RT-
PCR, was performed (Fig. 3.2.2ci). Initially, the pattern of mRNA expression
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R1 R2 R3 R4 R5 R6 R8 R9 R21 A1 MAX 1
123412341234 1234 1234 1234 1234 1234 1234 1234 1234
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Fig. 3.2.2a: Differential display gel showing changes in expression profiles of
cells either left untreated, or treated with GnRH.
L|JT2 cells were left untreated (lane 1), or treated with 1 pulse of GnRH (lane 2);
or 2 pulses of GnRH 30 minutes apart (lane 3); or 2 pulses of GnRH 90 minutes
apart (lane 4). Differential display was performed using the primers specified and
T12VC anchored primers. The arrow identifies Myosin light chain which was
up-regulated in response to 1 pulse, and 2 pulses of GnRH 90 minutes apart.
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Fig. 3.2.2c: Northern analysis of myosin light chain to confirm the mRNA
expression profile identified by differential display.
(i) RNA was extracted from LPT2 cells that were treated as follows: no GnRH (lane 1);
1 pulse of GnRH (lane 2); 2 pulses of GnRH 30 minutes apart (lane 3); and 2 pulses
of GnRH 90 minutes apart (lane 4) using RNazol B. A 10pg aliquot of each sample was
loaded per lane. The membrane was hybridised with a radiolabeled probe generated
from the cloned differential display product.
(ii) The same northern blot was stripped, and reprobed using an 18s probe. This was
used to quantify the hybridised bands produced by the myosin light chain.
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R1 R3 R4 R5 R6 R7 R8 R9 R21 SX TK
123123123123123123123123123123123
Fig. 3.2.2d: Differential display gel showing mRNA expression patterns 4 and 6 hours
post-GnRH treatment.
LPT2 cells were treated as follows: no GnRH (lane 1); 1 pulse of GnRH; harvesting the
RNA 4 hours later (lane 2); and 1 pulse of GnRH. harvesting the RNA 6 hours later
(lane 3). Differential display RT-PCR was performed with the specified primers and
T12VA anchored primer. The arrows mark the typical mRNA expression profiles obtained
using this regime.
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appeared unchanged, however quantification with an 18S ribosomal control
probe confirmed that the mRNA profile matched the differential display
pattern, but the profile was not as defined as that originally seen on the DD-
RT-PCR gel (Fig. 3.2.2cii). Although differences were identified using this
pulse regime, they were difficult to interpret since the expression patterns
appeared on the differential display gel as on/off signals, but further analysis
by northern blotting showed this not to be the case. With this in mind, a
simpler regime was adopted, involving a single GnRFl pulse of 15 minutes.
Initially, the RNA was harvested 0, 4 and 6 hours post-GnRH treatment,
however the mRNA expression profiles showed that transcripts were
induced by 4 hours, but had waned by 6 hours (Fig. 3.2.2d).
3.2.3 GnRH regulation of gene expression is rapid
Therefore, a shorter time course was used, and RNA was harvested 0, 1, 2
and 4 hours post-GnRH treatment. DD-RT-PCR was performed and
numerous differences in transcript levels were identified. The time course
experiment and DD-RT-PCR were carried out in duplicate. Samples were
loaded on the same gel, to enable expression profiles to be compared and
only differences that were consistent between the duplicates were isolated
and analysed. The results described below showed that mRNA expression
levels changed rapidly, within one hour of GnRH treatment and that in
general, the mRNA expression levels were up-regulated in response to
GnRH.
3.2.4 DD-RT-PCR produced fragments that contained
nucleotide repeat sequences.
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Having identified a GnRH pulse regime that generated reproducible results,
the first transcripts isolated tended to contain nucleotide repeats, which are
common in the 3' untranslated region sequences (3' UTR) of mRNA. These
clones when used as probes for northern blots, hybridised to numerous
transcripts, which presumably contained repeat sequences, this produced a
smear on the blot that was impossible to interpret (Fig 3.2.4a). Thus, it was
decided that clones would be screened by both Southern and bioinformatic
analysis, before continuing with further expression analysis. Using this
screen, one clone was identified as unsuitable for further analysis by
northern blot, or ribonuclease protection assay (RPA, Fig 3.2.4b), however
five other clones that passed this screening test were investigated and are
described below.
3.2.5 DD-RT-PCR has identified a novel sequence that is
regulated by GnRH
Differential display PCR was performed using the R1 and T12VC primer
combination, and two changing bands were identified with similar
expression patterns, these were named R13c and R18b (Fig. 3.2.5a, the results
of R18b will be covered in section 3.2.6). The expression profile suggested a
rapid up-regulation of expression within 1 hour, which peaked within 2
hours, returning to pre-GnRH treatment levels by 4 hours. The DNA was
isolated, amplified with the High Fidelity Extensor Taq polymerase (section
2.5.3h), cloned into psTBlue-1 (section 2.3.9b), and sequenced (section
2.3.11b). R13c (279bp) was compared with the high throughput sequencing
database using a BLAST search (section 2.5.3i), and an exact match was
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Fig. 3.2.4a: Investigation of cloned differential display products identified as
containing repeat DNA sequences as probes for Northern analysis.
(i) Differential display RT-PCR was performed on RNA that had been
isolated from cells treated as follows: no GnRH (lane 1); 1 pulse of GnRH
harvesting 4 and 6 hours later (lane 2 and 3); 2 pulses of GnRH 30 minutes
apart harvesting 4 and 6 hours later (lane 4 and 5); and 2 pulses
of GnRH 90 minutes apart harvesting 4 hours later (lane 6). A R4, T12VA
primer combination was used.
(ii) Northern hybridisation of a radiolabeled probe generated from clone d
(iii) Northern hybridisation of a radiolabeled probe generated from clone c
(iv) Full length DNA sequence of clone d, the repeat sequence has been
highlighted in bold and the primer sequence underlined.
(v) Full length DNA sequence of clone c, the repeat sequence has also
been highlighted in bold, and a sequence similar to the R4 primer has been
identified. 125


















Fig 3.2.4b: The R2c clone detects multiple discrete bands when used to probe a
Southern blot.
(i) Differential display gel identifying the R2c transcript. LPT2 cells were treated as follows:
no GnRH (lane 1); or 1 pulse of GnRH harvesting 1 hour (lane 2); 2 hours (lane 3); and 4
hours (lane 4) post-GnRH treatment. Differential display was performed using the R2 and
T12VC primers.
(ii) Southern blot analysis of BamHI and H/ndlll restricted mouse genomic DNA revealed
that the R2c probe generated from the cloned differential display product produced multiple
hybridising bands.
(iii) The 205bp sequence reveals a 54bp stretch of repeat sequence (highlighted
in bold) and the R2 primer sequence is underlined. A region of DNA sequence has also been
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Fig. 3.2.5a: Differential display gel showing transcripts R13c and R18b
are up-regulated in response to GnRH.
LPT2 cells were treated as follows: no GnRH (lane 1); or 1 pulse of GnRH
harvesting 1 hour later (lane 2); 2 hours later (lane 3); and 4 hours later (lane 4).
DD-RT-PCR was performed using the R1 and T12VC primers. Arrows denote
radiolabelled DNA size markers and transcripts R18b and R13c.
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Fig. 3.2.5c: Northern blot analysis of R13c probe, no hybridising band was seen.
LPT2 cells were treated as follows: no GnRH (lane 1); or one pulse of GnRH harvesting
at 1 hour (lane 2); 2 hours (lane 3); and 4 hours (lane 4). Total RNA was extracted from
these cells, 10pg was loaded into each well, and electrophoresed on a 1% denaturing
agarose gel. The RNA was transferred to a nylon membrane and hybridised with a
radiolabeled DNA probe derived from the cloned differential display product R13c. The
position of the ribosomal bands 28s and 18s are marked.
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Fig. 3.2.5d: RPA analysis of R13c did not detect a hybridising band.
An RPA using a radiolabeled in vitro T7 RNA polymerase transcribed RNA probe of R13c
was performed to confirm the mRNA expression profile of the differential display gel.
LPT2 cells were treated as follows: no GnRH (lane 6); or 1 pulse of GnRH, harvesting at
1 hour (lane 7); 2 hours (lane 8); and 4 hours (lane 9) post-GnRH treatment. Arrows denote
the unhybridised 18s probe (b, lane 1),the unhybridised R13c probe (a, lane 4). The 6%
polyacrylamide gel was electrophoresed with a 100bp DNAsize marker (lane 2) and
unhybridised 18s and R13c probes, which have been treated with ribonuclease (lanes 3 and 5).
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identified with a region on human chromosome 3 (Fig 3.2.5b). Northern
blot analysis did not produce any hybridising bands on lOpg of total RNA
(Fig 3.2.5c), therefore an RPA (section 2.3.18) was performed in an effort to
confirm the differential display gel pattern however, RPA analysis did not
produce any hybridising bands either (Fig. 3.2.5d).
3.2.6 DD-RT-PCR has identified a GnRH regulated transcript
that is found in the adult male testis
R18b (132bp) was isolated from the same gel as R13c (section 2.5.3f), and had
the same expression profile as R13c (Fig. 3.2.5a). Bioinformatics, however,
identified this transcript as having similarity with an expressed sequence tag
(EST), which is also present in the adult male testis (Fig. 3.2.6).
3.2.7 GnRH regulates a mRNA transcript that is found in the
mammary gland, CNS and brain
This transcript (R3c, 503bp in length) was isolated using the R3 and T12VC
primers (section 2.5.3a). The mRNA expression profile suggests de novo
synthesis by 1 hour post-GnRFl treatment, which peaked by 2 hours post-
GnRH treatment, and was sustained after 4 hours post-GnRH treatment (Fig.
3.2.7a). Bioinformatics has matched this clone with an EST in the Riken
mouse database, which is expressed in the lactating and pregnant mouse
mammary gland (Fig. 3.2.7b), and has some similarity with an EST that is
only expressed in the hypothalamus, cerebellum, spinal cord, retina,
diencephalon, medulla oblongata, hippocampus, and corpora quadrigenima.
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Fig 3.2.7a: Differential display gel identifying transcript R3c being up-regulated by GnRH.
Lf!T2 cells were treated as follows: no GnRH (lane 1); or 1 pulse of GnRH and harvested
1 hour (lane 2): 2hours (lane 3); and 4 hours (lane 4) post-GnRH treatment. Differential
display was performed using the R3 and T12VC primer combination. Arrows denote the
radiolabeled DNA size markers, and the R3c transcript.
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Fig. 3.2 7c The R3c radiolabelled probe generated a discrete 4kb
hybridising band on a Southern blot.
Mouse genomic DNA was digested with Ba/nHI and HindiII, and
electrophoresed on a 0.8% agarose gel, and transferred to a nylon
membrane. The membrane was probed with a radiolabeled probe
generated from the cloned ditferential display product. The DNA marker
corresponds to bacteriophage lambda DNA, restricted with Hindi 11 and BcoRl
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Fig. 3.2.7d: Northern blot analysis of R3c did not identify any hybridising bands.
LPT2 cells were treated as follows: no GnRH (lane 1); or one pulse of GnRH harvesting
at 1 hour (lane 2); 2 hours (lane 3); and 4 hours (lane 4). Total RNA was extracted
from these cells, 10pg was loaded into each well, and electrophoresed on a 1%
denaturing agarose gel. The RNA was transferred to a nylon membrane and hybridised
with a radiolabelled DNA probe derived from the cloned differential display product R3c.
The position of the ribosomal bands 28s and 18s are marked.
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Fig 3.2,7e: RPA analysis of R3c transcript.
L[3T2 cells were treated as follows: no GnRH (lane 2); or one pulse of GnRH harvesting
at one hour (lane 3); 2 hours (lane 4); and 4 hours (lane 5) post-GnRH treatment. The
cell lysate was hybridised with radiolabelled R3c and 18s in vitro translated RNA, and
electrophoresed on a 6% polyacrylamide gel with unhybridised R3c and 18s probes
(lanes 1 and 7, and arrows A and B respectively), and unhybridised R3c and 18s probe
which have been treated with ribonuclease (lanes 6 and 8 respectively). Arrows C and
D correspond to protected R3c and 18s bands respectively.
137
Southern blot analysis (section 2.3.12) identified a hybridising band of about
4.2kb (Fig. 3.2.7c), and confirmed that this clone was suitable as a probe for
northern analysis, however, hybridisation of this probe to a northern blot
with 10|ig of total RNA, did not identify any bands (Fig 3.2.7d). Therefore an
RPA was performed, but the results were inconclusive (Fig 3.2.7e).
3.2.8 DD-RT-PCR has identified a putative tyrosine
phosphatase that is tightly regulated by GnRH
This clone, initially identified as R21c (133bp in length), was isolated from a
differential display gel (section 2.5.3a) of reactions carried out with R21 and
T12VC primers (Fig 3.2.8a). The gel showed that expression was hugely up-
regulated within one hour post-GnRFl treatment, was maintained after two
hours, and returned to pre-GnRH treatment levels by four hours.
Bioinformatics identified a match at the 3' end of a putative tyrosine
phosphatase (Fig. 3.2.8b). The Southern blot identified a single hybridising
band of about 4.8kb, confirming the clone as a suitable probe for further
analysis (Fig. 3.2.8c). RPA analysis confirmed the expression profile shown
on the differential display gel (Fig. 3.2.8d) and quantification with 18s showed
that this putative tyrosine phosphatase was up-regulated 27-fold in response
to GnRH, with the mRNA expression levels waning after 4 hours (Fig.
3.2.8e).
3.2.9 DD-RT-PCR has identified that Fanconi's Anaemia
Complementation Group A (FAA) is regulated by GnRH
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Fig. 3.2.8a: Differential display expression profile of a putative tyrosine phosphatase.
L|iST2 cells were treated as follows: no GnRH (lane 1): or 1 pulse of GnRH and harvested
1 hour (lane 2); 2 hours (lane 3): and 4 hours (lane 4) post-GnRH treatment. Differential
display was performed using the R21 and T12VC primer combination. The arrows
denote the radiolabelled DNA size markers, and the putative tyrosine phosphatase profile.
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R21primer
R21cTCAGTCGGTGGAACTGGGACGAGTTGGAAGAGGGAGATCGTGTTCCCTTGTAAAGATCTGGGGCATTTTAGAT TyrosineGAACTGGGACGAGTTGGAAGAGGGAGATCGTGTTCCCTTGTAAAGATCTGGGGCATTTTAGAT Phosphatase T,VCprimer R21cGAAAACATAGTCACACTTATTTCAATCACACAACAGACACGTCGACGCTTTTTTTTTTTT TyrosineGAAAACATAGTCACACTTATTTCAATCACACAACAGACACGTCGAC Phosphatase Tyrosine Phosphatase 1bp R21
3566bp
1bp27bp























Fig 3.2.8c: The R21c probe from the cloned differential display product, generated
a 4.9kb hybridising band on a Southern blot.
Mouse genomic DNA was digested with BamHI and Hindi 11 overnight, and
electrophoresed on a 0.8% agarose gel, and transferred to a nylon membrane.
The membrane was hybridised using a radiolabeled probe generated from the
cloned differential display PCFt product R21 c, which has identity with a putative
tyrosine phosphatase. The DNA size markers correspond to bacteriophage lambda
restricted with FcoRI and Hindi 11.
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Fig. 3.2.8d: Confirmation of the mRNA expression profile by RPA analysis.
L(3T2 cells were treated with; no GnRH (lane 4), or 1 pulse of GnRH, harvesting
the cells into Direct Protect 1 hour (lane 5), 2 hours (lane 6) and 4 hours (lane 7)
post GnRH treatment. An aliquot of the cell lysate was incubated with the
radiolabelled tyrosine phosphatase and 18s RNA probes and electrophoresed
on a 6% polyacrylamide gel with 100bp marker (lane 1), and the unhybridised
tyrosine phosphatase probe (lane 2 and 18s probe (lane 3).
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Fig 3.2.8e: Quantification of the tyrosine phosphatase mRNA expression profile.
The 18s rRNA expression was used to quantify the tyrosine phosphatase mRNA
expression profile, using Imagequant (Molecular Dynamics), Excel (Microsoft), and
DeltaGraph (SPSS). Expression was up-regulated 27-fold within one hour of
GnRH stimulation.
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FAA was identified by differential display as being regulated by GnRH and it
was isolated from a differential display reaction using the R5 and t12vc
primers (see section 2.5.3a). The gel showed that FAA was up-regulated one
hour post-GnRH treatment, began to wane after two hours, and was at basal
levels after four hours post-GnRH treatment (Fig. 3.2.9a). Bioinformatics
identified a match in the 43rd exon of FAA, and with a penta-zinc finger that
overlaps the FAA gene between exons 35 and 43 (Fig. 3.2.9b). When the
FAA clone was used as a probe in Southern blot analysis, a single 6kb
hybridising band was identified (Fig. 3.2.9c), therefore the FAA clone was
used to probe 40pg of total RNA on a Northern blot. Two faint bands were
seen (Fig. 3.2.9d), however these bands were not informative, so an RPA was
performed. The RPA confirmed that FAA was regulated by GnRH, however
it showed that GnRH markedly down-regulated FAA mRNA levels one and
two hours post-GnRH treatment, with mRNA levels increasing after four
hours (Figs. 3.2.9e and 3.2.9f).
The results of differential display analysis of GnRH-responsive transcripts
isolated from L(3T2 cells are summarised in Table 3.
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Fig. 3.2.9a: Differential display gel identifying that Fanconi's Anaemia complementation group A (FAA)
mRNA is regulated by GnRH.
L|3T2 cells were left untreated (lane 1) or treated with 1 pulse of GnRH and harvested: 1 hour (lane 2);
2hours (lane 3); or 4 hours (lane 4) later. Differential display was performed using T12VC anchored
primers, and the random primers specified. The arrows denote the FAA mRNA expression profile,
and the radiolabeled DNA size markers.
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R5primerR5primer
R5CGGACCCTGGTAGAGGTCAAAGCTGGGGTCAGCCTGCTGCCTCTGCCGGAGGGCGTTGCTCACCCCAGGGTCCG MouseCCTGGTAGAGGTCAAAGCTGGGGTCAGCCTGCTGCCTCTGCCGGAGGGCGTTGCTCACCTCAGGGTC FAAcDNA R5 Mouse zfp276 FAA 1bp4500bp
zfp276
3100bpbp
R51bp79bpR5primerR5primer CGGACCCTGGGGTGAGCAACGCCCACCGGCAGAGGCAGCAGGCTGACCCCAGCTTTGACCTCTGCCAGGGTCCG I I GACCCTGGGGTGAGCAACGCCCACCGGCAGAGGCAGCAGGCTGACCCCAGCTTTGACCTCTGCCAGG





Fig. 3.2.9c: Confirmation of the suitability of the cloned differential display
PCR product for use as a probe by Southern blot analysis.
Mouse genomic DNA was digested with BamHI and Hind\\\, and
electrophoresed on a 0.8% agarose gel, and transferred to a nylon
membrane. The membrane was probed with a radiolabeled probe
generated from the cloned differential display produce. DNA markers







Fig. 3.2.9d: Northern blot analysis of 40,ug of total RNA probed with
radiolabeled FAA.
L(3T2 cells were left untreated (lane 1), or treated with one pulse of GnRH
harvesting at 1 hour (lane 2), 2 hours (lane 3) and 4 hours (lane 4).
Total RNA was extracted from these cells, 40ug was loaded into each
well, and electrophoresed on a 1% denaturing agarose gel. The RNA
was transferred to a nylon membrane and hybridised with a radiolabelled
FAA probed derived from the differential display clone. The arrows a and
b indicate possible FAA bands, and the position of the ribosomal bands
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Fig. 3.2.9e: RPA analysis to confirm that FAA is regulated by GnRH.
LPT2 cells were left untreated, or treated with 1 pulse of GnRH, and harvested into
lysis buffer, 1, 2, and 4 hours post-GnRH treatment. A 50pl aliquot was incubated with
either 1x105 c.p.m. antisense FAA probe, or with 6x10' c.p.m. antisense GAPDH probe,
and subjected to RPA analysis. The antisense FAA probe was also incubated with
50pl of a HeLa cell extract, which had previously been transfected with a FAA
construct, this was used as a positive control. Molecular size markers and undigested






Fig. 3.2.9f: Quantification of the FAA mRNA expression profile.
GAPDH was used to quantify the FAA mRNA expression profile using
Imagequant (molecular Dynamics), Excell (Microsoft) and DeltaGraph
(SPSS). The expression level was decreased almost to zero within one


























































































3.3.1 The different pulse regimes
The first experiments were designed to mimic the luteal and follicular phases
of the oestrus cycle, therefore LpT2 cells were treated with either one 15
minute pulse, or two 15 minute pulses of GnRH either 30 minutes apart
(follicular phase) or 90 minutes apart (luteal phase). In this way, it was hoped
that transcripts, which had a specific role in either of the two phases of the
oestrus cycle would be identified. However, the mRNA expression profiles
that were generated proved to be very complicated, and it was difficult to
identify if the changes seen, were real or artefactual. Therefore a simpler
regime, of one 15 minute pulse of GnRH, harvesting the RNA at 4 and 6
hours post-GnRH treatment, was used. The results of this regime showed
that regulation of mRNA expression occurred much earlier than 4 and 6
hours; expression levels had returned to pre-GnRH treatment levels by 6
hours. So, L|1T2 cells were again treated with a single pulse of GnRH, but
were harvested over a shorter time course of 0, 1, 2, and 4 hours, this
showed the mRNA expression levels changing rapidly over time. The most
striking result of this GnRH pulse regime was that the up-regulation of
mRNA levels was so rapid, a change was seen within 1 hour, which was
maintained after two hours, and generally began to wane after 4 hours.
The rapidity of the cells' response suggested a mitogen activated protein
kinase (MAPK) pathway was responsible for transmitting the signal from the
GnRH receptor. This is because MAPK are known to phosphorylate and
activate immediate early genes such as Elk-1 and serum response factor
(SRF), which are constitutively bound to the serum response element of the
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fos gene (Alberts, Bray et al. 1994). GnRH has been shown to stimulate
MAPK in aT3-l cells (Reiss, Llevi et al. 1997), and MAPK activity is increased
within 10 minutes of GnRH stimulation (Levi, Hanoch et al. 1998). Previous
evidence has suggested that the MAPK pathway transduces transcription in
aT3-l cells (Roberson 1995), and GnRH pulses are required to maintain
activation of MAPK (Haisenleder, Cox et al. 1998). So, GnRH binds to and
activates the GnRH-R, which activates the G protein Gq that activates
phospholipase C (PLC). This leads to the formation of inositol 1,4,5-
triphosphate (IP3), and diacylglycerol (DAG) leading to elevation of Ca2+ and
activation of protein kinase C (Alberts, Bray et al. 1994). Protein kinase C
(PKC) can then activate the MAPK cascade (Han and Conn 1999).
However GnRH is also known to activate other second messenger signalling
pathways. GnRH is known to activate expression of c-Jun N-terminal
protein (JNK) kinase (Levi, Hanoch et al. 1998), but this activation occurs at
least 30 to 60 minutes after GnRH stimulation. Since the majority of
transcripts were identified as being regulated within 1 hour, this suggests
that JNK may not be involved, but should be investigated. Therefore a
number of signalling pathways may be involved in transmitting the GnRH
signal to the nucleus, activation of which may be regulated by the GnRH
pulse regime.
3.3.2 DD-RT-PCR generated transcripts containing repeat
sequences that may correspond to 3' UTR
A number of the isolated transcripts contained repeat sequences, which are
commonly found in 3' UTRs. These repeats proved problematic, since clones
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containing repeats produced hybridising smears that were not informative.
Using Southern blot analysis to screen for clones that produced distinct
hybridising bands, identified those that could be used in further analysis e.g.
by northern blotting or RPA. This screen enabled the straightforward
clones, those lacking repeats, to be analysed first. The problematic clones,
those that contained repeats, were not used. However, had time allowed,
further analysis could be possible by generating full-length clones either by
5' or 3' rapid amplification of cDNA ends (RACE), which could then be used
to screen mouse cDNA libraries.
3.3.3 The cloned DD-RT-PCR products were smaller than
expected
All the cloned differential display products were smaller than expected, based
on the size of the bands isolated from the DD-RT-PCR gels. DNA sequence
analysis of the clones often identified priming sites that the upstream primer
could anneal to. Since the annealing temperature of the re-amplification PCR
is low (40°C), the re-amplification primers may be priming to internal primer
sites, or mis-priming to sequences that have similarity to the primers
themselves. Thus, the small size of the fragments may be due to internal
mis-priming during the re-amplification PCR.
3.3.4 Regulation of Myosin Light Chain mRNA by GnRH
Myosin was initially identified in skeletal muscle, and is involved in the
contractile mechanism of muscle fibres. There are a number of different
types of myosin, the most common being myosin-II, found in skeletal
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muscle fibres and smooth and non-muscle cells (Alberts, Bray et al. 1994).
There are a number of smaller myosins found in all cells (the best
characterised being myosin-I), which regulate vesicle transport, attach actin
filaments to the plasma membrane, or align two actin filaments together,
and allow them to slide past each other (Cheney and Mooseker 1992;
Mooseker and Cheney 1995; Mermall, Post et al. 1998). Myosin-I consists of
a single conserved motor head domain, which drives movement along the
actin filaments, and a variable tail domain, which determines the role of the
myosin in the cell. The tail domain of myosin-I consists of a heavy chain, and
a light chain (Stryer 1995), which can be phosphorylated by myosin light
chain kinase (MLCK). The activation of myosin depends on the
phosphorylation of myosin light chain (MLC), by MLCK (Alberts, Bray et al.
1994). MLCK activity is Ca2+ dependent. Activation of PLC and PKC can
induce a rise in Ca2+ levels. Ca2+ binds to calmodulin, a Ca2+ binding protein,
which then phosphorylates MLCK, activating the kinase. MLCK then
phosphorylates MLC, which activates the myosin motor (Alberts, Bray et al.
1994).
A previous paper has linked MLCK with a GnRH mediated Ca2+ dependent
exocytosis of LH from cultured rat pituitary cells by phosphorylation of MLC
(Rao, Paik et al. 1997), how MLC promotes exocytosis of the LH containing
vesicles, is unknown. MLC was identified and isolated using the
follicular/luteal phase pulse regime and the expression profile suggests that
MLC transcription is up-regulated during the luteal phase. The northern
analysis confirmed this pattern of expression, however the basal expression
level was higher than the differential display profile suggested. This
discrepancy may be explained by loading errors on the differential display
155
gel; thus the differential display expression pattern appears to show de novo
synthesis, rather than an up-regulation of transcription in response to GnRH.
MLC is an integral part of the cytoskeletal structure, which may also explain
the high basal mRNA expression levels shown on the northern blot.
The expression profile of MLC shows that the transcriptional up-regulation
of MLC mRNA was dependent on pulse frequency. This may be due to its
role in secretion, and evidence for different second messenger signalling
pathways involved in the control of transcription during the luteal and
follicular phases. GnRH via a Ca2+ mediated response induces an initial spike,
followed by a short sustained secretion of LH in rat pituitary cells.
Wortmannin, a specific inhibitor of MLCK, abolished the sustained release of
LH, indicating that this release required phosphorylation of MLC (Rao, Paik
et al. 1997). However, a two pulse GnRH regime indicated that MLCK
induced phosphorylation was inhibited by activation of protein kinase C
(PKC) in aT3-l cells (Rao, Paik et al. 1997). Therefore, there may be 2
mechanisms, which mediate LH release during the luteal and follicular
phases. In the luteal phase, the GnRH pulse interval is approximately one
per hour, with a concomitant release of LH. GnRH induces an influx of Ca2+
that activates the MLCK pathway, which induces a pulse of LH to be
secreted. When the GnRH pulses become more frequent, i.e. one every
fifteen minutes, as in the follicular phase, the PKC pathway is activated,
which inhibits phosphorylation of MLC by MLCK. This mechanism could
attenuate secretion of LH, and consequently increase the number of LH
containing vesicles. When the LH surge is triggered, these can be released en
masse. Thus, it is hypothesised that MLC may only be required for LH
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secretion during the luteal phase, and hence MLC mRNA levels are only up-
regulated during the luteal phase.
3,3.5 GnRH tightly regulates tyrosine phosphatase
A putative tyrosine phosphatase was identified as being regulated by GnRH,
by differential display analysis. It was massively up-regulated one hour
post-GnRH treatment, and the expression waned after 4 hours post-GnRH
treatment. There is evidence to suggest that GnRH binding to the GnRH
receptor (GnRH-R) up-regulates transcription of a tyrosine phosphatase in
pancreatic tumour cells (Liebow, Lee et al. 1990), though its role is not
entirely understood. In pancreatic tumour cells that have GnRH-R, tyrosine
phosphatases are activated after stimulation with GnRH, and act to suppress
the tyrosine kinase response induced by epidermal growth factor (EGR) by
de-phosphorylating the GnRH-R (Liebow, Lee et al. 1991). In a similar
manner, the signalling cascade activated by GnRH binding to GnRH-R may
likewise, regulate the GnRH response: activation of the MAPK pathway,
activates the PKC pathway, which induces a number of other
phosphorylation events involved in activating the GnRH response. One of
these events would be to induce transcription, translation, and
phosphorylation of tyrosine phosphatases, which dephosphorylate and
deactivate the signalling mechanisms. In this manner, the GnRH response
can be controlled, and down-regulated until the next GnRH signal. RPA
analysis confirmed the expression profile and after quantification, identified
the up-regulation as 27-fold. This massive up-regulation may be due to the
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fact that these L(3T2 cells are naive to GnRH therefore, the cells initiate a
"knee-jerk" reaction in response to GnRH, to regulate the signal pathways.
3.3.6 DD-RT-PCR identified a transcript that is found in the
mammary gland, brain and CNS
The transcript R3c was identified as being up-regulated by GnRH within one
hour of GnRH stimulation, which was maintained 4 hours post-GnRH
treatment. Searching the mouse EST database with R3c, identified a match
with an EST that was expressed in the mammary gland of a pregnant, and
lactating female mouse. There was also some similarity with an EST, that
localises to regions of the CNS and the brain, specifically, the hypothalamus,
pituitary, corpora quadrigemina, diencephalon, spinal cord, retina, neonatal
(day 0) cerebellum and cortex, and embryonic brain. These are regions of the
"old brain" that control the basic survival functions such as homeostasis,
breathing, heart rate, sensory and endocrine systems.
GnRH induces de novo synthesis of this transcript and expression is
maintained 4 hours post-GnRH treatment. This implies that this transcript
requires the presence of GnRH before it is expressed however, after the cells
have been exposed to GnRH, the transcript no longer requires GnRH to be
expressed. This may be an artefact of the cells, which are naive to GnRH and
hence will not express transcripts that are only GnRH responsive. This
transcript is also rare, northern blot analysis could not identify any bands,
therefore an RPA was performed, the results of which were inconclusive,
due to degradation of the RNA. A faint band can be seen at 300bp, however
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it is not possible to determine if this band is real or artefactual. Ideally, the
RPA should have been repeated, but time constraints have prevented this.
3.3.7 R13c is a novel transcript that matches a region on
chromosome 3, but is probably not a differential display
fragment
R13c was up-regulated within one hour of GnRH treatment, expression
levels peaked after two hours and waned after 4 hours post-GnRH
treatment. Bioinformatics identified an exact match with a region on human
chromosome 3, in the high throughput database. This, together with the
lack of a hybridising band on the RPA suggests that the PCR fragment that
was cloned was a result of contamination from a human source, since
bioinformatic analysis produced an exact nucleotide match, when some
divergence would be expected.
3.3.8 R18b has identity with an EST that is expressed in the
adult mouse testis
R18b is up-regulated within one hour of GnRH exposure, this is maintained
after 2 hours, but wanes after 4 hours. It matches an EST that is expressed in
the adult mouse testis, however its function is currently unknown.
3.3.9 FAA is regulated by GnRH
Fanconi's Anaemia (FA) is an autosomal recessive disorder characterised by
progressive bone marrow failure (Fanconi 1967). In addition, a number of
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other heterogeneous clinical manifestations may be present including; short
stature, limb deformities, abnormalities of major organs, skin
hyperpigmentation, microcephaly, and reduced fertility or infertility (Glanz
and Fraser 1982). Patients are also more susceptible to developing cancers,
most frequently acute myeloid leukemia (Carreau and Buchwald 1998). This
therefore suggests that the FA proteins are involved in DNA repair of
crosslinking DNA strands or control of the cell cycle (Porfirio, Smeets et al.
1991; Kruyt, Dijkmans et al. 1996; Kruyt, Dijkmans et al. 1997).
Complementation studies have identified seven complementation groups
Fanconi's anaemia complementation group A (FAA) to G (FAG) (Joenje,
Oostra et al. 1997; Joenje, Levitus et al. 2000) and mutation in any one of
these genes leads to FA (Carreau and Buchwald 1998). A majority of FA
patients have mutations in either FAA or Fanconi's anaemia
complementation group C (FAC) (D'Andrea and Grompe 1997), which cover
the entire range of possible genetic mutations (Lo Ten Foe, Rooimans et al.
1996; Savino, Ianzano et al. 1997; Lo Ten Foe, Kruyt et al. 1998; Morgan,
Tipping et al. 1999; Balta, de Winter et al. 2000; Faivre, Guardiola et al. 2000).
FAA mRNA was identified by differential display analysis as being up-
regulated by GnRH, however RPA analysis suggests that FAA mRNA levels
are down-regulated by GnRH. There may be two transcripts within this
band that are both regulated by GnRH, and the transcript that appeared to
be up-regulated by GnRH masked the transcript that was down-regulated
by GnRH. Analysis of the EMBL database using the BLAST search tool
identified an additional overlapping mRNA transcript. The zfp276 penta zinc
finger mRNA transcript overlaps the 3' end of the FAA mRNA transcript in
the opposite orientation (Wong, Alon et al. 2000). It is feasible that the
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pattern on the differential display gel corresponds to the amplification of this
transcript via priming of the downstream anchored primer and upstream
priming of R5. Thus zfp276 may be up-regulated in response to GnRH.
Further amplification of this cDNA prior to cloning may have generated an
internal sub-clone, flanked by two R5 priming sites, which was indeed the
case with this DD-RT-PCR clone (Fig3.2.9b). It is not known if this clone, and
hence the DD-RT-PCR mRNA expression profile, corresponds to zfp276 or
FAA (Fig. 3.3.9), this requires further clarification, but may explain the
differing band profiles. Northern blot analysis of 40pg of total RNA
identified very faint bands, which were not informative, but showed that
FAA transcripts were not abundant in gonadotrophs. The presence of
multiple bands is consistent with reports that FAA has multiple splice
variants (Ianzano, D'Apolito et al. 1997), which may be involved in the
regulation of FAA. The role of FAA protein has not been fully elucidated. It
has been isolated in a number of different tissue types at different stages of
development in mice. During mouse embryogenesis FAA mRNA
expression was identified in the whisker follicles, kidneys, liver, teeth and
limbs, which is consistent with the limb and major organ abnormalities seen
in FA patients, and suggests a role for FAA in the development of these
features. FAA expression at el3.5 was limited to the intermediate zone of
the developing cerebral cortex and the anterior part of the midbrain which
becomes restricted to the retina after birth (Abu-Issa, Eichele et al. 1999).
FAA protein expression analysis in the adult mouse showed that it was
expressed in numerous tissue types, with high levels of expression in the
ovary, testis, spleen and lymphoid tissues, but no expression was seen in the
brain (van de Vrugt, Cheng et al. 2000). The authors of this
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Genomic organisation of FAA and zfp276
Fig. 3.3.9: Diagram to show how the R5/FAA clone was isolated, and explain
why the RPA mRNA expression profile did not match the DD-RT-PCR mRNA
expression profile.
The LPT2 cells were treated with GnRH and the RNA extracted. During the RT-
PCR step (step 1) the 3' anchored primer annealed to the poly A tail of zfp276
mRNA producing a zfp276 cDNA. DD-PCR amplified this cDNA using the
anchored primer and the R5 primer (step 2), and the DD-RT-PCR gel identified
that this mRNA was up-regulated in response to GnRH. During the re-
amplification PCR (step 3), the R5 primer annealed to the 5' end and to an
additional R5 priming site that is present within the DD-PCR fragment, 5' to the
poly A tail. This smaller fragment was preferentially amplified and cloned. The
cloned fragment matches to the region of overlap between FAA and zfp276,
however the orientation of the fragment was unknown. Thus RPA analysis
identified that the mRNA expression levels of FAA not zfp276 were down-
regulated in response to GnRH. The mRNA expression profile of zfp276 has not
been confirmed.
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paper however, used the whole brain. Protein and mRNA expression
analysis of the different regions of the brain, including the anterior pituitary,
may clarify the presence or absence of FAA in the brain. Both FAA and FAC
have a role in reproduction. Recently, FAA and FAC gene disrupted mice
have been reported. Both transgenic mice show chromosomal instability,
however the major phenotype in the mice, appears to be reduced fertility
and not anaemia (Chen, Tomkins et al. 1996; Cheng, van de Vrugt et al.
2000). Therefore, there is a role for FAA in controlling reproduction and the
identification of FAA in the gonadotrophs indicates that it may be involved
at both the pituitary and gonadal level of the reproductive axis. FAA's role
in the gonadotrophs is explored in Chapter 4.
3,3.10 Conclusions
DD-RT-PCR has been successfully used to identify transcripts that are
regulated by GnRH. Previous to the work described in this thesis, there has
been evidence to suggest that two of the transcripts identified may be
regulated by GnRH. MLCK activity is regulated by GnRH and is involved in
regulating secretion in aT3-l cells (Rao, Paik et al. 1997). In addition, tyrosine
phosphatase activity is also regulated by GnRH in pancreatic tumour cells
(Liebow, Lee et al. 1990). This thesis provides first evidence and confirms
that GnRH regulates MLC and tyrosine phosphatase mRNA levels in
gonadotrophs. The identification of two novel transcripts whose function is
currently unknown, which are regulated by GnRH, validates the DD-RT-PCR
technique. Further analysis of these transcripts may involve generating full-
length clones by RACE and screening cDNA libraries, or by further
bioinformatics analysis.
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The expression profiles identified on differential display gels, have for the
majority of cases, been confirmed by northern and RPA analysis. In general,
the profiles shown by differential display are an accurate representation of
the mRNA expression levels found in the cells. The contrasting DD-RT-PCR
and RPA profiles of the FAA clone however, suggests that the expression
profile of all clones isolated from DD-RT-PCR should be confirmed, to ensure
the changes are indeed real. GnRH rapidly regulates mRNA expression
levels, however this regulation is also very tightly controlled, since mRNA
expression returns to basal levels four hours after GnRH treatment.
DD-RT-PCR has been very useful in identifying rare transcripts, which are
GnRH regulated, however the PCR nature of this technique means that
contamination from other sources may occur. Although this is a problem,
the sensitivity of the technique has identified a number of transcripts whose
function and identity are currently unknown, therefore it would be safe to
assume that such transcripts would not have been identified by other
techniques, such as cDNA arrays.
164
Chapter 4:
FAA regulates aGSU gene promoter activity
4.1 Introduction
Fanconi's anaemia (FA) is an autosomal recessive disorder characterised by
progressive bone marrow failure and aplastic anaemia (Fanconi 1967). Other
symptoms include short stature, limb deformities, abnormalities of major
organs, skin hyperpigmentation, microcephaly and reduced fertility or
infertility. In particular, male patients have underdeveloped gonads and
defective spermatogenesis (Bargman, Shahidi et al. 1977; Glanz and Fraser
1982; Alter 1993; D'Andrea and Grompe 1997). FA patients have an
increased likelihood of developing cancers, specifically acute myeloid
leukemias, and squamous cell carcinomas (Dosik, Hsu et al. 1970; Swift,
Zimmerman et al. 1971; Alter 1992; Somers, Tabrizi et al. 1995; Carreau and
Buchwald 1998), however diagnosis is complicated by the clinical
heterogeneity of the disease. The diagnosis of FA relies on the increased
sensitivity of FA cells to bifunctional alkylating agents. FA cells display
chromosomal instability which is amplified in the presence of crosslinking
agents such as mytomycin C (MMC) and diepoxybutane (DEB) (D'Andrea
and Grompe 1997).
Complementation studies have identified seven different genes that are
involved in this disorder (Joenje, Oostra et al. 1997; Joenje, Levitus et al.
2000). These were designated as Fanconi's anaemia complementation group
A (FAA), B (FAB), C (FAC), D (FAD), E (FAE), F (FAF) and G (FAG), and
mutations in any of these genes can cause the FA phenotype, suggesting that
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they act in a common pathway (Carreau and Buchwald 1998). The
nucleotide and amino acid sequences of FAA and FAC have no homology to
other lower eukaryotes, however they are conserved in humans and mice
(Strathdee, Gavish et al. 1992; Wevrick, Clarke et al. 1993; van de Vrugt,
Cheng et al. 2000). A human homolog of FAG was identified as XRCC9,
which is involved in DNA post-replication repair (de Winter, Waisfisz et al.
1998), and FAF has homology to the bacteria RNA binding protein ROM (de
Winter, Rooimans et al. 2000). Furthermore, FAA interacts directly with the
N-terminus of FAG (Lightfoot, Alon et al. 1999; Reuter, Herterich et al. 2000)
and with FAC through the C-terminus of FAG, this forms a functional
complex in the nucleus (Kuang, Garcia-Higuera et al. 2000), FAG also
interacts with FAF in the nucleus. Additionally, FAE can interact with FAC
directly, and with both FAA and FAG (Medhurst, Huber et al. 2001) (see Fig.
4.1).
Mutations in FAA account for 60% of all patients and include a wide range of
mutation types (Wijker, Morgan et al. 1999). The FAA gene contains 43
exons, spans 80kb and encodes a 4.5kb mRNA transcript, with a number of
alternative splice variants (Ianzano, D'Apolito et al. 1997). The FAA protein
is 162kDa and has a bipartite nuclear localisation signal (NLS) at the N-
terminus, which binds FAG and promotes nuclear accumulation of the FA
complex (Lightfoot, Alon et al. 1999; Garcia-Higuera, Kuang et al. 2000).
There are also two putative Src Homology module 2/3 domains (SH2/SH3),
a partial leucine zipper domain (van de Vrugt, Cheng et al. 2000), and a
peroxidase domain (Mian and Moser 1998). Unlike FAC, that has mutation
"hotspots" that determine if the FA phenotype is mild or severe, FAA
mutations are spread along the whole gene, and no correlation between
166
Fig. 4.1: A schematic representation of the interactions of the five known FA
proteins in non-gonadotroph cells.
FAA interacts with FAG to produce a stable complex. FAC interacts with
FAG and the complex is transported to the nucleus where FAF interacts
with FAC, this produces afunctional nuclear complex. FAE can interact
with FAG and FAA, however its role is not fully understood.
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mild or severe phenotypes has been observed (Carreau and Buchwald 1998).
Recently, the endocrinopathy of FA patients was reviewed, and showed that
FA patients had a number of endocrine abnormalities including growth
hormone (GH) insufficiency, hypothyroidism, glucose intolerance,
hyperinsulinism and/or overt diabetes mellitus (Wajnrajch, Gertner et al.
2001) and there was some correlation between phenotype and
complementation group (Faivre, Guardiola et al. 2000). There is also evidence
to suggest that a truncated FAA protein produces a more severe phenotype
than the absence of a FAA protein (Chen, Tomkins et al. 1996; Cheng, van de
Vrugt et al. 2000).
A FAC gene disrupted mouse was developed in 1996 (Chen, Tomkins et al.
1996). The mice showed no developmental or haematological abnormalities,
however the mice did have inducible chromosomal instability, and reduced
fertility. Homozygous matings produced no litters, and heterozygous
matings produced fewer and smaller litters than their wild-type
counterparts. During the course of the work in this thesis, a FAA gene
disrupted mouse was reported (Cheng, van de Vrugt et al. 2000). Again, this
transgenic mouse showed no developmental abnormalities, and only a mild
haematological phenotype. The embryonic fibroblast cells of these mice did
display chromosomal instability if challenged with mitomycin C and the mice
were hypogonadal and subfertile.
Since the mean age of survival for FA patients is 16 years (Wijker, Morgan et
al. 1999), there have been few studies on gonadotrophin synthesis and
secretion. Some FA patients show subfertility, and hypogonadism
(Bargman, Shahidi et al. 1977; Berkovitz, Zinkham et al. 1984), and
gonadotrophin serum levels of FA patients have been reported in a pair of
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siblings with FA (Berkovitz, Zinkham et al. 1984). Both patients presented
with hypergonadotrophic hypogonadism, and the serum levels in both
patients were significantly elevated, however the complementation group of
these patients was unknown. This, together with the novel discovery of
FAA in gonadotrophs using DD-RT-PCR, suggested that FAA might have a
role in controlling gonadotrophin synthesis or secretion.
4.2 Results
4.2.1 Transient transfection analysis of FAA and the LH|3 gene
promoter
Transient transfection assays were carried out in L|3T2 cells, and aT3-l cells to
identify a role for FAA in gonadotrophs. In order to identify if FAA affected
LH(3 transcription, an expression vector, containing the coding region of the
FAA mRNA, was co-transfected with either -1786bp (ppl786) or -700bp
(dLH2) of the ovine LH|3 promoter construct linked to a [3-galactosidase
reporter gene into L(3T2 cells (see sections 2.4.9, 2.4.11 and 2.4.12). The cells
were then either left untreated, or treated with GnRH 48 hours after
transfection, harvested 6 hours post-GnRFi treatment and assayed for (3-
galactosidase activity (see sections 2.4.8 and 2.4.11). The results indicated that
FAA did not affect basal, or GnRH regulated LH(3 promoter gene activity
(Fig. 4.2.1a and Fig 4.2.1b).
4.2.2 Transient transfection analysis of FAA and the aGSU
gene promoter in L|3T2 cells
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Since FAA had no effect on LH(3 gene promoter activity, it may have an
effect on aGSU gene promoter activity and possibly explain the infertile
phenotype of FAA gene disrupted mice. To test this, FAA was co-transfected
with -480bp of the aGSU gene promoter linked to a luciferase reporter gene
into L(3T2 cells (see section 2.4.9). This promoter fragment is known to target
aGSU expression to the gonadotroph cells of transgenic mice (Horn, Windle
et al. 1992) and contains both the GnRH-RE and PGBE regions (see section
1.4.4) (Schoderbek, Kim et al. 1992) required for both basal and GnRH
regulated transcription. The cells were left untreated, or treated with GnRH
48 hours after transfection, and harvested 6 hours post-GnRH treatment
before assaying for luciferase activity (see sections 2.4.8 and 2.4.10).
As expected, GnRH significantly up-regulated aGSU promoter activity in
L(3T2 cells (Fig. 4.2.2a). However, when FAA was co-transfected there was a
down-regulation of basal -480bp aGSU luciferase activity and when the cells
were co-transfected with FAA and treated with GnRH, the GnRH response
of the -480bp aGSU promoter was obliterated (Fig. 4.2.2a). In an effort to
map the region of promoter responsible for this effect, FAA was co-
transfected into LPT2 cells, with the -120bp aGSU promoter. This promoter
fragment contains a paired-like homeodomain binding site, and in this case
FAA significantly up-regulated the basal -120bp aGSU promoter activity
above the GnRH stimulated activity and this FAA induced activity was
abolished in the presence of GnRH (Fig. 4.2.2b). Clearly FAA regulates the
aGSU gene promoter and may act directly or indirectly, through the paired-
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4.2.3 Transient transfection analysis of FAA and the aGSU
gene promoter in aT3-l cells
Since FAA regulated aGSU expression in L|3T2 cells, it was decided to test if
the same mechanism was present in aT3-l gonadotroph cells. aT3-l cells are
of an earlier gonadotroph lineage to L(fT2 cells, however they do synthesise
and secrete aGSU (Windle, Weiner et al. 1990). The -480bp or -120bp aGSU
promoter was co-transfected with FAA into aT3-l cells, which were either
left untreated, or were treated with GnRH 48 hours after transfection (see
section 2.4.8 and 2.4.9). The cells were harvested 6 hours post-GnRH
treatment and assayed for luciferase activity (see section 2.4.10). In this
instance, FAA had no effect on the GnRH stimulated response of the -480bp
aGSU promoter in aT3-l cells (Fig. 4.2.3a). FAA significantly up-regulated
promoter activity of the basal -120bp aGSU fragment, however GnRH did
not abolish this up-regulation in aT3-l cells (Fig. 4.2.3b). This suggests that
FAA may act through the paired-like homeodomain binding site, and a
factor present in both aT3-l and L(3T2 cells interacts with FAA mediating an
up-regulation of the aGSU promoter activity.
4.2.4 RPA of FAA using ribo-probes generated from truncated
FAA DNA constructs
Modulation of aGSU gene promoter activity indicates a role for FAA in
gonadotrophin hormone production and resections of the aGSU gene
promoter demonstrated that FAA could down-regulate GnRH induced gene
expression over the entire promoter. Since results of DD-RT-PCR showed
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that the FAA mRNA was highly regulated by GnRH, it was decided to use an
RPA to determine if this was due to alternative exonic splicing, or perhaps
instability of the transcript. Therefore, to test this, the FAA cDNA was
truncated and manipulated to produce a 965bp, and a 2400bp fragment and
cloned into pcDNA3 (FAA965 and FAA2400 respectively, see sections 2.3.1
and 2.3.9 and Fig. 4.2.4a). RPA analysis was performed using antisense
probes generated from these truncated forms of FAA (see section 2.3.18 and
Fig. 4.2.4a). The FAA965 probe was generated by restricting the cDNA with
Eae I, this when transcribed with Sp6 RNA polymerase generated a 375bp
probe that when hybridised to FAA mRNA, would protect a 327bp
hybridising band. This probe was used in a RPA analysis of L(3T2 cells that
were either left untreated, or treated with GnRH. There was no change in
mRNA expression levels of this fragment of FAA in response to GnRH (Fig.
4.2.4b). The FAA2400 probe was also generated by restricting the cDNA
fragment with Eae I, which generated a 399bp long probe when transcribed,
that should protect a 354bp hybridising band (Fig. 4.2.4c). However, in this
experiment,the control FAA mRNA generated a 175bp hybridising band, this
is much smaller than expected, and requires more investigation (Fig. 4.2.4c).
4.2.5 Localisation of the FAA regulatory region
The truncated FAA cDNAs produced for the experiments described above
were also used to map the region of FAA protein that mediated the down-
regulation of the aGSU promoter. To facilitate this, when the cDNAs were
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Fig. 4.2.4b: RPA analysis showing that the mRNA of the first 965bp at the
5' end of FAA is not regulated by GnRH.
L(3T2 cells were either left untreated (lanes 1 and 5), or treated with one
15 minute pulse of GnRH and harvested into Direct Protect after 1 hour
(lanes 2 and 6); 2 hours (lanes 3 and 7); and 4 hours (lanes 4 and 8). The
cell lysate was hybridised with either radiolabeled FAA 965 (372bp) (lanes
5,6,7 and 8) or GAPDH (316bp) (lanes 1,2,3 and 4) in vitro translated RNA
and electrophoresed on a 6% polyacrylamide gel with unhybridised FAA965
and GAPDH probes (lanes 11 and 12 respectively and arrows b and a). The
FAA probe was also incubated with 20pl of a HeLa cell extract, which had
previously been transfected with a FAA expression construct, this was used
as a positive control (lane 9). Lane 10 is a negative control used to ensure
that the FAA965 probe did not self protect, and lane 13 is a 100bp marker.
Arrow c denotes the protected FAA965 (327bp) and GAPDH (316bp) bands.
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Fig. 4.2.4c: RPA analysis of the mRNA expression pattern of FAA in response
to GnRH using a probe generated from FAA2400.
LpT2 cells were either left untreated (lanes 6 and 10) or treated with GnRH
and harvested into Direct Protect 1 hour (lanes 7 and 11); 2 hours (lanes 8
and 12); or 4 hours (lanes 9 and 13) after treatment. The cell lysate was hybridised
with either radiolabeled FAA2400 (399bp) or radiolabeled GAPDH in vitro
translated RNA. These were then electrophoresed on a 6% polyacrylamide gel
with unhybridised FAA2400 or GAPDH probes (lanes 4 and 3 respectively), and a
10Obp marker (lane 1). A positive control of the FAA2400 probe hybridised to
HeLa cell lysate that had previously been transfected with an FAA expression
construct (lane 5), and a negative control of the FAA2400 probe hybridised to yeast
tRNA (lane 2), was also included. The positive control produced a hybridising
band of about 175bp.
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modification of a double stranded oligonucleotide, which encoded the FLAG
peptide (FLAG peptide sequence: Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Ser-
Arg-Ser), was inserted into the 3'end of the cDNA. This FLAG-tagged the
proteins that were encoded by these constructs. So, the FAA965 cDNA
should, when translated, produce a truncated FAA protein 322aa long and
the FAA2400 cDNA should produce a protein 800aa long. In addition, the
full-length FAA cDNA was also tagged by insertion of the FLAG-encoding
oligonucleotide into the coding region of the cDNA. This construct encodes a
1500aa protein (Fig. 4.2.5a). Therefore, to identify the region of the FAA
protein that may interact with the aGSU promoter, or mediate the
repression, either FAA965, or FAA2400 or the full-length FAA cDNA
construct, was co-transfected with the -480bp aGSU promoter into L(3T2
cells. These cells were either left untreated, or treated with GnRH 48 hours
after transfection (see sections 2.4.8 and 2.4.9). Cells were harvested 6 hours
post-GnRH treatment and assayed for luciferase activity (see section 2.4.10).
None of the co-transfected FAA constructs significantly affected basal aGSU
promoter activity, which agrees with the result described in section 4.2.2.
However, as already observed, there is a slight, but non-significant, decrease
in basal expression of the aGSU promoter. When compared to the GnRH
induced increase in activity of the aGSU promoter, co-transfection of all
three FAA constructs significantly attenuated this response (Fig. 4.2.5b). This
suggests that despite truncating the C-terminal region of the FAA protein
from 1500aa down to 322aa, the remaining region could still repress. Thus,
the regulatory region on FAA, lies in the region between amino acid residues
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Fig. 4.2.5b: FAA965 and FAA2400 are able to repress the GnRH stimulation of
the -480 a GSU promoter.
The -480bp of the aGSU promoter linked to a luciferase reporter gene and a
control [5-galactosidase reporter gene were transfected into LPT2 cells for all
treatments and the cells were either left without FAA (-FAA) or co-transfected with
FAA. The results are expressed as fold induction after correcting for protein
levels and transfection efficiency as determined by p-galactosidase activity. After
48 hrs the cells were then left untreated (-) or treated with GnRH (+) before
harvesting. ANOVA one-way analysis of variance was used to determine
significant differences; a, p<0.01 untreated vs. GnRH treated; b, p<0.05 untreated,
-FAA vs. GnRH treated, co-transfected with FAA965; c, p<0.01 GnRH treated, -
FAA vs. GnRH treated, transfected with FAA2400; d, p<0.001 GnRH treated, -
FAA vs. untreated, transfected with FAA4500, FAA2400 or FAA965; e, p<0.05
untreated, transfected with FAA2400 vs. GnRH treated transfected with either
FAA4500 or FAA965; f, p<0.05 GnRH treated, untransfected vs. transfected with
either FAA4500 or FAA965.
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4.3 Discussion
As described in chapter 3, FAA mRNA was isolated from gonadotrophs, and
was regulated by GnRH. A role for FAA in gonadotrophs was investigated
by transfection studies. Initially, the effect of FAA on LHp transcription was
studied. FAA was co-transfected with either -1786bp or -700bp of the LHp
promoter into LPT2 cells, which were either left untreated or were treated
with GnRH 48 hours later. Both LHp promoters were GnRH responsive and
co-transfection of FAA did not affect this response. Therefore, FAA was co-
transfected with -480bp or -120bp of the aGSU promoter into the LPT2 cell-
line, a fully differentiated gonadotroph cell-type and the aT3-l cell-line, a
progenitor gonadotroph cell-type. FAA obliterated the -480bp aGSU
promoter response to GnRH in LPT2 cells, and had no effect on the same
promoter in aT3-l cells. Conversely, FAA up-regulated the basal activity of
the smaller -120bp aGSU promoter fragment in both LPT2 and aT3-l cells,
suggesting that they share a common factor. GnRH down-regulated this
response in LPT2 cells, and had no effect in aT3-l cells, indicating that the
GnRH down-regulation of this response was specific. In an attempt to
localise the functional region of FAA, two deletion constructs were produced.
The leucine zipper domain of the full length FAA was removed in the
FAA2400 construct, and both the leucine zipper and the SF12 and SH3
domains were removed in the FAA965 construct. Transfection studies with
these constructs and the -480bp aGSU promoter in LPT2 cells mapped the
repressor domain to between laa and 322aa.
4.3.1 FAA specifically regulates the aGSU promoter
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A report in 1984 described two siblings, male and female, with FA that were
hypogonadal (Berkovitz, Zinkham et al. 1984). The serum LH and FSH
levels were measured in both patients and were elevated. Since FAA was
identified as being GnRH regulated in gonadotrophs (see section 3.2.9), and
some FA patients have been described with gonadal deformities (Bargman,
Shahidi et al. 1977), it was hypothesised that FAA may have a role in
regulating either the synthesis or secretion of the gonadotrophins. FAA has
no effect on LH(3 transcription, this result is consistent with an FAA gene
disrupted mouse that has been recently reported. The major phenotype of
this transgenic mouse was hypogonadism with delayed, impaired fertility,
however the mice did display a mild anaemia phenotype.
Immunocytochemistry of the anterior pituitary revealed normal amounts of
LH|3 and FSH(3, suggesting that FAA does not have a role in regulating
either gene (Cheng, van de Vrugt et al. 2000). However the authors did not
look at aGSU protein levels, which these results suggest, should be elevated.
The authors disrupted the 5' end of the FAA gene, specifically exons 4 to 7
and used an antibody to the 5' end of FAA to detect the protein. In the study
reported in this thesis, the repressor protein domain of FAA mapped to the
region deleted in the gene disrupted mice. Although it is possible that the 3'
end of the protein may remain intact and account for the progressive
infertility in the gene disrupted mice, it is more likely that the regulatory
region of FAA required to effect aGSU gene expression was disrupted in
these mice. The impaired fertility is consistent with our hypothesis that the
N-terminal 322aa region of FAA was responsible for repression of aGSU,
because the female gene disrupted mice produced smaller litters than their
wildtype littermates and were eventually completely infertile by 20 weeks.
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The male phenotype was less severe since the males were able to reproduce
for longer, but the number and size of the litters declined after 20 weeks,
with the majority of the adult males then failing to fertilise females.
Curiously, some males regained some fertility after being infertile for some
months. Histological examination of the ovaries and testes of these mice
revealed that the ovaries have few follicles and the testes were atrophic with
reduced spermatogenesis and hyperplasia of Leydig cells. In addition, the
testes of a male FA patient also showed an increased number of Leydig cells,
and a "Sertoli-cell-only" defect (Bargman, Shahidi et al. 1977). Since our
studies predict that disruption of FAA would increase aGSU serum levels, it
is not understood why this would impair fertility. Measurement of
gonadotrophin plasma levels in the gene disrupted mice would give some
indication if disrupting aGSU gene expression impacts on production of LH
and FSH hormone. It is known that aGSU can be secreted from
gonadotrophs into the plasma as a monomer, unbound to the |3-subunit
(Blomquist and Baenziger 1992), and evidence for a biological role for free
aGSU is emerging (Blithe 1990; Blithe, Richards et al. 1991; Moy, Kimzey et
al. 1996; Van Bael and Denef 1996; Nemansky, Moy et al. 1998; Chabot,
Magallon et al. 2000; Chabot, Gauthier et al. 2001).
Previously, a FAC gene disrupted mouse model was described with a mild
haematological phenotype, and subfertility (Chen, Tomkins et al. 1996).
Homozygous matings produced no litters, and heterozygous matings
produced smaller litters, than a wildtype mating. The testes of the FAC
transgenic mouse displayed vacuolar degeneration of the seminiferous
tubules, with spermidic giant cells. The ovaries of the FAC transgenic mice
were small with few follicles or mature corpora lutea. These defects may be
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due to the loss of the DNA repair function in the gonads, since similar
phenotypes have been seen in other DNA repair gene disrupted mice, such
as the ERCC1 gene disrupted mouse (personal communication with P. T. K.
Saunders). The similarities of the gonadal phenotypes of FAA and FAC gene
disrupted mice suggest that both FAA and FAC interact in the gonad. The
phenotype of the FAA and FAC gene disrupted mice also share some
similarity with the gonadal phenotype of transgenic mice and human
patients with defects in gonadotrophin subunit or gonadotrophin receptor
(Berthezene, Forest et al. 1979; Burns, Yan et al. 2001; Lei, Mishra et al. 2001).
It is not certain in these mice however, if there is also a defect in aGSU
synthesis, or viable gonadotrophin production. The results of the study in
this thesis shed some light on the role of the FA proteins on gonadotrophin
synthesis, since the regulatory domain of FAA was mapped to the region
that interacts with FAG, and FAC (Lightfoot, Alon et al. 1999). This may
mean that although the regulatory domain was mapped on FAA, this
domain actually corresponds to the region that interacts with FAG and FAC.
At the moment it is unknown if FAG and FAC are expressed in the
gonadotroph. However, it is known that FAG interacts with FAA via the
NLS in other cell types and it is possible that the same mechanism occurs in
gonadotrophs.
4.3.2 FAA may interact through the paired-like homeodomain
binding site on the aGSU promoter
FAA repressed the longer -480bp aGSU promoter in a cell-specific manner,
but not the shorter -120bp region. It was established that -480bp of the
188
aGSU promoter was sufficient to target a (f-galactosidase reporter to the
gonadotrophs of a transgenic mouse, so this region was necessary and
sufficient for aGSU transcription in vivo (Horn, Windie et al. 1992). Analysis
of this region has identified a number of transcription factor binding sites,
which can be broadly catagorised into two regions, a GnRH regulated region
(GnRH-RE), and a pituitary glycoprotein basal element (PGBE) (Schoderbek,
Roberson et al. 1993). Currently it is known that Lhx-2, p-Lim and an Ets
factor bind to the GnRH-RE and up-regulate GnRH regulated transcription
(Roberson, Schoderbek et al. 1994; Bach, Rhodes et al. 1995; Roberson 1995:
Glenn, 1999 #196). DNA sequence analysis has also identified the binding
sites that make up the PGBE, which include SF-1, Spl, GATA, and a paired-
like homeodomain binding site (Schoderbek, Roberson et al. 1993; Barnhart
and Mellon 1994; Tremblay, Marcil et al. 1999). Since repression of the
-480bp aGSU promoter is specific to L(3T2 cells, it would suggest that FAA
can interact with a factor that is unique to fully differentiated gonadotrophs.
aT3-l cells do not appear to have this factor despite being able to synthesise
and secrete aGSU, this may be because these cells are representative of an
earlier stage of development of the gonadotrophs (Windle, Weiner et al.
1990).
The -120bp aGSU promoter contains a paired-like homeodomain binding
site, which can bind homeobox proteins such as Pitxl, and Otx (Acampora,
Mazan et al. 1998; Treier, O'Connell et al. 2001) and FAA may act through the
paired-like homeodomain binding site to up-regulate expression levels. A
similar homeodomain binding site is present in the LH(3 promoter, and Pitxl
binds to this region, to up-regulate LH(3 transcription (Tremblay, Lanctot et
al. 1998; Quirk, Lozada et al. 2001). There is a single base-pair difference
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between the paired homeodomain region on the LH(3 promoter and the one
on the aGSU promoter (Tremblay, Lanctot et al. 1998). However FAA is not
a homeobox protein, therefore FAA may interact with a homeobox protein
that specifically binds to this region on the aGSU promoter. Since FAA up-
regulates the -120bp aGSU promoter in both L(3T2 and aT3-l cells, a
common factor that interacts with FAA, possibly through the homeodomain
binding site, is present in both cell types. This may be Pitxl or Pitx2, an
isoform of Pitxl, which when mutated causes Reiger syndrome (Lu,
Pressman et al. 1999) and is postulated to bind to this homeodomain binding
site.
Recent DNA sequence analysis of FAA has identified a penta zinc-finger
protein in an antisense orientation that overlaps, tail to tail, the 3' UTR and
exons 40 to 43 of the FAA gene (Wong, Alon et al. 2000). Zinc finger proteins
are involved in transcriptional regulation through sequence specific binding
to DNA, RNA and through protein-protein interactions (Stanojevic, Hoey et
al. 1989; el-Baradi and Pieler 1991; Seto, Lewis et al. 1993). Since this zinc
finger protein is co-expressed with FAA, it may interact with FAA to regulate
its action in other cell types, however it is not known if this protein is
expressed in gonadotroph cells. There have been previous reports of
antisense RNA interactions, which regulate gene expression and translation
in Xenopus, Dictyostelium, and C. elegans (Kimelman and Kirschner 1989;
Hildebrandt and Nellen 1992; Lee, Feinbaum et al. 1993), therefore levels of
these transcripts may be controlled by a mutual antisense regulatory
mechanism.
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4.3.3 The region that represses the aGSU promoter was
mapped to the N-Terminal 322aa
Although the FAA gene has been cloned, it has not been fully characterised,
certainly not its function in gonadotrophs, but some information is available
on how FAA may function in other cell-types. Reports have suggested that
FAA contains a bipartite nuclear localisation signal (NLS) at the N-terminus
of the FAA protein; two putative Src homology modules 2 and 3 (SH2/SH3)
domains; a peroxidase domain; and a partial leucine zipper (Mian and Moser
1998; van de Vrugt, Cheng et al. 2000). In order to identify the repressor
region, the FAA cDNA was truncated at 965bp (FAA965), and 2400bp
(FAA2400). FAA2400 contained the NLS and the SH2/SH3 domains, but not
the leucine zipper domain, and FAA965 only contained the NLS region. Co-
transfection with the -480 aGSU promoter identified that both truncated
proteins repressed the GnRH response as efficiently as the full-length protein
when compared to the GnRH response of the aGSU promoter in the absence
of FAA.
FAA exists both in the nucleus and the cytosol, indeed functional activation
of FAA requires it to form a complex with FAC, FAG and FAF (Naf, Kupfer
et al. 1998; Garcia-Higuera and D'Andrea 1999; Garcia-Higuera and D'Andrea
1999; Kupfer, Naf et al. 1999; Waisfisz, de Winter et al. 1999; de Winter, van
der Weel et al. 2000). Yeast 2-hybrid analysis has identified a strong
interaction between FAA and FAG, and other evidence suggests that the
FAA/FAG interaction is necessary and required for transporting FAA into
the nucleus (Naf, Kupfer et al. 1998; Kruyt, Abou-Zahr et al. 1999; Reuter,
Herterich et al. 2000). FAG was identified as XRCC9, a protein involved in
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DNA post-replication repair and cell cycle checkpoint control (de Winter,
Waisfisz et al. 1998). The bipartite NLS is functional in FAA, it is sufficient but
not essential for nuclear localisation, however the N-terminus region of FAG
is required to bind the NLS of FAA to ensure that FAA is translocated to the
nucleus (Kuang, Garcia-Higuera et al. 2000). Mutation of the NLS impedes
transport into the nucleus but does not prevent it. Additionally, mutant
forms of FAA with deletions of the C-terminal 70 or 260 amino acids localise
FAA to the cytoplasm (Lightfoot, Alon et al. 1999). This suggests that a
number of regions on FAA are involved in transporting it into the nucleus,
and that FAA shuttles between the nucleus and the cytoplasm.
FAC also has functional significance and complexes with FAA to impart
activity (Yamashita, Kupfer et al. 1998), however it does not bind FAA
directly, instead the C-terminus of FAG is required to bind FAC and form a
functional complex in the nucleus (Kuang, Garcia-Higuera et al. 2000; Reuter,
Herterich et al. 2000). The FAC protein can interact with a number of
different proteins with different functions and is localised to the cytoplasm
and, as part of the FA protein complex, in the nucleus (Kupfer, Naf et al.
1997; Hoatlin, Christianson et al. 1998; Kruyt and Youssoufian 1998). A novel
transcriptional repressor protein that contains a broad complex, tramtrack
and brie a brae/pox virus and zinc finger (BTB/POZ) domain, named
Fanconi anemia zinc finger protein (FAZF) interacts with FAC (Hoatlin, Zhi
et al. 1999). FAZF is homologous to the promyelocytic leukemia zinc finger
(PLZF) which acts as a repressor by recruiting co-repressors such as N-CoR
or Sin3 (David, Alland et al. 1998; Huynh and Bardwell 1998). PLZF represses
transcription of specific targets by recruitment of histone deacetylase
through the SMRT-mSin3-HDAC corepressor complex (David, Alland et al.
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1998) and mutations in this protein lead to acute promyelocytic leukemia
reminiscent of the FA phenotype (Melnick and Licht 1999). BTB/POZ
containing proteins are involved in oncogenesis (Baron, Nucifora et al. 1993;
Chen, Zelent et al. 1993; Chen, Brand et al. 1993), haemtopoeisis (Ye,
Cattoretti et al. 1997) and limb development (Grimm, Sporle et al. 1999).
Therefore, a mutation in FAC that prevents it from interacting with FAZF
could conceivably lead to the symptoms shown by FA patients. Additionally
a mutation in FAA that prevents FAC from interacting in the nucleus,
leading to a non-functioning complex, would also have the same outcome.
FAC can also interact with Grb94 to regulate its intracellular expression levels
and hence its activity (Hoshino, Wang et al. 1998). Grb94 is an adaptor
protein that interacts with SH2/SH3 domains and receptors to transduce
signals from the receptor to the second messenger signalling pathways
(Cowan and Henkemeyer 2001). FAC can also bind and facilitate the
activation of STATI by gamma interferon and haematopoietic growth
factors by controlling the trafficking and docking of STATI to the gamma
interferon receptor (Pang, Fagerlie et al. 2000). It also interacts with heat
shock protein 70 (Hsp70) (Pang, Keeble et al. 2001) and with glutathione S-
Transferase Pl-1 (GSTP1) to increase GSTP1 activity (Cumming, Lightfoot et
al. 2001), and both pathways prevent apoptosis in haematopoietic cells.
Therefore the bone marrow failure and anaemia seen in FA patients may be
due in part, to excessive apoptosis of the haematopoietic cells.
4.3.4 The FA proteins may interact in a transcription coupled
DNA repair pathway
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The FA protein complex can interact with BRCA1, a tumour suppressor gene
linked to familial breast and ovarian cancers (Hall, Lee et al. 1990; Garcia-
Higuera, Taniguchi et al. 2001). BRCA1 is involved in ionising radiation and
oxidative damage repair to DNA (Gowen, Avrutskaya et al. 1998). It
associates with the DNA repair proteins Rad50 and Rad51 in a mutually
exclusive manner to induce homologous recombination in DNA double
strand breaks (Zhong, Chen et al. 1999). Rad50 complexes with Mrell, p95
and BRCA1 and is responsible for end processing and Rad51 is involved in
strand exchange at a later stage. BRCA1 is also required for transcription
coupled repair (TCR) of oxidative DNA damage (Gowen, Avrutskaya et al.
1998). TCR is a process that repairs UV and oxidative induced damage on
transcriptionally active DNA faster than the genome as a whole (Hanawalt
1994). It requires an active RNA polymerase II, which also acts as a DNA
damage recognition complex to the DNA repair complex that is tethered to
it, therefore repair is carried out concurrently with transcription (Leadon and
Lawrence 1991; Christians and Hanawalt 1992). BRCA1 binds to RNA
polymerase II and several transcription factors including TFIIF, TFIIE and
TFIIH, and acts in concert with DNA repair enzymes during periods of rapid
growth (Scully, Anderson et al. 1997; Scully, Chen et al. 1997). BRCA1 can
interact with the FA proteins in a common pathway, and may provide a link
between DNA repair and FA (Garcia-Higuera, Taniguchi et al. 2001). The
interaction appears to be mediated through FAD2. The FAD
complementation group consists of two genes FAD1 and FAD2, which
function downstream of the FA nuclear complex since the nuclear complex
can form in FAD deficient cells (Yamashita, Kupfer et al. 1998; Timmers,
Taniguchi et al. 2001). Activation of FAD2 requires the protein to be mono-
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ubiquitinated, this occurs during S-phase and during DNA damage and only
in the presence of the FA nuclear complex and BRCA1 (Garcia-Higuera,
Taniguchi et al. 2001). FAD2 is highly conserved among lower eukaryotes
including Arabidopsis, Drosphila, and C.elegans (Timmers, Taniguchi et al.
2001) and appears to be the first described downstream effector of the FA
nuclear complex. However the BRCA1 null mouse does not display any of
the FA characteristics, which implies that the FA proteins interact in a
separate pathway (Garcia-Higuera, Taniguchi et al. 2001).
4.3.5 A region in FAA has homology to Ste5, a yeast MAPK
scaffold protein
The current literature suggests that the FA proteins act as a complex
involved in DNA repair and checkpoint control of mitosis, however
gonadotroph cells do not undergo mitosis, so what is FAA doing in
gonadotrophs? It is uncertain if the other FA proteins (B, C, D, E, F, G) are
present in these cells, so FAA may have either a similar or a completely
different role in gonadotrophs. Lightfoot et al identified a region between aa
residues 36 and 250 that was crucial for nuclear localisation. FAG binds to the
NLS region adjacent to this region, which is also involved in localising FAA
to the nucleus (Lightfoot, Alon et al. 1999; Kuang, Garcia-Higuera et al. 2000).
This region also has significant homology with the molecular scaffold protein
Ste5, which is involved in the pheromone mating response in S. cerevisiae
(Mahanty, Wang et al. 1999). In addition, this is the region that was deleted in
the FAA gene disrupted mice and shown to be pivotal in reproduction. Ste5
is a molecular scaffold, which in the absence of the yeast mating type
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pheromone factor, resides mainly in the nucleus and in the presence of
pheromone, is translocated from the nucleus to the plasma membrane (see
Fig 4.3.5a). Pheromone binds to and activates a G-protein coupled receptor
(GPCR) and additionally pheromone and GnRH are functionally conserved.
Therefore these similarities suggest that FAA and Ste5 may function in a
similar manner, this is conjecture, but forms the basis for a working
hypothesis of the role of FAA in gonadotrophs. Ste5 functions by binding
proteins of the MAPK pathway and translocating them to the plasma
membrane in response to pheromone. Thereafter, the G|3 subunit
transduces the pheromone signal by binding Ste20, a MAPKKKK (Leeuw,
Wu et al. 1998). Ste20 then activates Stell, which activates Ste7, which
activates the MAPKs Fus3 and Kssl. These kinases can then activate other
genes involved in the mating response (Gustin, Albertyn et al. 1998). Ste5
tethers these MAPK kinases in the presence and absence of pheromone, and
facilitates their activation in vivo by maintaining them in close proximity
(Choi, Satterberg et al. 1994; Kranz, Satterberg et al. 1994). This tethering
also provides specificity of this pathway to the mating response, since these
MAPKs are also involved in other signalling responses (Roberts and Fink
1994; Yashar, Irie et al. 1995; Posas and Saito 1997). In mammals, (l-arrestin
and JIP1 have also been suggested as scaffold proteins that facilitate JNK
signal transduction through GPCRs and the mixed lineage protein kinase
(MLK) group respectively (Dickens, Rogers et al. 1997; Ito, Yoshioka et al.
1999; McDonald, Chow et al. 2000; Miller and Lefkowitz 2001). (3-arrestins
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Basal Signalling Induced Signalling
Fig. 4.3.5a: Diagram showing how Ste5 shuttles from the nucleus to the
membrane in response to the pheromone signal.
Ste5 resides mainly in the nucleus in a phosphorylated form. When
pheromone activates the G-protein coupled receptor, Ste5 shuttles from the
nucleus to the plasma membrane and interacts with the receptor. The
receptor can then activate the MAPK proteins attached to Ste5 and activate
the signalling mechanisms to induce morphogenesis.
Fig.4.3.5b:Aschematicrepresent tionofthhyp t sisedolAAinul tingaGSUra scription. PhosphorylatedFAAitransportenthenucl usndinterac swithaGSUpromoter,i herdire ly indirectly.ThereforeaGSUtranscriptionmaintainedb s lr te.hG RHc rct v edwh GnRHbi ds.Itthenactivatesseco dm ssengerignallingpa hways,w ichcaup-regul tefa torsinvol ed inG RHregulatedtranscriptionandctiv tephospha asehadep o phorylat sFAA.T sp r ed fromthenucleus,andGSUa scriptioniup-regulated.
bind to the cytoplasmic tail of GPCRs and acts as a site of assembly for a
functional JNK signalling module (McDonald, Chow et al. 2000), but are not
able to bind the GnRH-R (Heding, Vrecl et al. 2000; Vrecl, Heding et al. 2000),
suggesting that a different mechanism must be used.
Although FAA does not appear to bind second messenger signalling
molecules, it may have a similar role as Ste5. So, it is hypothesised that in the
non-GnRH stimulated state, FAA (or the FA nuclear complex) resides in the
nucleus in a phosphorylated state, bound either directly or indirectly to the
aGSU promoter. It may interact with a co-repressor or with factors that are
involved in up-regulating aGSU transcription, thus controlling basal aGSU
transcription. When GnRH is present, the FAA protein (or complex) is de-
phosphorylated and transported from the nucleus, to the cytoplasm, thus
allowing GnRH stimulated up-regulation of aGSU transcription (Fig. 4.3.5b).
Since mammalian GnRH receptors do not have a cytoplasmic tail, it is not
certain how FAA would tether to them, however if FAA does bind, it may be
through a Grb adapter protein at the putative SH2/SH3 domains. Therefore,





L(3T2 cells are an in vivo derived cell line that represent fully differentiated
gonadotrophs (Turgeon, Kimura et al. 1996). Pulsatile administration of
GnRH induces synthesis of LHp mRNA and secretion of LH (Turgeon,
Kimura et al. 1996) and FSH(3 mRNA expression is only induced with activin
and GnRH (Graham, Nusser et al. 1999; Pernasetti, Vasilyev et al. 2001).
Therefore, these cells mimicked in vivo expression of gonadotrophins, in an
in vitro model system and hence were chosen for this project.
Differential display RT-PCR was used successfully, to identify GnRH
regulated mRNA transcripts in LpT2 cells. This PCR based technique was
developed by Liang et al to identify differentially expressed mRNAs (Liang
and Pardee 1992). Since it is a PCR based technique, it has the advantage of
being highly sensitive, so that low copy number transcripts are also included
in the analysis. In fact, most of the mRNA transcripts identified were low
copy number transcripts, and could only be detected by ribonuclease
protection assays (RPA). Although high frequencies of false positive results
have previously been reported, none were identified during the course of
this project. This may be due to the low complexity of the system used, since
LPT2 cells are an in vitro model of gonadotrophs and therefore, this system
is free of other contaminating mRNAs derived from other cell populations
found in tissue samples. Additionally, the GnRH pulse experiments were
carried out in duplicate so that only those transcripts that were differentially
expressed in both would be isolated.
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The initial pulse regime used was designed to mimic GnRH pulse frequencies
during the luteal and follicular phases. Although this regime identified
numerous changes in mRNA expression levels and identified that myosin
light chain mRNA levels were up-regulated during the luteal phase, other
differences were difficult to interpret, therefore a simpler regime was
adopted. This GnRH pulse regime identified that mRNA expression levels
changed rapidly, within one hour of GnRH stimulation, and usually returned
to pre-GnRH levels after 4 hours. The rapidity of this response suggest that
the GnRH response is transmitted through a mitogen activated protein
kinase pathway since Levi et al identified that MAPK activity was up-
regulated within 1 hour of GnRH stimulation (Levi, Hanoch et al. 1998). The
MAPK cascade can also induce transcription in «T3-1 cells and GnRH pulses
are required to maintain activation of MAPK (Roberson 1995; Haisenleder,
Cox et al. 1998).
The GnRH regulated mRNA transcripts that were identified included two
ESTs, one found in the mammary gland and the other in the testes, the
identity and function of these transcripts are currently unknown. Initially,
confirmation of their expression pattern is required by RPA analysis before
further characterisation. These clones (R3 and R18), could then be used to
screen a cDNA library or used as templates for rapid amplification of cDNA
ends (RACE), to generate full length clones that can be used in structural and
functional studies. From the cDNA sequences, protein sequences can be
determined. These can be used to predict and identify protein motifs or
homology to other known proteins that may offer some clue as to the
function of these proteins. The full length cDNAs could also be used to
screen yeast 2-hybrid libraries as bait proteins to identify interacting
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partners, and transfected into L(3T2 cells to identify a possible role for these
proteins in regulating gonadotrophin synthesis.
The other GnRH regulated mRNA transcripts were myosin light chain
(MLC), a putative tyrosine phosphatase and Fanconi's Anaemia
complementation group A (FAA). MLC forms part of myosin-I, a myosin
motor that is involved in intracellular vesicle transport (Cheney and
Mooseker 1992; Mermall, Post et al. 1998). It is involved in regulating the
activation of myosin-I by myosin light chain kinase (MLCK), whose
activation is also regulated by GnRH (Rao, Paik et al. 1997). Western blot
analysis of MLC could be carried out to show if the protein levels were
different in the luteal and follicular phases, which would further validate the
hypothesis that MLC is involved in luteal phase exocytosis of the LH
granules. Confocal microscopy could be used to show if MLC co-localised
with the LH secretory granules in L(3T2 cells, in the presence or absence of
GnRH, and under conditions that mimicked the luteal or the follicular phase.
Activation of the GnRH receptor by GnRH has been shown to up-regulate
the activity of a tyrosine phosphatase in pancreatic tumour cells and suppress
the tyrosine kinase response induced by epidermal growth factor (EGF) by
dephosphorylating the GnRH receptor (Liebow, Lee et al. 1990; Liebow, Lee
et al. 1991). Tyrosine kinases are involved in regulating growth and
differentiation of cells however in vivo, gonadotrophs are fully differentiated
and do not undergo further mitosis. Epidermal growth factor receptor, a
tyrosine kinase, has been shown to up-regulate LH|3 mRNA expression
levels in anterior pituitary cells, and recent evidence suggests that it may also
up-regulate translation in aT3-l cells (Armstrong and Childs 1997;
Sosnowski, Mellon et al. 2000). Therefore tyrosine kinases may be involved
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in regulating LH synthesis, and tyrosine phosphatases regulate tyrosine
kinases in a mechanism similar to negative feedback regulation (Alberts,
Bray et al. 1994). So, the tyrosine phosphatase identified may have an
indirect role in regulating LH(3 synthesis. It may be that the tyrosine
phosphatase is involved in controlling the GnRH response, down-regulating
it until the next GnRH pulse. To test this, a tyrosine phosphatase inhibitor
such as sodium orthovanadate could be added to L(TT2 cells before
stimulating the cells with GnRH. Then either a nuclear run on assay to
measure LH(1 transcription rate or an RPA to measure LH|1 mRNA levels
could be performed, and the results compared with L(3T2 cells that had not
been treated with the tyrosine phosphatase inhibitor. If the LHp mRNA
levels, or the rate of transcription was increased in cells treated with sodium
orthovanadate, this would provide further evidence for the role of tyrosine
kinases and phosphatases in regulating LHp transcription. It would also
provide evidence of another pathway involved in the differential regulation
of gonadotrophin gene expression.
DD-RT-PCR has shown that FAA is present in gonadotrophs, and is
regulated by GnRH. However, the ambiguity between the DD-RT-PCR
mRNA expression profile and the RPA profile needs to be clarified. The
identification of a penta zinc finger (zfp276) that is found at the 3' end of FAA
in the opposite orientation (Wong, Alon et al. 2000), requires further analysis
since it may be this transcript that is up-regulated in response to GnRH. To
test this, zfp276 will need to be isolated, cloned and used in RPA analysis to
identify if its mRNA expression profile matches the DD-RT-PCR expression
profile. If zfp276 mRNA expression levels are up-regulated in response to
GnRH, it would suggest that zfp276 may have an opposite effect to FAA and
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up-regulate aGSU promoter activity. To test this, zfp276 could be co-
transfected into L[3T2 cells with LHp, FSHp and aGSU promoter constructs
and into cxT3-l cells with the aGSU promoter constructs. This would identify
if zfp276 can regulate promoter activity in a cell-line and promoter specific
manner and would suggest that zfp276 and FAA lie on a common pathway.
FAA down-regulates aGSU promoter activity and has no effect on LHp
promoter activity. It is uncertain if FAA affects FSHp promoter activity,
although it would seem unlikely based on the specific action of FAA, which
has already been discussed. However, this must be addressed by co-
transfection of FAA with the FSHp gene promoter. FAA appears to have
two different effects on the aGSU promoter, a GnRH inhibitory effect on the
longer promoter that is specific to LPT2 cells, and a basal stimulatory effect
on the shorter promoter, which is common to LPT2 and aT3-l cells. This
suggests that a factor common to both LPT2 and aT3-l cells is involved in
basal regulation of aGSU transcription, and a factor that is specific to LPT2
cells is involved in GnRH regulated aGSU transcription. To identify these
factors, the two regulatory regions on the aGSU promoter have to be
further localised. So, a series of aGSU promoter resections could be made
and co-transfected with FAA to isolate the inhibitory region on the -480bp
aGSU promoter. Electrophoretic mobility shift assays (EMSAs) using this
region could be performed to identify if a protein binds directly to this
region in the presence or absence of GnRH. To identify if this protein is FAA
a supershift assay, using a FAA antibody, could be performed. If however
FAA does not bind this region, then a number of techniques could be used to
identify the protein that does bind. The DNA with the protein binding
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region could be covalently linked to biotinylated beads and mixed with
crude cytosolic or nuclear extracts, to isolate and separate proteins that bind
to this DNA fragment using a streptavidin coated matrix column.
Alternatively, the DNA fragment containing the protein binding region
could be used to screen a cDNA expression library. The isolated cDNA could
then be in vitro transcribed and translated and the resulting protein could be
analysed. Additionally, this protein could be used to identify if it interacts
with FAA by yeast 2-hybrid analysis. A similar approach could be used to
localise the region on the -120bp aGSU promoter that up-regulates the basal
transcription rate of the promoter. Initially, the homeobox domain binding
site on the -120bp aGSU promoter should be mutated to demonstrate if the
FAA response is mediated through this site. If this was the case, promoter
resections would be unnecessary and the homeobox domain binding site
could be used in the experiments described above.
A western blot of untreated and GnRH treated L(3T2 nuclear and cytosolic
preparations could also be performed to identify if FAA shuttles between the
nucleus and cytoplasm in response to GnRFF. Additionally
immunocytochemistry could be performed on L|3T2 cells that were either left
untreated or treated with GnRH. This would identify if FAA is translocated
from the nucleus in response to GnRH stimulation. This would provide
evidence that FAA could be acting as a shuttling protein, and strengthen the
hypothesis that it may be acting as a scaffold protein.
It is not known if any of the other FA proteins are present in gonadotrophs.
To determine if the other FA proteins are present, RT-PCR using primers
designed to FAG and FAC could be performed. If the other FA proteins are
present, it is most likely that FAA acts as part of a complex. If this is the case,
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then FAC is the likely candidate for interactions with other proteins since
there is evidence that FAC can interact with a number of different effectors
(Hoatlin, Zhi et al. 1999; Cumming, Lightfoot et al. 2001; Pang, Keeble et al.
2001). Therefore FAC and FAG could be cloned from L(3T2 cells and used in
transfection assays to determine if they have any effect on the aGSU
promoter either alone or together with FAA. If the other FA proteins are
not present, then it suggests that FAA may be involved in a novel pathway
that regulates the aGSU promoter. Screening a yeast 2-hybrid library may
also identify other proteins that have not previously been described and it
may also identify if FAA interacts with zfp276.
The FAA regulatory region has been provisionally mapped between laa and
322aa. To confirm this, a further transfection experiment should be carried
out using the construct described in Fig. 4.2.5a that is currently under
construction. This construct is missing the first 322aa of the N-terminus,
which appears to be responsible for mediating repression of aGSU promoter
activity, therefore this construct should be unable to repress the GnRH
regulated activity of the aGSU promoter. This would identify if this region is
necessary for repression. Lightfoot et al identified that the region between
36 and 250aa was crucial for nuclear localisation, this region has significant
homology with Ste5 and it is hypothesised that this region may be
responsible for mediating repression. Therefore, two further FAA deletion
constructs could be created; one that contained the amino acid residues
between 36aa and 322aa, and the other containing the first 36aa, and the
NLS. Co-transfection of these constructs with the -480bp promoter would
determine if the repressor function was mediated through the NLS and
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therefore FAG/FAC interaction, or through this Ste5-like region via an as
yet unknown protein interaction.
The aim of this thesis and this project was to identify GnRH regulated factors
that may be involved in differentially regulating gonadotrophin biosynthesis
and secretion, and add to the knowledge of the downstream effects of
GnRH. This thesis has described a number of factors that are rapidly
regulated by GnRH, which are involved in regulating synthesis and secretion
of the gonadotrophins. Additionally, this work has shown that DD-RT-PCR
is a reliable technique to use to identify changes in mRNA expression profiles
in L(fT2 cells, since the mRNA expression profiles of those transcripts tested
have been confirmed. Therefore the mRNA expression profiles identified by
DD-RT-PCR are true representations of the actual mRNA expression
patterns in the cell, although further clarification of the mRNA expression
profile of FAA needs to be carried out, since the expression profile on the
DD-RT-PCR gel could be representative of zfp276. Since the GnRH regulated
mRNA transcripts identified by DD-RT-PCR are involved in secretion,
signalling and transcription of the gonadotrophins, then the LjlT2 cell line has
also proved to be a good in vitro model of gonadotrophs. Furthermore
there is previous evidence showing that a few of these factors may be GnRH
regulated, therefore all the machinery involved in the synthesis and secretion
of LH and FSH is present in these cells and respond as expected to GnRH.
The novel discovery that GnRH regulates FAA, which in turn regulates
aGSU transcription provides evidence for a unique role for FAA in the
gonadotrophs and may provide further insight into the role of this protein
out-with the gonadotroph cell.
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